id	sid	tid	token	lemma	pos
iajs-3030	1	1	ihjpas	ihjpas	PROPN
iajs-3030	1	2	.	.	PUNCT
iajs-3030	2	1	36	36	NUM
iajs-3030	2	2	(	(	PUNCT
iajs-3030	2	3	3	3	NUM
iajs-3030	2	4	)	)	PUNCT
iajs-3030	2	5	2023	2023	NUM
iajs-3030	2	6	167	167	NUM
iajs-3030	2	7	this	this	DET
iajs-3030	2	8	work	work	NOUN
iajs-3030	2	9	is	be	AUX
iajs-3030	2	10	licensed	license	VERB
iajs-3030	2	11	under	under	ADP
iajs-3030	2	12	a	a	DET
iajs-3030	2	13	creative	creative	ADJ
iajs-3030	2	14	commons	common	NOUN
iajs-3030	2	15	attribution	attribution	NOUN
iajs-3030	2	16	4.0	4.0	NUM
iajs-3030	2	17	international	international	ADJ
iajs-3030	2	18	license	license	NOUN
iajs-3030	2	19	*	*	PUNCT
iajs-3030	2	20	corresponding	correspond	VERB
iajs-3030	2	21	author	author	NOUN
iajs-3030	2	22	:	:	PUNCT
iajs-3030	2	23	sarah.wathib@gmail.com	sarah.wathib@gmail.com	X
iajs-3030	2	24	abstract	abstract	ADJ
iajs-3030	2	25	type	type	NOUN
iajs-3030	2	26	i	i	PRON
iajs-3030	2	27	diabetes	diabetes	VERB
iajs-3030	2	28	(	(	PUNCT
iajs-3030	2	29	t1	t1	NOUN
iajs-3030	2	30	dm	dm	NOUN
iajs-3030	2	31	)	)	PUNCT
iajs-3030	2	32	is	be	AUX
iajs-3030	2	33	a	a	DET
iajs-3030	2	34	chronic	chronic	ADJ
iajs-3030	2	35	immune	immune	ADJ
iajs-3030	2	36	system	system	NOUN
iajs-3030	2	37	disease	disease	NOUN
iajs-3030	2	38	characterized	characterize	VERB
iajs-3030	2	39	by	by	ADP
iajs-3030	2	40	the	the	DET
iajs-3030	2	41	devastation	devastation	NOUN
iajs-3030	2	42	or	or	CCONJ
iajs-3030	2	43	injury	injury	NOUN
iajs-3030	2	44	of	of	ADP
iajs-3030	2	45	ß	ß	NOUN
iajs-3030	2	46	-	-	NOUN
iajs-3030	2	47	cells	cell	NOUN
iajs-3030	2	48	in	in	ADP
iajs-3030	2	49	the	the	DET
iajs-3030	2	50	langerhans	langerhans	PROPN
iajs-3030	2	51	island	island	NOUN
iajs-3030	2	52	,	,	PUNCT
iajs-3030	2	53	resulting	result	VERB
iajs-3030	2	54	in	in	ADP
iajs-3030	2	55	insulin	insulin	NOUN
iajs-3030	2	56	deficiency	deficiency	NOUN
iajs-3030	2	57	and	and	CCONJ
iajs-3030	2	58	hyperglycemia	hyperglycemia	NOUN
iajs-3030	2	59	.	.	PUNCT
iajs-3030	3	1	this	this	DET
iajs-3030	3	2	study	study	NOUN
iajs-3030	3	3	determines	determine	VERB
iajs-3030	3	4	the	the	DET
iajs-3030	3	5	new	new	ADJ
iajs-3030	3	6	marker	marker	NOUN
iajs-3030	3	7	f	f	NOUN
iajs-3030	3	8	-	-	PUNCT
iajs-3030	3	9	box	box	PROPN
iajs-3030	3	10	and	and	CCONJ
iajs-3030	3	11	wd	wd	PROPN
iajs-3030	3	12	repeat	repeat	NOUN
iajs-3030	3	13	domain	domain	NOUN
iajs-3030	3	14	containing	contain	VERB
iajs-3030	3	15	7	7	NUM
iajs-3030	3	16	(	(	PUNCT
iajs-3030	3	17	fbxw7	fbxw7	PROPN
iajs-3030	3	18	)	)	PUNCT
iajs-3030	3	19	.	.	PUNCT
iajs-3030	4	1	one	one	NUM
iajs-3030	4	2	hundred	hundred	NUM
iajs-3030	4	3	twenty	twenty	NUM
iajs-3030	4	4	type	type	NOUN
iajs-3030	4	5	1	1	NUM
iajs-3030	4	6	diabetic	diabetic	ADJ
iajs-3030	4	7	patients	patient	NOUN
iajs-3030	4	8	from	from	ADP
iajs-3030	4	9	three	three	NUM
iajs-3030	4	10	different	different	ADJ
iajs-3030	4	11	places	place	NOUN
iajs-3030	4	12	(	(	PUNCT
iajs-3030	4	13	central	central	ADJ
iajs-3030	4	14	child	child	NOUN
iajs-3030	4	15	hospital	hospital	NOUN
iajs-3030	4	16	,	,	PUNCT
iajs-3030	4	17	alkindi	alkindi	NOUN
iajs-3030	4	18	center	center	VERB
iajs-3030	4	19	for	for	ADP
iajs-3030	4	20	diabetes	diabetes	NOUN
iajs-3030	4	21	and	and	CCONJ
iajs-3030	4	22	endocrinology	endocrinology	NOUN
iajs-3030	4	23	,	,	PUNCT
iajs-3030	4	24	children	child	NOUN
iajs-3030	4	25	’s	’s	PART
iajs-3030	4	26	education	education	NOUN
iajs-3030	4	27	hospital	hospital	NOUN
iajs-3030	4	28	)	)	PUNCT
iajs-3030	4	29	in	in	ADP
iajs-3030	4	30	iraq	iraq	PROPN
iajs-3030	4	31	during	during	ADP
iajs-3030	4	32	the	the	DET
iajs-3030	4	33	period	period	NOUN
iajs-3030	4	34	from	from	ADP
iajs-3030	4	35	(	(	PUNCT
iajs-3030	4	36	20	20	NUM
iajs-3030	4	37	december	december	PROPN
iajs-3030	4	38	2021	2021	NUM
iajs-3030	4	39	to	to	ADP
iajs-3030	4	40	25	25	NUM
iajs-3030	4	41	march	march	NOUN
iajs-3030	4	42	2022	2022	NUM
iajs-3030	4	43	)	)	PUNCT
iajs-3030	4	44	an	an	DET
iajs-3030	4	45	age	age	NOUN
iajs-3030	4	46	ranges	range	VERB
iajs-3030	4	47	of	of	ADP
iajs-3030	4	48	(	(	PUNCT
iajs-3030	4	49	4	4	NUM
iajs-3030	4	50	-	-	SYM
iajs-3030	4	51	17	17	NUM
iajs-3030	4	52	)	)	PUNCT
iajs-3030	4	53	years	year	NOUN
iajs-3030	4	54	.	.	PUNCT
iajs-3030	5	1	the	the	DET
iajs-3030	5	2	patient	patient	ADJ
iajs-3030	5	3	group	group	NOUN
iajs-3030	5	4	consisted	consist	VERB
iajs-3030	5	5	of	of	ADP
iajs-3030	5	6	being	be	AUX
iajs-3030	5	7	derived	derive	VERB
iajs-3030	5	8	to	to	ADP
iajs-3030	5	9	three	three	NUM
iajs-3030	5	10	groups	group	NOUN
iajs-3030	5	11	:	:	PUNCT
iajs-3030	5	12	group	group	NOUN
iajs-3030	5	13	one	one	NUM
iajs-3030	5	14	healthy	healthy	ADJ
iajs-3030	5	15	patient	patient	NOUN
iajs-3030	5	16	group	group	NOUN
iajs-3030	5	17	(	(	PUNCT
iajs-3030	5	18	33	33	NUM
iajs-3030	5	19	)	)	PUNCT
iajs-3030	5	20	was	be	AUX
iajs-3030	5	21	included	include	VERB
iajs-3030	5	22	as	as	ADP
iajs-3030	5	23	healthy	healthy	ADJ
iajs-3030	5	24	patient	patient	NOUN
iajs-3030	5	25	,	,	PUNCT
iajs-3030	5	26	group	group	NOUN
iajs-3030	5	27	two	two	NUM
iajs-3030	5	28	(	(	PUNCT
iajs-3030	5	29	20	20	NUM
iajs-3030	5	30	)	)	PUNCT
iajs-3030	5	31	newly	newly	ADV
iajs-3030	5	32	diagnosed	diagnose	VERB
iajs-3030	5	33	t1	t1	PROPN
iajs-3030	5	34	dm	dm	PROPN
iajs-3030	5	35	and	and	CCONJ
iajs-3030	5	36	(	(	PUNCT
iajs-3030	5	37	67	67	NUM
iajs-3030	5	38	)	)	PUNCT
iajs-3030	5	39	type	type	NOUN
iajs-3030	5	40	1	1	NUM
iajs-3030	5	41	diabetic	diabetic	NOUN
iajs-3030	5	42	with	with	ADP
iajs-3030	5	43	insulin	insulin	NOUN
iajs-3030	5	44	treatment	treatment	NOUN
iajs-3030	5	45	.	.	PUNCT
iajs-3030	6	1	the	the	DET
iajs-3030	6	2	quantitative	quantitative	ADJ
iajs-3030	6	3	enzyme	enzyme	NOUN
iajs-3030	6	4	-	-	PUNCT
iajs-3030	6	5	linked	link	VERB
iajs-3030	6	6	immunosorbent	immunosorbent	NOUN
iajs-3030	6	7	assay	assay	PROPN
iajs-3030	6	8	(	(	PUNCT
iajs-3030	6	9	elisa	elisa	NOUN
iajs-3030	6	10	)	)	PUNCT
iajs-3030	6	11	biochemical	biochemical	ADJ
iajs-3030	6	12	parameters	parameter	NOUN
iajs-3030	6	13	were	be	AUX
iajs-3030	6	14	used	use	VERB
iajs-3030	6	15	to	to	PART
iajs-3030	6	16	quantify	quantify	VERB
iajs-3030	6	17	the	the	DET
iajs-3030	6	18	protein	protein	NOUN
iajs-3030	6	19	fbxw-7	fbxw-7	NOUN
iajs-3030	6	20	levels	level	NOUN
iajs-3030	6	21	.	.	PUNCT
iajs-3030	7	1	fbg	fbg	PROPN
iajs-3030	7	2	,	,	PUNCT
iajs-3030	7	3	cholesterol	cholesterol	NOUN
iajs-3030	7	4	,	,	PUNCT
iajs-3030	7	5	triglyceride	triglyceride	ADJ
iajs-3030	7	6	,	,	PUNCT
iajs-3030	7	7	hdl	hdl	PROPN
iajs-3030	7	8	,	,	PUNCT
iajs-3030	7	9	ldl	ldl	NOUN
iajs-3030	7	10	,	,	PUNCT
iajs-3030	7	11	vldl	vldl	PROPN
iajs-3030	7	12	,	,	PUNCT
iajs-3030	7	13	hba1c	hba1c	PROPN
iajs-3030	7	14	,	,	PUNCT
iajs-3030	7	15	got	get	VERB
iajs-3030	7	16	,	,	PUNCT
iajs-3030	7	17	gpt	gpt	NOUN
iajs-3030	7	18	,	,	PUNCT
iajs-3030	7	19	total	total	ADJ
iajs-3030	7	20	oxidant	oxidant	ADJ
iajs-3030	7	21	status	status	NOUN
iajs-3030	7	22	,	,	PUNCT
iajs-3030	7	23	and	and	CCONJ
iajs-3030	7	24	total	total	ADJ
iajs-3030	7	25	antioxidant	antioxidant	ADJ
iajs-3030	7	26	status	status	NOUN
iajs-3030	7	27	were	be	AUX
iajs-3030	7	28	measured	measure	VERB
iajs-3030	7	29	through	through	ADP
iajs-3030	7	30	spectrophotometry	spectrophotometry	NOUN
iajs-3030	7	31	.	.	PUNCT
iajs-3030	8	1	serum	serum	PROPN
iajs-3030	8	2	fbxw-7	fbxw-7	NUM
iajs-3030	8	3	protein	protein	NOUN
iajs-3030	8	4	levels	level	NOUN
iajs-3030	8	5	were	be	AUX
iajs-3030	8	6	considerably	considerably	ADV
iajs-3030	8	7	elevated	elevate	VERB
iajs-3030	8	8	noticeably	noticeably	ADV
iajs-3030	8	9	(	(	PUNCT
iajs-3030	8	10	p	p	NOUN
iajs-3030	8	11	-	-	PUNCT
iajs-3030	8	12	value	value	NOUN
iajs-3030	8	13	=	=	NOUN
iajs-3030	8	14	0.00	0.00	NUM
iajs-3030	8	15	)	)	PUNCT
iajs-3030	8	16	.	.	PUNCT
iajs-3030	9	1	in	in	ADP
iajs-3030	9	2	terms	term	NOUN
iajs-3030	9	3	of	of	ADP
iajs-3030	9	4	fbxw7	fbxw7	NOUN
iajs-3030	9	5	protein	protein	NOUN
iajs-3030	9	6	,	,	PUNCT
iajs-3030	9	7	there	there	PRON
iajs-3030	9	8	was	be	VERB
iajs-3030	9	9	a	a	DET
iajs-3030	9	10	significant	significant	ADJ
iajs-3030	9	11	variation	variation	NOUN
iajs-3030	9	12	between	between	ADP
iajs-3030	9	13	the	the	DET
iajs-3030	9	14	new	new	ADJ
iajs-3030	9	15	and	and	CCONJ
iajs-3030	9	16	therapy	therapy	NOUN
iajs-3030	9	17	groups	group	NOUN
iajs-3030	9	18	.	.	PUNCT
iajs-3030	10	1	there	there	PRON
iajs-3030	10	2	was	be	VERB
iajs-3030	10	3	no	no	DET
iajs-3030	10	4	significant	significant	ADJ
iajs-3030	10	5	variation	variation	NOUN
iajs-3030	10	6	in	in	ADP
iajs-3030	10	7	protein	protein	NOUN
iajs-3030	10	8	levels	level	NOUN
iajs-3030	10	9	between	between	ADP
iajs-3030	10	10	the	the	DET
iajs-3030	10	11	new	new	ADJ
iajs-3030	10	12	compared	compare	VERB
iajs-3030	10	13	to	to	ADP
iajs-3030	10	14	healthy	healthy	ADJ
iajs-3030	10	15	groups	group	NOUN
iajs-3030	10	16	.	.	PUNCT
iajs-3030	11	1	serum	serum	NOUN
iajs-3030	11	2	fbxw-7	fbxw-7	NUM
iajs-3030	11	3	protein	protein	NOUN
iajs-3030	11	4	was	be	AUX
iajs-3030	11	5	positively	positively	ADV
iajs-3030	11	6	correlated	correlate	VERB
iajs-3030	11	7	with	with	ADP
iajs-3030	11	8	fbg	fbg	PROPN
iajs-3030	11	9	,	,	PUNCT
iajs-3030	11	10	tg	tg	PROPN
iajs-3030	11	11	,	,	PUNCT
iajs-3030	11	12	cholesterol	cholesterol	NOUN
iajs-3030	11	13	,	,	PUNCT
iajs-3030	11	14	got	get	VERB
iajs-3030	11	15	,	,	PUNCT
iajs-3030	11	16	gpt	gpt	NOUN
iajs-3030	11	17	,	,	PUNCT
iajs-3030	11	18	ldl	ldl	NOUN
iajs-3030	11	19	,	,	PUNCT
iajs-3030	11	20	and	and	CCONJ
iajs-3030	11	21	vldl	vldl	NOUN
iajs-3030	11	22	,	,	PUNCT
iajs-3030	11	23	and	and	CCONJ
iajs-3030	11	24	was	be	AUX
iajs-3030	11	25	negatively	negatively	ADV
iajs-3030	11	26	correlated	correlate	VERB
iajs-3030	11	27	with	with	ADP
iajs-3030	11	28	hdl	hdl	PROPN
iajs-3030	11	29	in	in	ADP
iajs-3030	11	30	the	the	DET
iajs-3030	11	31	patient	patient	NOUN
iajs-3030	11	32	group	group	NOUN
iajs-3030	11	33	.	.	PUNCT
iajs-3030	12	1	according	accord	VERB
iajs-3030	12	2	to	to	ADP
iajs-3030	12	3	roc	roc	PROPN
iajs-3030	12	4	analysis	analysis	NOUN
iajs-3030	12	5	,	,	PUNCT
iajs-3030	12	6	the	the	DET
iajs-3030	12	7	cutoff	cutoff	NOUN
iajs-3030	12	8	value	value	NOUN
iajs-3030	12	9	for	for	ADP
iajs-3030	12	10	fbxw-7	fbxw-7	NUM
iajs-3030	12	11	protein	protein	NOUN
iajs-3030	12	12	was	be	AUX
iajs-3030	12	13	(	(	PUNCT
iajs-3030	12	14	1.9	1.9	NUM
iajs-3030	12	15	)	)	PUNCT
iajs-3030	12	16	in	in	ADP
iajs-3030	12	17	the	the	DET
iajs-3030	12	18	newly	newly	ADJ
iajs-3030	12	19	group	group	NOUN
iajs-3030	12	20	and	and	CCONJ
iajs-3030	12	21	(	(	PUNCT
iajs-3030	12	22	2.1	2.1	NUM
iajs-3030	12	23	)	)	PUNCT
iajs-3030	12	24	in	in	ADP
iajs-3030	12	25	the	the	DET
iajs-3030	12	26	treatment	treatment	NOUN
iajs-3030	12	27	group	group	NOUN
iajs-3030	12	28	.	.	PUNCT
iajs-3030	13	1	levels	level	NOUN
iajs-3030	13	2	of	of	ADP
iajs-3030	13	3	fbxw-7	fbxw-7	NUM
iajs-3030	13	4	protein	protein	NOUN
iajs-3030	13	5	are	be	AUX
iajs-3030	13	6	elevated	elevate	VERB
iajs-3030	13	7	in	in	ADP
iajs-3030	13	8	dm	dm	PROPN
iajs-3030	13	9	patients	patient	NOUN
iajs-3030	13	10	.	.	PUNCT
iajs-3030	14	1	fbxwdoi.org/10.30526/36.3.3030	fbxwdoi.org/10.30526/36.3.3030	PROPN
iajs-3030	14	2	article	article	NOUN
iajs-3030	14	3	history	history	NOUN
iajs-3030	14	4	:	:	PUNCT
iajs-3030	14	5	received	receive	VERB
iajs-3030	14	6	21	21	NUM
iajs-3030	14	7	september	september	PROPN
iajs-3030	14	8	2022	2022	NUM
iajs-3030	14	9	,	,	PUNCT
iajs-3030	14	10	accepted	accept	VERB
iajs-3030	14	11	21	21	NUM
iajs-3030	14	12	december	december	PROPN
iajs-3030	14	13	2022	2022	NUM
iajs-3030	14	14	,	,	PUNCT
iajs-3030	14	15	published	publish	VERB
iajs-3030	14	16	in	in	ADP
iajs-3030	14	17	july	july	PROPN
iajs-3030	14	18	2023	2023	NUM
iajs-3030	14	19	.	.	PUNCT
iajs-3030	15	1	ibn	ibn	PROPN
iajs-3030	15	2	al	al	PROPN
iajs-3030	15	3	-	-	PUNCT
iajs-3030	15	4	haitham	haitham	PROPN
iajs-3030	15	5	journal	journal	PROPN
iajs-3030	15	6	for	for	ADP
iajs-3030	15	7	pure	pure	ADJ
iajs-3030	15	8	and	and	CCONJ
iajs-3030	15	9	applied	applied	ADJ
iajs-3030	15	10	sciences	sciences	PROPN
iajs-3030	15	11	journal	journal	PROPN
iajs-3030	15	12	homepage	homepage	NOUN
iajs-3030	15	13	:	:	PUNCT
iajs-3030	15	14	jih.uobaghdad.edu.iq	jih.uobaghdad.edu.iq	NOUN
iajs-3030	15	15	role	role	NOUN
iajs-3030	15	16	of	of	ADP
iajs-3030	15	17	f	f	PROPN
iajs-3030	15	18	-	-	PUNCT
iajs-3030	15	19	box	box	NOUN
iajs-3030	15	20	wd	wd	PROPN
iajs-3030	15	21	repeat	repeat	NOUN
iajs-3030	15	22	domain	domain	NOUN
iajs-3030	15	23	containing	contain	VERB
iajs-3030	15	24	7	7	NUM
iajs-3030	15	25	in	in	ADP
iajs-3030	15	26	type	type	NOUN
iajs-3030	15	27	1	1	NUM
iajs-3030	15	28	diabetes	diabetes	NOUN
iajs-3030	15	29	sarah	sarah	PROPN
iajs-3030	15	30	w.	w.	PROPN
iajs-3030	15	31	mohammed	mohammed	PROPN
iajs-3030	15	32	*	*	PROPN
iajs-3030	15	33	department	department	PROPN
iajs-3030	15	34	of	of	ADP
iajs-3030	15	35	chemistry	chemistry	NOUN
iajs-3030	15	36	,	,	PUNCT
iajs-3030	15	37	college	college	NOUN
iajs-3030	15	38	of	of	ADP
iajs-3030	15	39	science	science	NOUN
iajs-3030	15	40	for	for	ADP
iajs-3030	15	41	women	woman	NOUN
iajs-3030	15	42	,	,	PUNCT
iajs-3030	15	43	university	university	NOUN
iajs-3030	15	44	of	of	ADP
iajs-3030	15	45	baghdad	baghdad	PROPN
iajs-3030	15	46	,	,	PUNCT
iajs-3030	15	47	al	al	PROPN
iajs-3030	15	48	-	-	PUNCT
iajs-3030	15	49	jadriya	jadriya	PROPN
iajs-3030	15	50	,	,	PUNCT
iajs-3030	15	51	baghdad	baghdad	PROPN
iajs-3030	15	52	10001	10001	NUM
iajs-3030	15	53	,	,	PUNCT
iajs-3030	15	54	iraq	iraq	PROPN
iajs-3030	15	55	.	.	PUNCT
iajs-3030	16	1	sarah.wathib@gmail.com	sarah.wathib@gmail.com	X
iajs-3030	16	2	zainab	zainab	PROPN
iajs-3030	16	3	m.qassam	m.qassam	PROPN
iajs-3030	16	4	department	department	PROPN
iajs-3030	16	5	of	of	ADP
iajs-3030	16	6	chemistry	chemistry	NOUN
iajs-3030	16	7	,	,	PUNCT
iajs-3030	16	8	college	college	NOUN
iajs-3030	16	9	of	of	ADP
iajs-3030	16	10	science	science	NOUN
iajs-3030	16	11	for	for	ADP
iajs-3030	16	12	women	woman	NOUN
iajs-3030	16	13	,	,	PUNCT
iajs-3030	16	14	university	university	NOUN
iajs-3030	16	15	of	of	ADP
iajs-3030	16	16	baghdad	baghdad	PROPN
iajs-3030	16	17	,	,	PUNCT
iajs-3030	16	18	al	al	PROPN
iajs-3030	16	19	-	-	PUNCT
iajs-3030	16	20	jadriya	jadriya	PROPN
iajs-3030	16	21	,	,	PUNCT
iajs-3030	16	22	baghdad	baghdad	PROPN
iajs-3030	16	23	10001	10001	NUM
iajs-3030	16	24	,	,	PUNCT
iajs-3030	16	25	iraq	iraq	PROPN
iajs-3030	16	26	.	.	PUNCT
iajs-3030	17	1	zainab.moh589@gmail.com	zainab.moh589@gmail.com	PROPN
iajs-3030	17	2	nameer	nameer	PROPN
iajs-3030	17	3	m.	m.	PROPN
iajs-3030	17	4	salih	salih	PROPN
iajs-3030	17	5	alkindi	alkindi	PROPN
iajs-3030	17	6	center	center	VERB
iajs-3030	17	7	for	for	ADP
iajs-3030	17	8	diabetes	diabetes	NOUN
iajs-3030	17	9	and	and	CCONJ
iajs-3030	17	10	endocrinology	endocrinology	NOUN
iajs-3030	17	11	,	,	PUNCT
iajs-3030	17	12	welfare	welfare	NOUN
iajs-3030	17	13	teaching	teaching	NOUN
iajs-3030	17	14	hospital	hospital	NOUN
iajs-3030	17	15	/	/	SYM
iajs-3030	17	16	baghdad	baghdad	PROPN
iajs-3030	17	17	city	city	NOUN
iajs-3030	17	18	.	.	PUNCT
iajs-3030	18	1	nameermahdi@yahoo.com	nameermahdi@yahoo.com	X
iajs-3030	18	2	ekhlass	ekhlass	PROPN
iajs-3030	18	3	m.	m.	PROPN
iajs-3030	18	4	taha	taha	PROPN
iajs-3030	18	5	department	department	PROPN
iajs-3030	18	6	of	of	ADP
iajs-3030	18	7	chemistry	chemistry	NOUN
iajs-3030	18	8	,	,	PUNCT
iajs-3030	18	9	college	college	NOUN
iajs-3030	18	10	of	of	ADP
iajs-3030	18	11	science	science	NOUN
iajs-3030	18	12	for	for	ADP
iajs-3030	18	13	women	woman	NOUN
iajs-3030	18	14	,	,	PUNCT
iajs-3030	18	15	university	university	NOUN
iajs-3030	18	16	of	of	ADP
iajs-3030	18	17	baghdad	baghdad	PROPN
iajs-3030	18	18	,	,	PUNCT
iajs-3030	18	19	al	al	PROPN
iajs-3030	18	20	-	-	PUNCT
iajs-3030	18	21	jadriya	jadriya	PROPN
iajs-3030	18	22	,	,	PUNCT
iajs-3030	18	23	baghdad	baghdad	PROPN
iajs-3030	18	24	10001	10001	NUM
iajs-3030	18	25	,	,	PUNCT
iajs-3030	18	26	iraq	iraq	PROPN
iajs-3030	18	27	.	.	PUNCT
iajs-3030	19	1	ikhlasmb_chem@csw.uobaghdad.edu.iq	ikhlasmb_chem@csw.uobaghdad.edu.iq	PROPN
iajs-3030	19	2	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
iajs-3030	19	3	mailto:sarah.wathib@gmail.com	mailto:sarah.wathib@gmail.com	PROPN
iajs-3030	19	4	mailto:sarah.wathib@gmail.com	mailto:sarah.wathib@gmail.com	PROPN
iajs-3030	19	5	mailto:sarah.wathib@gmail.com	mailto:sarah.wathib@gmail.com	X
iajs-3030	19	6	mailto:zainab.moh589@gmail.com	mailto:zainab.moh589@gmail.com	X
iajs-3030	19	7	mailto:zainab.moh589@gmail.com	mailto:zainab.moh589@gmail.com	X
iajs-3030	19	8	mailto:nameermahdi@yahoo.com	mailto:nameermahdi@yahoo.com	PROPN
iajs-3030	19	9	mailto:nameermahdi@yahoo.com	mailto:nameermahdi@yahoo.com	PROPN
iajs-3030	19	10	mailto:ikhlasmb_chem@csw.uobaghdad.edu.iq	mailto:ikhlasmb_chem@csw.uobaghdad.edu.iq	ADJ
iajs-3030	19	11	mailto:ikhlasmb_chem@csw.uobaghdad.edu.iq	mailto:ikhlasmb_chem@csw.uobaghdad.edu.iq	ADJ
iajs-3030	19	12	ihjpas	ihjpa	NOUN
iajs-3030	19	13	.	.	PUNCT
iajs-3030	20	1	36	36	NUM
iajs-3030	20	2	(	(	PUNCT
iajs-3030	20	3	3	3	NUM
iajs-3030	20	4	)	)	PUNCT
iajs-3030	20	5	2023	2023	NUM
iajs-3030	20	6	168	168	NUM
iajs-3030	20	7	7	7	NUM
iajs-3030	20	8	protein	protein	NOUN
iajs-3030	20	9	was	be	AUX
iajs-3030	20	10	significantly	significantly	ADV
iajs-3030	20	11	different	different	ADJ
iajs-3030	20	12	in	in	ADP
iajs-3030	20	13	the	the	DET
iajs-3030	20	14	treatment	treatment	NOUN
iajs-3030	20	15	group	group	NOUN
iajs-3030	20	16	but	but	CCONJ
iajs-3030	20	17	not	not	PART
iajs-3030	20	18	different	different	ADJ
iajs-3030	20	19	in	in	ADP
iajs-3030	20	20	the	the	DET
iajs-3030	20	21	newly	newly	ADJ
iajs-3030	20	22	group	group	NOUN
iajs-3030	20	23	when	when	SCONJ
iajs-3030	20	24	compared	compare	VERB
iajs-3030	20	25	with	with	ADP
iajs-3030	20	26	the	the	DET
iajs-3030	20	27	healthy	healthy	ADJ
iajs-3030	20	28	group	group	NOUN
iajs-3030	20	29	.	.	PUNCT
iajs-3030	21	1	keywords	keyword	NOUN
iajs-3030	21	2	:	:	PUNCT
iajs-3030	21	3	fbxw7	fbxw7	PROPN
iajs-3030	21	4	protein	protein	NOUN
iajs-3030	21	5	,	,	PUNCT
iajs-3030	21	6	newly	newly	ADV
iajs-3030	21	7	diagnosis	diagnosis	NOUN
iajs-3030	21	8	,	,	PUNCT
iajs-3030	21	9	type	type	NOUN
iajs-3030	21	10	1	1	NUM
iajs-3030	21	11	diabetes	diabetes	NOUN
iajs-3030	21	12	.	.	PUNCT
iajs-3030	22	1	1	1	X
iajs-3030	22	2	.	.	X
iajs-3030	22	3	introduction	introduction	NOUN
iajs-3030	22	4	type	type	NOUN
iajs-3030	22	5	1	1	NUM
iajs-3030	22	6	diabetes	diabetes	NOUN
iajs-3030	22	7	mellitus	mellitus	NOUN
iajs-3030	22	8	(	(	PUNCT
iajs-3030	22	9	t1	t1	NOUN
iajs-3030	22	10	dm	dm	PROPN
iajs-3030	22	11	)	)	PUNCT
iajs-3030	22	12	,	,	PUNCT
iajs-3030	22	13	commonly	commonly	ADV
iajs-3030	22	14	known	know	VERB
iajs-3030	22	15	as	as	ADP
iajs-3030	22	16	autoimmune	autoimmune	ADJ
iajs-3030	22	17	diabetes	diabetes	NOUN
iajs-3030	22	18	,	,	PUNCT
iajs-3030	22	19	is	be	AUX
iajs-3030	22	20	a	a	DET
iajs-3030	22	21	chronic	chronic	ADJ
iajs-3030	22	22	illness	illness	NOUN
iajs-3030	22	23	that	that	PRON
iajs-3030	22	24	causes	cause	VERB
iajs-3030	22	25	hyperglycemia	hyperglycemia	NOUN
iajs-3030	22	26	owing	owe	VERB
iajs-3030	22	27	to	to	ADP
iajs-3030	22	28	insulin	insulin	NOUN
iajs-3030	22	29	insufficiency	insufficiency	NOUN
iajs-3030	22	30	caused	cause	VERB
iajs-3030	22	31	by	by	ADP
iajs-3030	22	32	pancreatic	pancreatic	ADJ
iajs-3030	22	33	beta	beta	NOUN
iajs-3030	22	34	-	-	PUNCT
iajs-3030	22	35	cell	cell	NOUN
iajs-3030	22	36	death	death	NOUN
iajs-3030	22	37	.	.	PUNCT
iajs-3030	23	1	the	the	DET
iajs-3030	23	2	pathophysiology	pathophysiology	NOUN
iajs-3030	23	3	of	of	ADP
iajs-3030	23	4	the	the	DET
iajs-3030	23	5	disease	disease	NOUN
iajs-3030	23	6	is	be	AUX
iajs-3030	23	7	considered	consider	VERB
iajs-3030	23	8	to	to	PART
iajs-3030	23	9	be	be	AUX
iajs-3030	23	10	t	t	NOUN
iajs-3030	23	11	-	-	PUNCT
iajs-3030	23	12	cell	cell	NOUN
iajs-3030	23	13	-	-	PUNCT
iajs-3030	23	14	mediated	mediate	VERB
iajs-3030	23	15	destruction	destruction	NOUN
iajs-3030	23	16	of	of	ADP
iajs-3030	23	17	beta	beta	ADJ
iajs-3030	23	18	cells	cell	NOUN
iajs-3030	23	19	.	.	PUNCT
iajs-3030	24	1	t1	t1	NOUN
iajs-3030	24	2	dm	dm	PROPN
iajs-3030	24	3	pathophysiology	pathophysiology	NOUN
iajs-3030	24	4	may	may	AUX
iajs-3030	24	5	be	be	AUX
iajs-3030	24	6	classified	classify	VERB
iajs-3030	24	7	into	into	ADP
iajs-3030	24	8	three	three	NUM
iajs-3030	24	9	phases	phase	NOUN
iajs-3030	24	10	based	base	VERB
iajs-3030	24	11	on	on	ADP
iajs-3030	24	12	the	the	DET
iajs-3030	24	13	presence	presence	NOUN
iajs-3030	24	14	or	or	CCONJ
iajs-3030	24	15	absence	absence	NOUN
iajs-3030	24	16	of	of	ADP
iajs-3030	24	17	hyperglycemia	hyperglycemia	NOUN
iajs-3030	24	18	and	and	CCONJ
iajs-3030	24	19	hyperglycemia	hyperglycemia	NOUN
iajs-3030	24	20	-	-	PUNCT
iajs-3030	24	21	related	relate	VERB
iajs-3030	24	22	symptoms	symptom	NOUN
iajs-3030	24	23	(	(	PUNCT
iajs-3030	24	24	such	such	ADJ
iajs-3030	24	25	as	as	ADP
iajs-3030	24	26	polyuria	polyuria	NOUN
iajs-3030	24	27	and	and	CCONJ
iajs-3030	24	28	thirst	thirst	NOUN
iajs-3030	24	29	)	)	PUNCT
iajs-3030	24	30	.	.	PUNCT
iajs-3030	25	1	insulin	insulin	NOUN
iajs-3030	25	2	is	be	AUX
iajs-3030	25	3	the	the	DET
iajs-3030	25	4	primary	primary	ADJ
iajs-3030	25	5	therapy	therapy	NOUN
iajs-3030	25	6	for	for	ADP
iajs-3030	25	7	all	all	DET
iajs-3030	25	8	patients	patient	NOUN
iajs-3030	25	9	with	with	ADP
iajs-3030	25	10	t1	t1	PROPN
iajs-3030	25	11	dm	dm	PROPN
iajs-3030	25	12	.	.	PUNCT
iajs-3030	26	1	patients	patient	NOUN
iajs-3030	26	2	with	with	ADP
iajs-3030	26	3	t1	t1	PROPN
iajs-3030	26	4	dm	dm	PROPN
iajs-3030	26	5	will	will	AUX
iajs-3030	26	6	require	require	VERB
iajs-3030	26	7	numerous	numerous	ADJ
iajs-3030	26	8	daily	daily	ADJ
iajs-3030	26	9	injections	injection	NOUN
iajs-3030	26	10	at	at	ADP
iajs-3030	26	11	the	the	DET
iajs-3030	26	12	time	time	NOUN
iajs-3030	26	13	of	of	ADP
iajs-3030	26	14	diagnosis	diagnosis	NOUN
iajs-3030	26	15	,	,	PUNCT
iajs-3030	26	16	as	as	ADV
iajs-3030	26	17	well	well	ADV
iajs-3030	26	18	as	as	ADP
iajs-3030	26	19	innovative	innovative	ADJ
iajs-3030	26	20	insulin	insulin	NOUN
iajs-3030	26	21	therapy	therapy	NOUN
iajs-3030	26	22	techniques	technique	NOUN
iajs-3030	26	23	such	such	ADJ
iajs-3030	26	24	as	as	ADP
iajs-3030	26	25	insulin	insulin	NOUN
iajs-3030	26	26	pumps	pump	NOUN
iajs-3030	26	27	and	and	CCONJ
iajs-3030	26	28	continuous	continuous	ADJ
iajs-3030	26	29	glucose	glucose	NOUN
iajs-3030	26	30	monitoring	monitoring	NOUN
iajs-3030	26	31	[	[	X
iajs-3030	26	32	1	1	NUM
iajs-3030	26	33	]	]	PUNCT
iajs-3030	26	34	.	.	PUNCT
iajs-3030	27	1	hypoglycemia	hypoglycemia	NOUN
iajs-3030	27	2	,	,	PUNCT
iajs-3030	27	3	hyperglycemia	hyperglycemia	NOUN
iajs-3030	27	4	,	,	PUNCT
iajs-3030	27	5	and	and	CCONJ
iajs-3030	27	6	diabetic	diabetic	ADJ
iajs-3030	27	7	ketoacidosis	ketoacidosis	NOUN
iajs-3030	27	8	(	(	PUNCT
iajs-3030	27	9	dka	dka	NOUN
iajs-3030	27	10	)	)	PUNCT
iajs-3030	27	11	are	be	AUX
iajs-3030	27	12	the	the	DET
iajs-3030	27	13	most	most	ADV
iajs-3030	27	14	prevalent	prevalent	ADJ
iajs-3030	27	15	complications	complication	NOUN
iajs-3030	27	16	in	in	ADP
iajs-3030	27	17	children	child	NOUN
iajs-3030	27	18	and	and	CCONJ
iajs-3030	27	19	adolescents	adolescent	NOUN
iajs-3030	27	20	with	with	ADP
iajs-3030	27	21	t1	t1	PROPN
iajs-3030	27	22	dm	dm	PROPN
iajs-3030	27	23	.	.	PUNCT
iajs-3030	27	24	long	long	ADJ
iajs-3030	27	25	-	-	PUNCT
iajs-3030	27	26	term	term	NOUN
iajs-3030	27	27	consequences	consequence	NOUN
iajs-3030	27	28	(	(	PUNCT
iajs-3030	27	29	such	such	ADJ
iajs-3030	27	30	as	as	ADP
iajs-3030	27	31	retinopathy	retinopathy	ADJ
iajs-3030	27	32	,	,	PUNCT
iajs-3030	27	33	nephropathy	nephropathy	ADJ
iajs-3030	27	34	,	,	PUNCT
iajs-3030	27	35	neuropathy	neuropathy	ADJ
iajs-3030	27	36	,	,	PUNCT
iajs-3030	27	37	and	and	CCONJ
iajs-3030	27	38	cardiovascular	cardiovascular	ADJ
iajs-3030	27	39	disease	disease	NOUN
iajs-3030	27	40	)	)	PUNCT
iajs-3030	27	41	begin	begin	VERB
iajs-3030	27	42	to	to	PART
iajs-3030	27	43	develop	develop	VERB
iajs-3030	27	44	in	in	ADP
iajs-3030	27	45	childhood	childhood	NOUN
iajs-3030	27	46	[	[	X
iajs-3030	27	47	2	2	NUM
iajs-3030	27	48	]	]	PUNCT
iajs-3030	27	49	.	.	PUNCT
iajs-3030	28	1	to	to	PART
iajs-3030	28	2	lower	lower	VERB
iajs-3030	28	3	the	the	DET
iajs-3030	28	4	risk	risk	NOUN
iajs-3030	28	5	of	of	ADP
iajs-3030	28	6	long	long	ADJ
iajs-3030	28	7	-	-	PUNCT
iajs-3030	28	8	term	term	NOUN
iajs-3030	28	9	diabetes	diabetes	NOUN
iajs-3030	28	10	-	-	PUNCT
iajs-3030	28	11	related	relate	VERB
iajs-3030	28	12	complications	complication	NOUN
iajs-3030	28	13	,	,	PUNCT
iajs-3030	28	14	the	the	DET
iajs-3030	28	15	american	american	ADJ
iajs-3030	28	16	diabetes	diabetes	PROPN
iajs-3030	28	17	association	association	PROPN
iajs-3030	28	18	(	(	PUNCT
iajs-3030	28	19	ada	ada	PROPN
iajs-3030	28	20	)	)	PUNCT
iajs-3030	28	21	treatment	treatment	NOUN
iajs-3030	28	22	recommendations	recommendation	NOUN
iajs-3030	28	23	recommend	recommend	VERB
iajs-3030	28	24	a	a	DET
iajs-3030	28	25	goal	goal	NOUN
iajs-3030	28	26	to	to	PART
iajs-3030	28	27	be	be	AUX
iajs-3030	28	28	hba1c	hba1c	PROPN
iajs-3030	28	29	less	less	ADJ
iajs-3030	28	30	than	than	ADP
iajs-3030	28	31	7.0	7.0	NUM
iajs-3030	28	32	%	%	NOUN
iajs-3030	28	33	(	(	PUNCT
iajs-3030	28	34	53	53	NUM
iajs-3030	28	35	mmol	mmol	NOUN
iajs-3030	28	36	/	/	SYM
iajs-3030	28	37	mol	mol	NOUN
iajs-3030	28	38	)	)	PUNCT
iajs-3030	28	39	in	in	ADP
iajs-3030	28	40	people	people	NOUN
iajs-3030	28	41	with	with	ADP
iajs-3030	28	42	t1d	t1d	PROPN
iajs-3030	28	43	(	(	PUNCT
iajs-3030	28	44	7.5	7.5	NUM
iajs-3030	28	45	%	%	NOUN
iajs-3030	28	46	for	for	ADP
iajs-3030	28	47	the	the	DET
iajs-3030	28	48	patient	patient	NOUN
iajs-3030	28	49	with	with	ADP
iajs-3030	28	50	t1d	t1d	NOUN
iajs-3030	28	51	)	)	PUNCT
iajs-3030	29	1	[	[	X
iajs-3030	29	2	3	3	NUM
iajs-3030	29	3	]	]	PUNCT
iajs-3030	29	4	.	.	PUNCT
iajs-3030	30	1	the	the	DET
iajs-3030	30	2	f	f	PROPN
iajs-3030	30	3	-	-	PUNCT
iajs-3030	30	4	box	box	NOUN
iajs-3030	30	5	protein	protein	NOUN
iajs-3030	30	6	,	,	PUNCT
iajs-3030	30	7	skp1	skp1	PROPN
iajs-3030	30	8	,	,	PUNCT
iajs-3030	30	9	cullin	cullin	PROPN
iajs-3030	30	10	1	1	NUM
iajs-3030	30	11	,	,	PUNCT
iajs-3030	30	12	and	and	CCONJ
iajs-3030	30	13	roc1	roc1	NOUN
iajs-3030	30	14	/	/	SYM
iajs-3030	30	15	rbx1	rbx1	NOUN
iajs-3030	30	16	/	/	SYM
iajs-3030	30	17	hrt1	hrt1	PROPN
iajs-3030	30	18	are	be	AUX
iajs-3030	30	19	the	the	DET
iajs-3030	30	20	primary	primary	ADJ
iajs-3030	30	21	components	component	NOUN
iajs-3030	30	22	of	of	ADP
iajs-3030	30	23	the	the	DET
iajs-3030	30	24	skp1	skp1	PROPN
iajs-3030	30	25	-	-	PUNCT
iajs-3030	30	26	cul1	cul1	PROPN
iajs-3030	30	27	-	-	PUNCT
iajs-3030	30	28	f	f	PROPN
iajs-3030	30	29	-	-	PUNCT
iajs-3030	30	30	box	box	NOUN
iajs-3030	30	31	(	(	PUNCT
iajs-3030	30	32	scf	scf	PROPN
iajs-3030	30	33	)	)	PUNCT
iajs-3030	30	34	ubiquitin	ubiquitin	NOUN
iajs-3030	30	35	ligases	ligase	NOUN
iajs-3030	30	36	.	.	PUNCT
iajs-3030	31	1	f	f	X
iajs-3030	31	2	-	-	PUNCT
iajs-3030	31	3	box	box	NOUN
iajs-3030	31	4	/	/	SYM
iajs-3030	31	5	wd	wd	PROPN
iajs-3030	31	6	repeat	repeat	NOUN
iajs-3030	31	7	-	-	PUNCT
iajs-3030	31	8	containing	contain	VERB
iajs-3030	31	9	protein	protein	NOUN
iajs-3030	31	10	7	7	NUM
iajs-3030	31	11	(	(	PUNCT
iajs-3030	31	12	fbxw7	fbxw7	PROPN
iajs-3030	31	13	)	)	PUNCT
iajs-3030	31	14	belongs	belong	VERB
iajs-3030	31	15	to	to	ADP
iajs-3030	31	16	the	the	DET
iajs-3030	31	17	f	f	PROPN
iajs-3030	31	18	-	-	PUNCT
iajs-3030	31	19	box	box	NOUN
iajs-3030	31	20	protein	protein	NOUN
iajs-3030	31	21	family	family	NOUN
iajs-3030	31	22	and	and	CCONJ
iajs-3030	31	23	serves	serve	VERB
iajs-3030	31	24	as	as	ADP
iajs-3030	31	25	the	the	DET
iajs-3030	31	26	substrate	substrate	NOUN
iajs-3030	31	27	recognition	recognition	NOUN
iajs-3030	31	28	component	component	NOUN
iajs-3030	31	29	of	of	ADP
iajs-3030	31	30	the	the	DET
iajs-3030	31	31	scf	scf	PROPN
iajs-3030	31	32	e3	e3	NOUN
iajs-3030	31	33	ubiquitin	ubiquitin	ADJ
iajs-3030	31	34	ligase	ligase	NOUN
iajs-3030	31	35	[	[	X
iajs-3030	31	36	4	4	NUM
iajs-3030	31	37	]	]	PUNCT
iajs-3030	31	38	.	.	PUNCT
iajs-3030	32	1	fbxw7	fbxw7	PROPN
iajs-3030	32	2	is	be	AUX
iajs-3030	32	3	located	locate	VERB
iajs-3030	32	4	in	in	ADP
iajs-3030	32	5	chromosome	chromosome	NOUN
iajs-3030	32	6	4	4	NUM
iajs-3030	32	7	and	and	CCONJ
iajs-3030	32	8	comprises	comprise	VERB
iajs-3030	32	9	707	707	NUM
iajs-3030	32	10	amino	amino	ADJ
iajs-3030	32	11	acids	acid	NOUN
iajs-3030	32	12	and	and	CCONJ
iajs-3030	32	13	has	have	VERB
iajs-3030	32	14	a	a	DET
iajs-3030	32	15	molecular	molecular	ADJ
iajs-3030	32	16	weight	weight	NOUN
iajs-3030	32	17	of	of	ADP
iajs-3030	32	18	approximately	approximately	ADV
iajs-3030	32	19	79	79	NUM
iajs-3030	32	20	kd	kd	NOUN
iajs-3030	33	1	[	[	X
iajs-3030	33	2	5	5	NUM
iajs-3030	33	3	]	]	PUNCT
iajs-3030	33	4	.	.	PUNCT
iajs-3030	34	1	there	there	PRON
iajs-3030	34	2	are	be	VERB
iajs-3030	34	3	three	three	NUM
iajs-3030	34	4	structures	structure	NOUN
iajs-3030	34	5	of	of	ADP
iajs-3030	34	6	proteins	protein	NOUN
iajs-3030	34	7	:	:	PUNCT
iajs-3030	34	8	fbxw7α	fbxw7α	NOUN
iajs-3030	34	9	,	,	PUNCT
iajs-3030	34	10	fbxw7β	fbxw7β	PROPN
iajs-3030	34	11	,	,	PUNCT
iajs-3030	34	12	and	and	CCONJ
iajs-3030	34	13	fbxw7	fbxw7	PROPN
iajs-3030	34	14	γ	γ	X
iajs-3030	34	15	[	[	X
iajs-3030	34	16	6	6	NUM
iajs-3030	34	17	]	]	PUNCT
iajs-3030	34	18	.	.	PUNCT
iajs-3030	35	1	it	it	PRON
iajs-3030	35	2	has	have	VERB
iajs-3030	35	3	a	a	DET
iajs-3030	35	4	different	different	ADJ
iajs-3030	35	5	cell	cell	NOUN
iajs-3030	35	6	location	location	NOUN
iajs-3030	35	7	;	;	PUNCT
iajs-3030	35	8	fbxw7α	fbxw7α	NOUN
iajs-3030	35	9	found	find	VERB
iajs-3030	35	10	in	in	ADP
iajs-3030	35	11	the	the	DET
iajs-3030	35	12	nucleoplasm	nucleoplasm	NOUN
iajs-3030	35	13	,	,	PUNCT
iajs-3030	35	14	fbxw7β	fbxw7β	NOUN
iajs-3030	35	15	found	find	VERB
iajs-3030	35	16	in	in	ADP
iajs-3030	35	17	the	the	DET
iajs-3030	35	18	cytoplasm	cytoplasm	NOUN
iajs-3030	35	19	,	,	PUNCT
iajs-3030	35	20	and	and	CCONJ
iajs-3030	35	21	fbxw7	fbxw7	PROPN
iajs-3030	35	22	γ	γ	X
iajs-3030	35	23	in	in	ADP
iajs-3030	35	24	nuclear	nuclear	NOUN
iajs-3030	35	25	[	[	X
iajs-3030	35	26	7	7	NUM
iajs-3030	35	27	]	]	PUNCT
iajs-3030	35	28	.	.	PUNCT
iajs-3030	36	1	hba1c	hba1c	PROPN
iajs-3030	36	2	is	be	AUX
iajs-3030	36	3	the	the	DET
iajs-3030	36	4	most	most	ADV
iajs-3030	36	5	often	often	ADV
iajs-3030	36	6	used	use	VERB
iajs-3030	36	7	marker	marker	NOUN
iajs-3030	36	8	for	for	ADP
iajs-3030	36	9	the	the	DET
iajs-3030	36	10	diagnosis	diagnosis	NOUN
iajs-3030	36	11	of	of	ADP
iajs-3030	36	12	prediabetes	prediabete	NOUN
iajs-3030	36	13	,	,	PUNCT
iajs-3030	36	14	coupled	couple	VERB
iajs-3030	36	15	with	with	ADP
iajs-3030	36	16	fasting	fast	VERB
iajs-3030	36	17	plasma	plasma	NOUN
iajs-3030	36	18	glucose	glucose	NOUN
iajs-3030	36	19	(	(	PUNCT
iajs-3030	36	20	fpg	fpg	PROPN
iajs-3030	36	21	)	)	PUNCT
iajs-3030	36	22	.	.	PUNCT
iajs-3030	37	1	fpg	fpg	PROPN
iajs-3030	37	2	findings	finding	NOUN
iajs-3030	37	3	may	may	AUX
iajs-3030	37	4	change	change	VERB
iajs-3030	37	5	depending	depend	VERB
iajs-3030	37	6	on	on	ADP
iajs-3030	37	7	food	food	NOUN
iajs-3030	37	8	influences	influence	NOUN
iajs-3030	37	9	and	and	CCONJ
iajs-3030	37	10	fasting	fast	VERB
iajs-3030	37	11	length	length	NOUN
iajs-3030	37	12	.	.	PUNCT
iajs-3030	38	1	the	the	DET
iajs-3030	38	2	oral	oral	ADJ
iajs-3030	38	3	glucose	glucose	NOUN
iajs-3030	38	4	tolerance	tolerance	NOUN
iajs-3030	38	5	test	test	NOUN
iajs-3030	38	6	used	use	VERB
iajs-3030	38	7	to	to	PART
iajs-3030	38	8	diagnose	diagnose	VERB
iajs-3030	38	9	ifg	ifg	NOUN
iajs-3030	38	10	and	and	CCONJ
iajs-3030	38	11	igt	igt	PROPN
iajs-3030	38	12	is	be	AUX
iajs-3030	38	13	difficult	difficult	ADJ
iajs-3030	38	14	for	for	SCONJ
iajs-3030	38	15	patients	patient	NOUN
iajs-3030	38	16	to	to	PART
iajs-3030	38	17	complete	complete	VERB
iajs-3030	38	18	in	in	ADP
iajs-3030	38	19	a	a	DET
iajs-3030	38	20	clinical	clinical	ADJ
iajs-3030	38	21	environment	environment	NOUN
iajs-3030	38	22	since	since	SCONJ
iajs-3030	38	23	it	it	PRON
iajs-3030	38	24	is	be	AUX
iajs-3030	38	25	time	time	NOUN
iajs-3030	38	26	-	-	PUNCT
iajs-3030	38	27	consuming	consume	VERB
iajs-3030	38	28	and	and	CCONJ
iajs-3030	38	29	involves	involve	VERB
iajs-3030	38	30	numerous	numerous	ADJ
iajs-3030	38	31	blood	blood	NOUN
iajs-3030	38	32	samples	sample	NOUN
iajs-3030	38	33	[	[	X
iajs-3030	38	34	8	8	NUM
iajs-3030	38	35	]	]	PUNCT
iajs-3030	38	36	.	.	PUNCT
iajs-3030	39	1	the	the	DET
iajs-3030	39	2	purpose	purpose	NOUN
iajs-3030	39	3	of	of	ADP
iajs-3030	39	4	this	this	DET
iajs-3030	39	5	study	study	NOUN
iajs-3030	39	6	was	be	AUX
iajs-3030	39	7	to	to	PART
iajs-3030	39	8	study	study	VERB
iajs-3030	39	9	the	the	DET
iajs-3030	39	10	role	role	NOUN
iajs-3030	39	11	of	of	ADP
iajs-3030	39	12	fbxw7	fbxw7	NOUN
iajs-3030	39	13	and	and	CCONJ
iajs-3030	39	14	type	type	NOUN
iajs-3030	39	15	1	1	NUM
iajs-3030	39	16	diabetes	diabetes	NOUN
iajs-3030	39	17	and	and	CCONJ
iajs-3030	39	18	to	to	PART
iajs-3030	39	19	compare	compare	VERB
iajs-3030	39	20	the	the	DET
iajs-3030	39	21	newly	newly	ADV
iajs-3030	39	22	diagnosed	diagnose	VERB
iajs-3030	39	23	patients	patient	NOUN
iajs-3030	39	24	that	that	PRON
iajs-3030	39	25	have	have	AUX
iajs-3030	39	26	taken	take	VERB
iajs-3030	39	27	insulin	insulin	NOUN
iajs-3030	39	28	therapy	therapy	NOUN
iajs-3030	39	29	.	.	PUNCT
iajs-3030	40	1	2	2	X
iajs-3030	40	2	.	.	X
iajs-3030	40	3	materials	material	NOUN
iajs-3030	40	4	and	and	CCONJ
iajs-3030	40	5	methods	method	NOUN
iajs-3030	40	6	patients	patient	NOUN
iajs-3030	40	7	a	a	DET
iajs-3030	40	8	case	case	NOUN
iajs-3030	40	9	control	control	NOUN
iajs-3030	40	10	study	study	NOUN
iajs-3030	40	11	was	be	AUX
iajs-3030	40	12	conducted	conduct	VERB
iajs-3030	40	13	in	in	ADP
iajs-3030	40	14	iraq	iraq	PROPN
iajs-3030	40	15	to	to	PART
iajs-3030	40	16	investigate	investigate	VERB
iajs-3030	40	17	fbxw-7	fbxw-7	NUM
iajs-3030	40	18	levels	level	NOUN
iajs-3030	40	19	in	in	ADP
iajs-3030	40	20	individuals	individual	NOUN
iajs-3030	40	21	with	with	ADP
iajs-3030	40	22	type	type	NOUN
iajs-3030	40	23	1	1	NUM
iajs-3030	40	24	diabetes	diabetes	NOUN
iajs-3030	40	25	.	.	PUNCT
iajs-3030	41	1	this	this	DET
iajs-3030	41	2	research	research	NOUN
iajs-3030	41	3	included	include	VERB
iajs-3030	41	4	120	120	NUM
iajs-3030	41	5	participants	participant	NOUN
iajs-3030	41	6	ranging	range	VERB
iajs-3030	41	7	in	in	ADP
iajs-3030	41	8	age	age	NOUN
iajs-3030	41	9	from	from	ADP
iajs-3030	41	10	4	4	NUM
iajs-3030	41	11	to	to	PART
iajs-3030	41	12	17	17	NUM
iajs-3030	41	13	years	year	NOUN
iajs-3030	41	14	.	.	PUNCT
iajs-3030	42	1	they	they	PRON
iajs-3030	42	2	were	be	AUX
iajs-3030	42	3	classified	classify	VERB
iajs-3030	42	4	into	into	ADP
iajs-3030	42	5	three	three	NUM
iajs-3030	42	6	groups	group	NOUN
iajs-3030	42	7	:	:	PUNCT
iajs-3030	42	8	a	a	DET
iajs-3030	42	9	total	total	NOUN
iajs-3030	42	10	of	of	ADP
iajs-3030	42	11	90	90	NUM
iajs-3030	42	12	individuals	individual	NOUN
iajs-3030	42	13	with	with	ADP
iajs-3030	42	14	type	type	NOUN
iajs-3030	42	15	1	1	NUM
iajs-3030	42	16	diabetes	diabetes	NOUN
iajs-3030	42	17	were	be	AUX
iajs-3030	42	18	recruited	recruit	VERB
iajs-3030	42	19	from	from	ADP
iajs-3030	42	20	(	(	PUNCT
iajs-3030	42	21	central	central	ADJ
iajs-3030	42	22	child	child	NOUN
iajs-3030	42	23	hospital	hospital	NOUN
iajs-3030	42	24	,	,	PUNCT
iajs-3030	42	25	alkindi	alkindi	NOUN
iajs-3030	42	26	center	center	VERB
iajs-3030	42	27	for	for	ADP
iajs-3030	42	28	diabetes	diabetes	NOUN
iajs-3030	42	29	and	and	CCONJ
iajs-3030	42	30	endocrinology	endocrinology	NOUN
iajs-3030	42	31	,	,	PUNCT
iajs-3030	42	32	child	child	NOUN
iajs-3030	42	33	protection	protection	NOUN
iajs-3030	42	34	teaching	teaching	NOUN
iajs-3030	42	35	hospital	hospital	NOUN
iajs-3030	42	36	)	)	PUNCT
iajs-3030	42	37	during	during	ADP
iajs-3030	42	38	the	the	DET
iajs-3030	42	39	period	period	NOUN
iajs-3030	42	40	from	from	ADP
iajs-3030	42	41	20	20	NUM
iajs-3030	42	42	december	december	PROPN
iajs-3030	42	43	2021	2021	NUM
iajs-3030	42	44	to	to	ADP
iajs-3030	42	45	25	25	NUM
iajs-3030	42	46	march	march	NOUN
iajs-3030	42	47	2022	2022	NUM
iajs-3030	42	48	.	.	PUNCT
iajs-3030	43	1	these	these	DET
iajs-3030	43	2	patients	patient	NOUN
iajs-3030	43	3	were	be	AUX
iajs-3030	43	4	divided	divide	VERB
iajs-3030	43	5	into	into	ADP
iajs-3030	43	6	two	two	NUM
iajs-3030	43	7	groups	group	NOUN
iajs-3030	43	8	:	:	PUNCT
iajs-3030	43	9	group	group	NOUN
iajs-3030	43	10	1	1	NUM
iajs-3030	43	11	included	include	VERB
iajs-3030	43	12	(	(	PUNCT
iajs-3030	43	13	67	67	NUM
iajs-3030	43	14	)	)	PUNCT
iajs-3030	43	15	individuals	individual	NOUN
iajs-3030	43	16	children	child	NOUN
iajs-3030	43	17	(	(	PUNCT
iajs-3030	43	18	33	33	NUM
iajs-3030	43	19	girls	girl	NOUN
iajs-3030	43	20	,	,	PUNCT
iajs-3030	43	21	34	34	NUM
iajs-3030	43	22	boys	boy	NOUN
iajs-3030	43	23	)	)	PUNCT
iajs-3030	43	24	of	of	ADP
iajs-3030	43	25	t1	t1	PROPN
iajs-3030	43	26	dm	dm	PROPN
iajs-3030	43	27	with	with	ADP
iajs-3030	43	28	insulin	insulin	NOUN
iajs-3030	43	29	injection	injection	NOUN
iajs-3030	43	30	treatment	treatment	NOUN
iajs-3030	43	31	,	,	PUNCT
iajs-3030	43	32	and	and	CCONJ
iajs-3030	43	33	group	group	NOUN
iajs-3030	43	34	2	2	NUM
iajs-3030	43	35	included	include	VERB
iajs-3030	43	36	(	(	PUNCT
iajs-3030	43	37	20	20	NUM
iajs-3030	43	38	)	)	PUNCT
iajs-3030	43	39	child	child	NOUN
iajs-3030	43	40	(	(	PUNCT
iajs-3030	43	41	9	9	NUM
iajs-3030	43	42	girls	girl	NOUN
iajs-3030	43	43	,	,	PUNCT
iajs-3030	43	44	11	11	NUM
iajs-3030	43	45	boys	boy	NOUN
iajs-3030	43	46	)	)	PUNCT
iajs-3030	43	47	individuals	individual	NOUN
iajs-3030	43	48	of	of	ADP
iajs-3030	43	49	newly	newly	ADV
iajs-3030	43	50	diagnosed	diagnose	VERB
iajs-3030	43	51	.	.	PUNCT
iajs-3030	44	1	in	in	ADP
iajs-3030	44	2	addition	addition	NOUN
iajs-3030	44	3	(	(	PUNCT
iajs-3030	44	4	33	33	NUM
iajs-3030	44	5	)	)	PUNCT
iajs-3030	44	6	child	child	NOUN
iajs-3030	44	7	(	(	PUNCT
iajs-3030	44	8	14	14	NUM
iajs-3030	44	9	girls	girl	NOUN
iajs-3030	44	10	,	,	PUNCT
iajs-3030	44	11	19	19	NUM
iajs-3030	44	12	boys	boy	NOUN
iajs-3030	44	13	)	)	PUNCT
iajs-3030	44	14	as	as	ADP
iajs-3030	44	15	a	a	DET
iajs-3030	44	16	control	control	NOUN
iajs-3030	44	17	group	group	NOUN
iajs-3030	44	18	.	.	PUNCT
iajs-3030	45	1	ihjpas	ihjpas	PROPN
iajs-3030	45	2	.	.	PUNCT
iajs-3030	46	1	36	36	NUM
iajs-3030	46	2	(	(	PUNCT
iajs-3030	46	3	3	3	NUM
iajs-3030	46	4	)	)	PUNCT
iajs-3030	46	5	2023	2023	NUM
iajs-3030	46	6	169	169	NUM
iajs-3030	46	7	blood	blood	NOUN
iajs-3030	46	8	sample	sample	NOUN
iajs-3030	46	9	collection	collection	NOUN
iajs-3030	46	10	the	the	DET
iajs-3030	46	11	blood	blood	NOUN
iajs-3030	46	12	sample	sample	NOUN
iajs-3030	46	13	was	be	AUX
iajs-3030	46	14	taken	take	VERB
iajs-3030	46	15	following	follow	VERB
iajs-3030	46	16	an	an	DET
iajs-3030	46	17	overnight	overnight	ADJ
iajs-3030	46	18	fast	fast	NOUN
iajs-3030	46	19	.	.	PUNCT
iajs-3030	47	1	5	5	NUM
iajs-3030	47	2	ml	ml	NOUN
iajs-3030	47	3	of	of	ADP
iajs-3030	47	4	blood	blood	NOUN
iajs-3030	47	5	was	be	AUX
iajs-3030	47	6	taken	take	VERB
iajs-3030	47	7	from	from	ADP
iajs-3030	47	8	every	every	DET
iajs-3030	47	9	patients	patient	NOUN
iajs-3030	47	10	and	and	CCONJ
iajs-3030	47	11	control	control	VERB
iajs-3030	47	12	through	through	ADP
iajs-3030	47	13	venipuncture	venipuncture	NOUN
iajs-3030	47	14	using	use	VERB
iajs-3030	47	15	a	a	DET
iajs-3030	47	16	10	10	NUM
iajs-3030	47	17	ml	ml	NOUN
iajs-3030	47	18	syringe	syringe	NOUN
iajs-3030	47	19	.	.	PUNCT
iajs-3030	48	1	two	two	NUM
iajs-3030	48	2	milliliters	milliliter	NOUN
iajs-3030	48	3	of	of	ADP
iajs-3030	48	4	blood	blood	NOUN
iajs-3030	48	5	were	be	AUX
iajs-3030	48	6	discharged	discharge	VERB
iajs-3030	48	7	into	into	ADP
iajs-3030	48	8	a	a	DET
iajs-3030	48	9	tube	tube	NOUN
iajs-3030	48	10	containing	contain	VERB
iajs-3030	48	11	ethylene	ethylene	NOUN
iajs-3030	48	12	diamine	diamine	NOUN
iajs-3030	48	13	tetracetic	tetracetic	ADJ
iajs-3030	48	14	acid	acid	PROPN
iajs-3030	48	15	(	(	PUNCT
iajs-3030	48	16	edta	edta	NOUN
iajs-3030	48	17	)	)	PUNCT
iajs-3030	48	18	,	,	PUNCT
iajs-3030	48	19	and	and	CCONJ
iajs-3030	48	20	this	this	DET
iajs-3030	48	21	blood	blood	NOUN
iajs-3030	48	22	was	be	AUX
iajs-3030	48	23	used	use	VERB
iajs-3030	48	24	to	to	PART
iajs-3030	48	25	calculate	calculate	VERB
iajs-3030	48	26	hba1c	hba1c	PROPN
iajs-3030	48	27	.	.	PUNCT
iajs-3030	49	1	serum	serum	PROPN
iajs-3030	49	2	was	be	AUX
iajs-3030	49	3	used	use	VERB
iajs-3030	49	4	to	to	PART
iajs-3030	49	5	calculate	calculate	VERB
iajs-3030	49	6	fasting	fast	VERB
iajs-3030	49	7	blood	blood	NOUN
iajs-3030	49	8	glucose	glucose	NOUN
iajs-3030	49	9	(	(	PUNCT
iajs-3030	49	10	fbg),glutamic	fbg),glutamic	ADJ
iajs-3030	49	11	oxaloacetate	oxaloacetate	NOUN
iajs-3030	49	12	transaminase	transaminase	NOUN
iajs-3030	49	13	(	(	PUNCT
iajs-3030	49	14	got	got	NOUN
iajs-3030	49	15	)	)	PUNCT
iajs-3030	49	16	,	,	PUNCT
iajs-3030	49	17	glutamic	glutamic	ADJ
iajs-3030	49	18	pyruvic	pyruvic	ADJ
iajs-3030	49	19	transaminase	transaminase	NOUN
iajs-3030	49	20	(	(	PUNCT
iajs-3030	49	21	gpt	gpt	NOUN
iajs-3030	49	22	)	)	PUNCT
iajs-3030	49	23	,	,	PUNCT
iajs-3030	49	24	cholesterol	cholesterol	NOUN
iajs-3030	49	25	,	,	PUNCT
iajs-3030	49	26	triglyceride	triglyceride	INTJ
iajs-3030	49	27	,	,	PUNCT
iajs-3030	49	28	oxidant	oxidant	ADJ
iajs-3030	49	29	status	status	NOUN
iajs-3030	49	30	,	,	PUNCT
iajs-3030	49	31	antioxidant	antioxidant	ADJ
iajs-3030	49	32	oxidant	oxidant	ADJ
iajs-3030	49	33	status	status	NOUN
iajs-3030	49	34	,	,	PUNCT
iajs-3030	49	35	oxidative	oxidative	ADJ
iajs-3030	49	36	stress	stress	NOUN
iajs-3030	49	37	index	index	NOUN
iajs-3030	49	38	,	,	PUNCT
iajs-3030	49	39	high	high	ADJ
iajs-3030	49	40	density	density	NOUN
iajs-3030	49	41	lipoprotein	lipoprotein	ADJ
iajs-3030	49	42	(	(	PUNCT
iajs-3030	49	43	hdl	hdl	NOUN
iajs-3030	49	44	)	)	PUNCT
iajs-3030	49	45	,	,	PUNCT
iajs-3030	49	46	low	low	ADJ
iajs-3030	49	47	density	density	NOUN
iajs-3030	49	48	lipoprotein	lipoprotein	ADJ
iajs-3030	49	49	(	(	PUNCT
iajs-3030	49	50	ldl	ldl	NOUN
iajs-3030	49	51	)	)	PUNCT
iajs-3030	49	52	,	,	PUNCT
iajs-3030	49	53	very	very	ADV
iajs-3030	49	54	low	low	ADJ
iajs-3030	49	55	density	density	NOUN
iajs-3030	49	56	lipoprotein	lipoprotein	ADJ
iajs-3030	49	57	(	(	PUNCT
iajs-3030	49	58	vldl	vldl	NOUN
iajs-3030	49	59	)	)	PUNCT
iajs-3030	49	60	and	and	CCONJ
iajs-3030	49	61	fbox	fbox	NOUN
iajs-3030	49	62	and	and	CCONJ
iajs-3030	49	63	wd	wd	PROPN
iajs-3030	49	64	repeat	repeat	NOUN
iajs-3030	49	65	domain	domain	NOUN
iajs-3030	49	66	containing	contain	VERB
iajs-3030	49	67	7	7	NUM
iajs-3030	49	68	(	(	PUNCT
iajs-3030	49	69	fbxw7	fbxw7	PROPN
iajs-3030	49	70	)	)	PUNCT
iajs-3030	49	71	(	(	PUNCT
iajs-3030	49	72	fbxw-7	fbxw-7	NUM
iajs-3030	49	73	protein	protein	NOUN
iajs-3030	49	74	)	)	PUNCT
iajs-3030	49	75	.	.	PUNCT
iajs-3030	50	1	determination	determination	NOUN
iajs-3030	50	2	of	of	ADP
iajs-3030	50	3	diabetic‐related	diabetic‐related	ADJ
iajs-3030	50	4	parameters	parameter	NOUN
iajs-3030	50	5	all	all	PRON
iajs-3030	50	6	of	of	ADP
iajs-3030	50	7	serum	serum	NOUN
iajs-3030	50	8	glucose	glucose	NOUN
iajs-3030	50	9	,	,	PUNCT
iajs-3030	50	10	cholesterol	cholesterol	NOUN
iajs-3030	50	11	,	,	PUNCT
iajs-3030	50	12	triglyceride	triglyceride	ADJ
iajs-3030	50	13	,	,	PUNCT
iajs-3030	50	14	and	and	CCONJ
iajs-3030	50	15	hdl	hdl	PROPN
iajs-3030	50	16	were	be	AUX
iajs-3030	50	17	measured	measure	VERB
iajs-3030	50	18	using	use	VERB
iajs-3030	50	19	a	a	DET
iajs-3030	50	20	total	total	ADJ
iajs-3030	50	21	enzymatic	enzymatic	ADJ
iajs-3030	50	22	colorimetric	colorimetric	ADJ
iajs-3030	50	23	technique	technique	NOUN
iajs-3030	50	24	from	from	ADP
iajs-3030	50	25	a	a	DET
iajs-3030	50	26	kit	kit	NOUN
iajs-3030	50	27	supplied	supply	VERB
iajs-3030	50	28	by	by	ADP
iajs-3030	50	29	linear	linear	PROPN
iajs-3030	50	30	chemicals	chemical	NOUN
iajs-3030	50	31	,	,	PUNCT
iajs-3030	50	32	barcelona	barcelona	PROPN
iajs-3030	50	33	,	,	PUNCT
iajs-3030	50	34	spain	spain	PROPN
iajs-3030	50	35	.	.	PUNCT
iajs-3030	51	1	hba1c	hba1c	PROPN
iajs-3030	51	2	was	be	AUX
iajs-3030	51	3	measured	measure	VERB
iajs-3030	51	4	using	use	VERB
iajs-3030	51	5	a	a	DET
iajs-3030	51	6	kit	kit	NOUN
iajs-3030	51	7	supplied	supply	VERB
iajs-3030	51	8	from	from	ADP
iajs-3030	51	9	a	a	DET
iajs-3030	51	10	randox	randox	NOUN
iajs-3030	51	11	in	in	ADP
iajs-3030	51	12	the	the	DET
iajs-3030	51	13	united	united	ADJ
iajs-3030	51	14	kingdom	kingdom	PROPN
iajs-3030	51	15	and	and	CCONJ
iajs-3030	51	16	the	the	DET
iajs-3030	51	17	rx	rx	ADJ
iajs-3030	51	18	daytona+	daytona+	X
iajs-3030	51	19	clinical	clinical	ADJ
iajs-3030	51	20	chemistry	chemistry	NOUN
iajs-3030	51	21	analyzer	analyzer	NOUN
iajs-3030	51	22	programmer	programmer	NOUN
iajs-3030	51	23	;	;	PUNCT
iajs-3030	51	24	this	this	DET
iajs-3030	51	25	test	test	NOUN
iajs-3030	51	26	is	be	AUX
iajs-3030	51	27	based	base	VERB
iajs-3030	51	28	on	on	ADP
iajs-3030	51	29	latex	latex	PROPN
iajs-3030	51	30	immunoagglutination	immunoagglutination	PROPN
iajs-3030	51	31	.	.	PUNCT
iajs-3030	52	1	gpt	gpt	PROPN
iajs-3030	52	2	was	be	AUX
iajs-3030	52	3	performed	perform	VERB
iajs-3030	52	4	out	out	ADP
iajs-3030	52	5	with	with	ADP
iajs-3030	52	6	the	the	DET
iajs-3030	52	7	use	use	NOUN
iajs-3030	52	8	of	of	ADP
iajs-3030	52	9	a	a	DET
iajs-3030	52	10	kit	kit	NOUN
iajs-3030	52	11	given	give	VERB
iajs-3030	52	12	by	by	ADP
iajs-3030	52	13	genway	genway	NOUN
iajs-3030	52	14	biotech	biotech	NOUN
iajs-3030	52	15	in	in	ADP
iajs-3030	52	16	the	the	DET
iajs-3030	52	17	united	united	PROPN
iajs-3030	52	18	states	states	PROPN
iajs-3030	52	19	.	.	PUNCT
iajs-3030	53	1	got	get	VERB
iajs-3030	53	2	was	be	AUX
iajs-3030	53	3	performed	perform	VERB
iajs-3030	53	4	out	out	ADP
iajs-3030	53	5	using	use	VERB
iajs-3030	53	6	a	a	DET
iajs-3030	53	7	kit	kit	NOUN
iajs-3030	53	8	provided	provide	VERB
iajs-3030	53	9	by	by	ADP
iajs-3030	53	10	sigma	sigma	PROPN
iajs-3030	53	11	-	-	PUNCT
iajs-3030	53	12	aldrich	aldrich	PROPN
iajs-3030	53	13	in	in	ADP
iajs-3030	53	14	the	the	DET
iajs-3030	53	15	united	united	PROPN
iajs-3030	53	16	states	states	PROPN
iajs-3030	53	17	.	.	PUNCT
iajs-3030	54	1	ldl	ldl	NOUN
iajs-3030	54	2	is	be	AUX
iajs-3030	54	3	calculated	calculate	VERB
iajs-3030	54	4	using	use	VERB
iajs-3030	54	5	the	the	DET
iajs-3030	54	6	equation	equation	NOUN
iajs-3030	54	7	ldl	ldl	NOUN
iajs-3030	54	8	-	-	PUNCT
iajs-3030	54	9	c	c	NOUN
iajs-3030	54	10	=	=	NOUN
iajs-3030	54	11	cholesterol	cholesterol	NOUN
iajs-3030	54	12	(	(	PUNCT
iajs-3030	54	13	tg/5	tg/5	ADJ
iajs-3030	54	14	)	)	PUNCT
iajs-3030	54	15	hdl	hdl	PROPN
iajs-3030	54	16	-	-	PUNCT
iajs-3030	54	17	c	c	PROPN
iajs-3030	54	18	,	,	PUNCT
iajs-3030	54	19	vldl	vldl	PROPN
iajs-3030	54	20	is	be	AUX
iajs-3030	54	21	also	also	ADV
iajs-3030	54	22	is	be	AUX
iajs-3030	54	23	calculated	calculate	VERB
iajs-3030	54	24	using	use	VERB
iajs-3030	54	25	the	the	DET
iajs-3030	54	26	equation	equation	NOUN
iajs-3030	54	27	vldl	vldl	NOUN
iajs-3030	55	1	-	-	PUNCT
iajs-3030	55	2	c	c	NOUN
iajs-3030	56	1	=	=	SYM
iajs-3030	56	2	tg	tg	PROPN
iajs-3030	56	3	/	/	SYM
iajs-3030	56	4	5	5	NUM
iajs-3030	56	5	.	.	PUNCT
iajs-3030	56	6	tas	ta	NOUN
iajs-3030	56	7	and	and	CCONJ
iajs-3030	56	8	total	total	ADJ
iajs-3030	56	9	oxidants	oxidant	NOUN
iajs-3030	56	10	status	status	NOUN
iajs-3030	56	11	was	be	AUX
iajs-3030	56	12	determined	determine	VERB
iajs-3030	56	13	by	by	ADP
iajs-3030	56	14	measuring	measure	VERB
iajs-3030	56	15	absorbance	absorbance	NOUN
iajs-3030	56	16	using	use	VERB
iajs-3030	56	17	a	a	DET
iajs-3030	56	18	spectrophotometer	spectrophotometer	NOUN
iajs-3030	56	19	instrument	instrument	NOUN
iajs-3030	56	20	,	,	PUNCT
iajs-3030	56	21	while	while	SCONJ
iajs-3030	56	22	osi	osi	PROPN
iajs-3030	56	23	was	be	AUX
iajs-3030	56	24	computed	compute	VERB
iajs-3030	56	25	using	use	VERB
iajs-3030	56	26	the	the	DET
iajs-3030	56	27	equation	equation	NOUN
iajs-3030	56	28	osi	osi	NOUN
iajs-3030	56	29	=	=	SYM
iajs-3030	56	30	tos	tos	PROPN
iajs-3030	56	31	(	(	PUNCT
iajs-3030	56	32	mmol	mmol	NOUN
iajs-3030	56	33	h2o2	h2o2	NOUN
iajs-3030	56	34	/	/	SYM
iajs-3030	56	35	l	l	NOUN
iajs-3030	56	36	/	/	SYM
iajs-3030	56	37	tas	tas	NOUN
iajs-3030	56	38	mmol	mmol	NOUN
iajs-3030	56	39	vit.c	vit.c	PROPN
iajs-3030	56	40	/	/	SYM
iajs-3030	56	41	l	l	NOUN
iajs-3030	56	42	)	)	PUNCT
iajs-3030	56	43	.	.	PUNCT
iajs-3030	57	1	estimation	estimation	NOUN
iajs-3030	57	2	of	of	ADP
iajs-3030	57	3	fbxw-7	fbxw-7	NUM
iajs-3030	57	4	protein	protein	NOUN
iajs-3030	57	5	protein	protein	NOUN
iajs-3030	57	6	was	be	AUX
iajs-3030	57	7	measured	measure	VERB
iajs-3030	57	8	using	use	VERB
iajs-3030	57	9	sandwich	sandwich	NOUN
iajs-3030	57	10	enzyme	enzyme	NOUN
iajs-3030	57	11	immunoassay	immunoassay	ADJ
iajs-3030	57	12	method	method	NOUN
iajs-3030	57	13	and	and	CCONJ
iajs-3030	57	14	a	a	DET
iajs-3030	57	15	kit	kit	NOUN
iajs-3030	57	16	provided	provide	VERB
iajs-3030	57	17	by	by	ADP
iajs-3030	57	18	biosource	biosource	NOUN
iajs-3030	57	19	,	,	PUNCT
iajs-3030	57	20	usa	usa	PROPN
iajs-3030	57	21	.	.	PUNCT
iajs-3030	58	1	the	the	DET
iajs-3030	58	2	samples	sample	NOUN
iajs-3030	58	3	were	be	AUX
iajs-3030	58	4	placed	place	VERB
iajs-3030	58	5	in	in	ADP
iajs-3030	58	6	the	the	DET
iajs-3030	58	7	wells	well	NOUN
iajs-3030	58	8	for	for	ADP
iajs-3030	58	9	one	one	NUM
iajs-3030	58	10	hour	hour	NOUN
iajs-3030	58	11	,	,	PUNCT
iajs-3030	58	12	and	and	CCONJ
iajs-3030	58	13	then	then	ADV
iajs-3030	58	14	washed	wash	VERB
iajs-3030	58	15	three	three	NUM
iajs-3030	58	16	and	and	CCONJ
iajs-3030	58	17	a	a	DET
iajs-3030	58	18	half	half	NOUN
iajs-3030	58	19	times	time	NOUN
iajs-3030	58	20	.	.	PUNCT
iajs-3030	59	1	the	the	DET
iajs-3030	59	2	(	(	PUNCT
iajs-3030	59	3	hrp	hrp	PROPN
iajs-3030	59	4	enzyme	enzyme	NOUN
iajs-3030	59	5	)	)	PUNCT
iajs-3030	59	6	conjugated	conjugate	VERB
iajs-3030	59	7	was	be	AUX
iajs-3030	59	8	added	add	VERB
iajs-3030	59	9	to	to	ADP
iajs-3030	59	10	the	the	DET
iajs-3030	59	11	washed	wash	VERB
iajs-3030	59	12	well	well	ADV
iajs-3030	59	13	and	and	CCONJ
iajs-3030	59	14	waited	wait	VERB
iajs-3030	59	15	for	for	ADP
iajs-3030	59	16	half	half	DET
iajs-3030	59	17	an	an	DET
iajs-3030	59	18	hour	hour	NOUN
iajs-3030	59	19	,	,	PUNCT
iajs-3030	59	20	then	then	ADV
iajs-3030	59	21	washed	wash	VERB
iajs-3030	59	22	three	three	NUM
iajs-3030	59	23	and	and	CCONJ
iajs-3030	59	24	a	a	DET
iajs-3030	59	25	half	half	NOUN
iajs-3030	59	26	times	time	NOUN
iajs-3030	59	27	.	.	PUNCT
iajs-3030	60	1	the	the	DET
iajs-3030	60	2	tmb	tmb	PROPN
iajs-3030	60	3	was	be	AUX
iajs-3030	60	4	introduced	introduce	VERB
iajs-3030	60	5	,	,	PUNCT
iajs-3030	60	6	and	and	CCONJ
iajs-3030	60	7	the	the	DET
iajs-3030	60	8	color	color	NOUN
iajs-3030	60	9	was	be	AUX
iajs-3030	60	10	created	create	VERB
iajs-3030	60	11	as	as	ADP
iajs-3030	60	12	a	a	DET
iajs-3030	60	13	result	result	NOUN
iajs-3030	60	14	of	of	ADP
iajs-3030	60	15	the	the	DET
iajs-3030	60	16	reaction	reaction	NOUN
iajs-3030	60	17	.	.	PUNCT
iajs-3030	61	1	stop	stop	VERB
iajs-3030	61	2	solution	solution	NOUN
iajs-3030	61	3	was	be	AUX
iajs-3030	61	4	added	add	VERB
iajs-3030	61	5	to	to	ADP
iajs-3030	61	6	the	the	DET
iajs-3030	61	7	mixture	mixture	NOUN
iajs-3030	61	8	,	,	PUNCT
iajs-3030	61	9	causing	cause	VERB
iajs-3030	61	10	the	the	DET
iajs-3030	61	11	color	color	NOUN
iajs-3030	61	12	change	change	NOUN
iajs-3030	61	13	to	to	PART
iajs-3030	61	14	yellow	yellow	VERB
iajs-3030	61	15	and	and	CCONJ
iajs-3030	61	16	being	be	AUX
iajs-3030	61	17	measured	measure	VERB
iajs-3030	61	18	at	at	ADP
iajs-3030	61	19	450	450	NUM
iajs-3030	61	20	nm	nm	NOUN
iajs-3030	61	21	with	with	ADP
iajs-3030	61	22	a	a	DET
iajs-3030	61	23	human	human	ADJ
iajs-3030	61	24	readerhs	readerhs	ADJ
iajs-3030	61	25	.	.	PUNCT
iajs-3030	62	1	statistical	statistical	ADJ
iajs-3030	62	2	analysis	analysis	NOUN
iajs-3030	62	3	the	the	DET
iajs-3030	62	4	findings	finding	NOUN
iajs-3030	62	5	were	be	AUX
iajs-3030	62	6	analyzed	analyze	VERB
iajs-3030	62	7	using	use	VERB
iajs-3030	62	8	a	a	DET
iajs-3030	62	9	statistical	statistical	ADJ
iajs-3030	62	10	analysis	analysis	NOUN
iajs-3030	62	11	tool	tool	NOUN
iajs-3030	62	12	(	(	PUNCT
iajs-3030	62	13	spss	spss	PROPN
iajs-3030	62	14	25	25	NUM
iajs-3030	62	15	)	)	PUNCT
iajs-3030	62	16	.	.	PUNCT
iajs-3030	63	1	to	to	PART
iajs-3030	63	2	explain	explain	VERB
iajs-3030	63	3	the	the	DET
iajs-3030	63	4	major	major	ADJ
iajs-3030	63	5	findings	finding	NOUN
iajs-3030	63	6	,	,	PUNCT
iajs-3030	63	7	the	the	DET
iajs-3030	63	8	general	general	ADJ
iajs-3030	63	9	descriptive	descriptive	ADJ
iajs-3030	63	10	statistic	statistic	NOUN
iajs-3030	63	11	was	be	AUX
iajs-3030	63	12	utilized	utilize	VERB
iajs-3030	63	13	,	,	PUNCT
iajs-3030	63	14	and	and	CCONJ
iajs-3030	63	15	the	the	DET
iajs-3030	63	16	one	one	NUM
iajs-3030	63	17	-	-	PUNCT
iajs-3030	63	18	way	way	NOUN
iajs-3030	63	19	analysis	analysis	NOUN
iajs-3030	63	20	of	of	ADP
iajs-3030	63	21	variance	variance	NOUN
iajs-3030	63	22	test	test	NOUN
iajs-3030	63	23	was	be	AUX
iajs-3030	63	24	performed	perform	VERB
iajs-3030	63	25	to	to	PART
iajs-3030	63	26	compare	compare	VERB
iajs-3030	63	27	groups	group	NOUN
iajs-3030	63	28	.	.	PUNCT
iajs-3030	64	1	results	result	NOUN
iajs-3030	64	2	were	be	AUX
iajs-3030	64	3	expressed	express	VERB
iajs-3030	64	4	as	as	ADP
iajs-3030	64	5	mean±sd	mean±sd	ADP
iajs-3030	64	6	spearman	spearman	NOUN
iajs-3030	64	7	correlation	correlation	NOUN
iajs-3030	64	8	was	be	AUX
iajs-3030	64	9	used	use	VERB
iajs-3030	64	10	to	to	PART
iajs-3030	64	11	perform	perform	VERB
iajs-3030	64	12	the	the	DET
iajs-3030	64	13	correlation	correlation	NOUN
iajs-3030	64	14	.	.	PUNCT
iajs-3030	65	1	receiver	receiver	ADJ
iajs-3030	65	2	operating	operate	VERB
iajs-3030	65	3	characteristic	characteristic	ADJ
iajs-3030	65	4	curve	curve	NOUN
iajs-3030	65	5	(	(	PUNCT
iajs-3030	65	6	roc	roc	PROPN
iajs-3030	65	7	)	)	PUNCT
iajs-3030	65	8	analysis	analysis	NOUN
iajs-3030	65	9	were	be	AUX
iajs-3030	65	10	also	also	ADV
iajs-3030	65	11	utilized	utilize	VERB
iajs-3030	65	12	to	to	PART
iajs-3030	65	13	determine	determine	VERB
iajs-3030	65	14	the	the	DET
iajs-3030	65	15	cutoff	cutoff	NOUN
iajs-3030	65	16	value	value	NOUN
iajs-3030	65	17	for	for	ADP
iajs-3030	65	18	the	the	DET
iajs-3030	65	19	parameters	parameter	NOUN
iajs-3030	65	20	.	.	PUNCT
iajs-3030	66	1	3.results	3.results	NUM
iajs-3030	66	2	and	and	CCONJ
iajs-3030	66	3	discussion	discussion	NOUN
iajs-3030	66	4	statistical	statistical	ADJ
iajs-3030	66	5	distribution	distribution	NOUN
iajs-3030	66	6	of	of	ADP
iajs-3030	66	7	studied	study	VERB
iajs-3030	66	8	groups	group	NOUN
iajs-3030	66	9	was	be	AUX
iajs-3030	66	10	presented	present	VERB
iajs-3030	66	11	in	in	ADP
iajs-3030	66	12	figure	figure	NOUN
iajs-3030	66	13	1	1	NUM
iajs-3030	66	14	,	,	PUNCT
iajs-3030	66	15	as	as	SCONJ
iajs-3030	66	16	shown	show	VERB
iajs-3030	66	17	the	the	DET
iajs-3030	66	18	three	three	NUM
iajs-3030	66	19	groups	group	NOUN
iajs-3030	66	20	were	be	AUX
iajs-3030	66	21	:	:	PUNCT
iajs-3030	66	22	g1	g1	PROPN
iajs-3030	66	23	(	(	PUNCT
iajs-3030	66	24	control	control	NOUN
iajs-3030	66	25	)	)	PUNCT
iajs-3030	66	26	,	,	PUNCT
iajs-3030	66	27	g2	g2	PROPN
iajs-3030	66	28	(	(	PUNCT
iajs-3030	66	29	dm	dm	PROPN
iajs-3030	66	30	without	without	ADP
iajs-3030	66	31	treatment	treatment	NOUN
iajs-3030	66	32	)	)	PUNCT
iajs-3030	66	33	and	and	CCONJ
iajs-3030	66	34	g3	g3	PROPN
iajs-3030	66	35	(	(	PUNCT
iajs-3030	66	36	dm	dm	PROPN
iajs-3030	66	37	with	with	ADP
iajs-3030	66	38	treatment	treatment	NOUN
iajs-3030	66	39	)	)	PUNCT
iajs-3030	66	40	,	,	PUNCT
iajs-3030	66	41	those	those	DET
iajs-3030	66	42	groups	group	NOUN
iajs-3030	66	43	were	be	AUX
iajs-3030	66	44	subdivided	subdivide	VERB
iajs-3030	66	45	according	accord	VERB
iajs-3030	66	46	to	to	ADP
iajs-3030	66	47	gender	gender	NOUN
iajs-3030	66	48	.	.	PUNCT
iajs-3030	67	1	ihjpas	ihjpas	PROPN
iajs-3030	67	2	.	.	PUNCT
iajs-3030	68	1	36	36	NUM
iajs-3030	68	2	(	(	PUNCT
iajs-3030	68	3	3	3	NUM
iajs-3030	68	4	)	)	PUNCT
iajs-3030	68	5	2023	2023	NUM
iajs-3030	68	6	170	170	NUM
iajs-3030	68	7	figure1	figure1	X
iajs-3030	68	8	.	.	PUNCT
iajs-3030	69	1	groups	group	NOUN
iajs-3030	69	2	distribution	distribution	NOUN
iajs-3030	69	3	in	in	ADP
iajs-3030	69	4	the	the	DET
iajs-3030	69	5	studied	studied	ADJ
iajs-3030	69	6	population	population	NOUN
iajs-3030	69	7	anthropometric	anthropometric	ADJ
iajs-3030	69	8	characteristics	characteristic	NOUN
iajs-3030	69	9	were	be	AUX
iajs-3030	69	10	measured	measure	VERB
iajs-3030	69	11	it	it	PRON
iajs-3030	69	12	was	be	AUX
iajs-3030	69	13	illustrated	illustrate	VERB
iajs-3030	69	14	in	in	ADP
iajs-3030	69	15	table	table	NOUN
iajs-3030	69	16	1	1	NUM
iajs-3030	69	17	.	.	PUNCT
iajs-3030	69	18	table	table	NOUN
iajs-3030	69	19	1	1	NUM
iajs-3030	69	20	.	.	PUNCT
iajs-3030	69	21	demographic	demographic	ADJ
iajs-3030	69	22	factor	factor	NOUN
iajs-3030	69	23	distribution	distribution	NOUN
iajs-3030	69	24	in	in	ADP
iajs-3030	69	25	studied	study	VERB
iajs-3030	69	26	groups	group	NOUN
iajs-3030	69	27	parameters	parameter	NOUN
iajs-3030	69	28	mean±	mean±	PROPN
iajs-3030	69	29	se	se	PROPN
iajs-3030	70	1	p	p	PROPN
iajs-3030	70	2	-	-	PUNCT
iajs-3030	70	3	valu	valu	NOUN
iajs-3030	70	4	age	age	NOUN
iajs-3030	70	5	g1	g1	NOUN
iajs-3030	70	6	9.9667±0.578	9.9667±0.578	NUM
iajs-3030	70	7	0.006	0.006	NUM
iajs-3030	70	8	g2	g2	PROPN
iajs-3030	70	9	9.35±0.703c	9.35±0.703c	PROPN
iajs-3030	70	10	g3	g3	PROPN
iajs-3030	70	11	11.53±0.354b	11.53±0.354b	PROPN
iajs-3030	70	12	,	,	PUNCT
iajs-3030	70	13	c	c	PROPN
iajs-3030	70	14	bmi	bmi	PROPN
iajs-3030	70	15	g1	g1	VERB
iajs-3030	70	16	16.51±0.530	16.51±0.530	PROPN
iajs-3030	70	17	0.002	0.002	NUM
iajs-3030	70	18	g2	g2	PROPN
iajs-3030	70	19	16.36±0.715c	16.36±0.715c	NUM
iajs-3030	70	20	g3	g3	PROPN
iajs-3030	70	21	18.37±0.325b	18.37±0.325b	NUM
iajs-3030	70	22	,	,	PUNCT
iajs-3030	70	23	c	c	PROPN
iajs-3030	70	24	the	the	DET
iajs-3030	70	25	mean	mean	ADJ
iajs-3030	70	26	difference	difference	NOUN
iajs-3030	70	27	is	be	AUX
iajs-3030	70	28	significant	significant	ADJ
iajs-3030	70	29	at	at	ADP
iajs-3030	70	30	the	the	DET
iajs-3030	70	31	0.05	0.05	NUM
iajs-3030	70	32	level	level	NOUN
iajs-3030	70	33	have	have	AUX
iajs-3030	70	34	been	be	AUX
iajs-3030	70	35	identified	identify	VERB
iajs-3030	70	36	using	use	VERB
iajs-3030	70	37	anova	anova	PROPN
iajs-3030	70	38	test	test	NOUN
iajs-3030	70	39	.	.	PUNCT
iajs-3030	71	1	a	a	DET
iajs-3030	71	2	:	:	PUNCT
iajs-3030	71	3	significant	significant	ADJ
iajs-3030	71	4	difference	difference	NOUN
iajs-3030	71	5	between	between	ADP
iajs-3030	71	6	g1	g1	PROPN
iajs-3030	71	7	(	(	PUNCT
iajs-3030	71	8	control	control	NOUN
iajs-3030	71	9	)	)	PUNCT
iajs-3030	71	10	and	and	CCONJ
iajs-3030	71	11	g2	g2	PROPN
iajs-3030	71	12	(	(	PUNCT
iajs-3030	71	13	dm	dm	PROPN
iajs-3030	71	14	without	without	ADP
iajs-3030	71	15	treatment	treatment	NOUN
iajs-3030	71	16	)	)	PUNCT
iajs-3030	71	17	b	b	NOUN
iajs-3030	71	18	:	:	PUNCT
iajs-3030	71	19	significant	significant	ADJ
iajs-3030	71	20	difference	difference	NOUN
iajs-3030	71	21	between	between	ADP
iajs-3030	71	22	control	control	NOUN
iajs-3030	71	23	g1	g1	PROPN
iajs-3030	71	24	(	(	PUNCT
iajs-3030	71	25	control	control	NOUN
iajs-3030	71	26	)	)	PUNCT
iajs-3030	71	27	and	and	CCONJ
iajs-3030	71	28	g3	g3	PROPN
iajs-3030	71	29	(	(	PUNCT
iajs-3030	71	30	dm	dm	NOUN
iajs-3030	71	31	with	with	ADP
iajs-3030	71	32	treatment	treatment	NOUN
iajs-3030	71	33	)	)	PUNCT
iajs-3030	71	34	c	c	NOUN
iajs-3030	71	35	:	:	PUNCT
iajs-3030	71	36	significant	significant	ADJ
iajs-3030	71	37	difference	difference	NOUN
iajs-3030	71	38	between	between	ADP
iajs-3030	71	39	g2	g2	PROPN
iajs-3030	71	40	(	(	PUNCT
iajs-3030	71	41	dm	dm	PROPN
iajs-3030	71	42	without	without	ADP
iajs-3030	71	43	treatment	treatment	NOUN
iajs-3030	71	44	)	)	PUNCT
iajs-3030	71	45	and	and	CCONJ
iajs-3030	71	46	g3	g3	PROPN
iajs-3030	71	47	9	9	NUM
iajs-3030	71	48	dm	dm	NOUN
iajs-3030	71	49	with	with	ADP
iajs-3030	71	50	treatment	treatment	NOUN
iajs-3030	71	51	)	)	PUNCT
iajs-3030	71	52	age	age	NOUN
iajs-3030	71	53	and	and	CCONJ
iajs-3030	71	54	bmi	bmi	NOUN
iajs-3030	71	55	showed	show	VERB
iajs-3030	71	56	a	a	DET
iajs-3030	71	57	significant	significant	ADJ
iajs-3030	71	58	increase	increase	NOUN
iajs-3030	71	59	in	in	ADP
iajs-3030	71	60	dm	dm	PROPN
iajs-3030	71	61	patients	patient	NOUN
iajs-3030	71	62	who	who	PRON
iajs-3030	71	63	are	be	AUX
iajs-3030	71	64	under	under	ADP
iajs-3030	71	65	treatment	treatment	NOUN
iajs-3030	71	66	g2	g2	PROPN
iajs-3030	71	67	compared	compare	VERB
iajs-3030	71	68	to	to	PART
iajs-3030	71	69	control	control	VERB
iajs-3030	71	70	subjects	subject	NOUN
iajs-3030	71	71	g1	g1	NOUN
iajs-3030	71	72	,	,	PUNCT
iajs-3030	71	73	also	also	ADV
iajs-3030	71	74	significant	significant	ADJ
iajs-3030	71	75	increments	increment	NOUN
iajs-3030	71	76	were	be	AUX
iajs-3030	71	77	observed	observe	VERB
iajs-3030	71	78	when	when	SCONJ
iajs-3030	71	79	comparing	compare	VERB
iajs-3030	71	80	the	the	DET
iajs-3030	71	81	treatment	treatment	NOUN
iajs-3030	71	82	group	group	NOUN
iajs-3030	71	83	g3	g3	PROPN
iajs-3030	71	84	to	to	ADP
iajs-3030	71	85	the	the	DET
iajs-3030	71	86	new	new	ADJ
iajs-3030	71	87	diagnostic	diagnostic	ADJ
iajs-3030	71	88	group	group	NOUN
iajs-3030	71	89	g2	g2	PROPN
iajs-3030	71	90	.	.	PUNCT
iajs-3030	72	1	(	(	PUNCT
iajs-3030	72	2	k.	k.	PROPN
iajs-3030	72	3	o.	o.	PROPN
iajs-3030	72	4	kyvik	kyvik	PROPN
iajs-3030	72	5	,	,	PUNCT
iajs-3030	72	6	2004	2004	NUM
iajs-3030	72	7	)	)	PUNCT
iajs-3030	72	8	pointed	point	VERB
iajs-3030	72	9	in	in	ADP
iajs-3030	72	10	there	there	ADV
iajs-3030	72	11	studied	study	VERB
iajs-3030	72	12	that	that	DET
iajs-3030	72	13	type	type	NOUN
iajs-3030	72	14	1	1	NUM
iajs-3030	72	15	diabetes	diabetes	NOUN
iajs-3030	72	16	is	be	AUX
iajs-3030	72	17	less	less	ADV
iajs-3030	72	18	common	common	ADJ
iajs-3030	72	19	in	in	ADP
iajs-3030	72	20	adults	adult	NOUN
iajs-3030	72	21	than	than	ADP
iajs-3030	72	22	in	in	ADP
iajs-3030	72	23	children	child	NOUN
iajs-3030	72	24	,	,	PUNCT
iajs-3030	72	25	and	and	CCONJ
iajs-3030	72	26	the	the	DET
iajs-3030	72	27	range	range	NOUN
iajs-3030	72	28	of	of	ADP
iajs-3030	72	29	occurrence	occurrence	NOUN
iajs-3030	72	30	is	be	AUX
iajs-3030	72	31	considerably	considerably	ADV
iajs-3030	72	32	narrower	narrow	ADJ
iajs-3030	72	33	[	[	X
iajs-3030	72	34	9	9	NUM
iajs-3030	72	35	]	]	PUNCT
iajs-3030	72	36	.	.	PUNCT
iajs-3030	73	1	according	accord	VERB
iajs-3030	73	2	to	to	ADP
iajs-3030	73	3	(	(	PUNCT
iajs-3030	73	4	ferrara	ferrara	NOUN
iajs-3030	73	5	,	,	PUNCT
iajs-3030	73	6	2017	2017	NUM
iajs-3030	73	7	)	)	PUNCT
iajs-3030	73	8	study	study	NOUN
iajs-3030	73	9	,	,	PUNCT
iajs-3030	73	10	having	have	VERB
iajs-3030	73	11	a	a	DET
iajs-3030	73	12	high	high	ADJ
iajs-3030	73	13	bmi	bmi	NOUN
iajs-3030	73	14	is	be	AUX
iajs-3030	73	15	connected	connect	VERB
iajs-3030	73	16	with	with	ADP
iajs-3030	73	17	an	an	DET
iajs-3030	73	18	increased	increase	VERB
iajs-3030	73	19	risk	risk	NOUN
iajs-3030	73	20	of	of	ADP
iajs-3030	73	21	type	type	NOUN
iajs-3030	73	22	1	1	NUM
iajs-3030	73	23	diabetes	diabetes	NOUN
iajs-3030	73	24	development	development	NOUN
iajs-3030	73	25	,	,	PUNCT
iajs-3030	73	26	but	but	CCONJ
iajs-3030	73	27	the	the	DET
iajs-3030	73	28	effect	effect	NOUN
iajs-3030	73	29	varies	vary	VERB
iajs-3030	73	30	by	by	ADP
iajs-3030	73	31	gender	gender	NOUN
iajs-3030	73	32	and	and	CCONJ
iajs-3030	73	33	age	age	NOUN
iajs-3030	73	34	[	[	X
iajs-3030	73	35	10	10	NUM
iajs-3030	73	36	]	]	PUNCT
iajs-3030	73	37	.	.	PUNCT
iajs-3030	74	1	fsg	fsg	PROPN
iajs-3030	74	2	,	,	PUNCT
iajs-3030	74	3	tg	tg	PROPN
iajs-3030	74	4	,	,	PUNCT
iajs-3030	74	5	cholesterol	cholesterol	NOUN
iajs-3030	74	6	,	,	PUNCT
iajs-3030	74	7	hdl	hdl	PROPN
iajs-3030	74	8	,	,	PUNCT
iajs-3030	74	9	ldl	ldl	NOUN
iajs-3030	74	10	,	,	PUNCT
iajs-3030	74	11	vldl	vldl	PROPN
iajs-3030	74	12	,	,	PUNCT
iajs-3030	74	13	got	get	VERB
iajs-3030	74	14	,	,	PUNCT
iajs-3030	74	15	gpt	gpt	NOUN
iajs-3030	74	16	and	and	CCONJ
iajs-3030	74	17	hba1c	hba1c	PROPN
iajs-3030	74	18	levels	level	NOUN
iajs-3030	74	19	showed	show	VERB
iajs-3030	74	20	statistically	statistically	ADV
iajs-3030	74	21	significant	significant	ADJ
iajs-3030	74	22	variations	variation	NOUN
iajs-3030	74	23	between	between	ADP
iajs-3030	74	24	study	study	NOUN
iajs-3030	74	25	groups	group	NOUN
iajs-3030	74	26	,	,	PUNCT
iajs-3030	74	27	as	as	SCONJ
iajs-3030	74	28	shown	show	VERB
iajs-3030	74	29	in	in	ADP
iajs-3030	74	30	table	table	NOUN
iajs-3030	74	31	2	2	NUM
iajs-3030	74	32	.	.	PUNCT
iajs-3030	75	1	ihjpas	ihjpas	PROPN
iajs-3030	75	2	.	.	PUNCT
iajs-3030	76	1	36	36	NUM
iajs-3030	76	2	(	(	PUNCT
iajs-3030	76	3	3	3	NUM
iajs-3030	76	4	)	)	PUNCT
iajs-3030	76	5	2023	2023	NUM
iajs-3030	76	6	171	171	NUM
iajs-3030	76	7	table	table	NOUN
iajs-3030	76	8	2	2	NUM
iajs-3030	76	9	.	.	PUNCT
iajs-3030	76	10	clinical	clinical	ADJ
iajs-3030	76	11	data	datum	NOUN
iajs-3030	76	12	in	in	ADP
iajs-3030	76	13	patient	patient	NOUN
iajs-3030	76	14	having	have	VERB
iajs-3030	76	15	diabetes	diabete	NOUN
iajs-3030	76	16	mellitus	mellitus	NOUN
iajs-3030	76	17	and	and	CCONJ
iajs-3030	76	18	control	control	NOUN
iajs-3030	76	19	(	(	PUNCT
iajs-3030	76	20	g1	g1	PROPN
iajs-3030	76	21	control	control	PROPN
iajs-3030	76	22	group	group	NOUN
iajs-3030	76	23	,	,	PUNCT
iajs-3030	76	24	g2	g2	PROPN
iajs-3030	76	25	newly	newly	ADV
iajs-3030	76	26	diagnosis	diagnosis	NOUN
iajs-3030	76	27	dm	dm	NOUN
iajs-3030	76	28	,	,	PUNCT
iajs-3030	76	29	g3	g3	NOUN
iajs-3030	76	30	with	with	ADP
iajs-3030	76	31	treatment	treatment	NOUN
iajs-3030	76	32	)	)	PUNCT
iajs-3030	76	33	.	.	PUNCT
iajs-3030	77	1	parameters	parameter	NOUN
iajs-3030	77	2	mean	mean	VERB
iajs-3030	77	3	±	±	NUM
iajs-3030	77	4	se	se	X
iajs-3030	78	1	p	p	NOUN
iajs-3030	78	2	-	-	PUNCT
iajs-3030	78	3	value	value	NOUN
iajs-3030	78	4	fbg	fbg	NOUN
iajs-3030	78	5	g1	g1	NOUN
iajs-3030	78	6	108.43±2.55	108.43±2.55	NUM
iajs-3030	78	7	0.00	0.00	NUM
iajs-3030	78	8	g2	g2	PROPN
iajs-3030	78	9	124.86±6.13a	124.86±6.13a	NUM
iajs-3030	78	10	,	,	PUNCT
iajs-3030	78	11	c	c	PROPN
iajs-3030	78	12	g3	g3	PROPN
iajs-3030	78	13	153.12±	153.12±	NUM
iajs-3030	78	14	2.70b	2.70b	NUM
iajs-3030	78	15	,	,	PUNCT
iajs-3030	78	16	c	c	PROPN
iajs-3030	78	17	hba1c	hba1c	PROPN
iajs-3030	78	18	g1	g1	PROPN
iajs-3030	78	19	4.69±0.05	4.69±0.05	NOUN
iajs-3030	78	20	0.00	0.00	NUM
iajs-3030	78	21	g2	g2	PROPN
iajs-3030	78	22	10.62±0.54a	10.62±0.54a	NUM
iajs-3030	78	23	,	,	PUNCT
iajs-3030	78	24	c	c	PROPN
iajs-3030	78	25	g3	g3	PROPN
iajs-3030	78	26	9.18±0.20b	9.18±0.20b	NUM
iajs-3030	78	27	,	,	PUNCT
iajs-3030	78	28	c	c	PROPN
iajs-3030	78	29	tg	tg	PROPN
iajs-3030	78	30	g1	g1	PROPN
iajs-3030	78	31	147.61±	147.61±	NUM
iajs-3030	78	32	3.77	3.77	NUM
iajs-3030	78	33	0.02	0.02	NUM
iajs-3030	78	34	g2	g2	PROPN
iajs-3030	78	35	151.15±5.8	151.15±5.8	PROPN
iajs-3030	78	36	g3	g3	PROPN
iajs-3030	78	37	163.05±	163.05±	NUM
iajs-3030	78	38	3.73b	3.73b	NUM
iajs-3030	78	39	cholesterol	cholesterol	NOUN
iajs-3030	78	40	g1	g1	NOUN
iajs-3030	78	41	178.60±	178.60±	PROPN
iajs-3030	78	42	3.56	3.56	NUM
iajs-3030	78	43	0.00	0.00	NUM
iajs-3030	78	44	g2	g2	NOUN
iajs-3030	78	45	192.2±	192.2±	NUM
iajs-3030	78	46	6.24a	6.24a	NUM
iajs-3030	78	47	,	,	PUNCT
iajs-3030	78	48	c	c	PROPN
iajs-3030	78	49	g3	g3	PROPN
iajs-3030	79	1	212.48±	212.48±	NUM
iajs-3030	79	2	2.14b	2.14b	NUM
iajs-3030	79	3	,	,	PUNCT
iajs-3030	79	4	c	c	PROPN
iajs-3030	79	5	hdl	hdl	PROPN
iajs-3030	79	6	g1	g1	PROPN
iajs-3030	79	7	48.89±	48.89±	DET
iajs-3030	79	8	0.94	0.94	NUM
iajs-3030	79	9	0.00	0.00	NUM
iajs-3030	79	10	g2	g2	PROPN
iajs-3030	79	11	46.59±1.56	46.59±1.56	PROPN
iajs-3030	79	12	g3	g3	PROPN
iajs-3030	79	13	42.19±	42.19±	NUM
iajs-3030	79	14	0.84	0.84	NUM
iajs-3030	79	15	b	b	NOUN
iajs-3030	79	16	,	,	PUNCT
iajs-3030	79	17	c	c	PROPN
iajs-3030	79	18	ldl	ldl	NOUN
iajs-3030	79	19	g1	g1	PROPN
iajs-3030	79	20	100.18±	100.18±	NUM
iajs-3030	80	1	2.43	2.43	NUM
iajs-3030	80	2	0.00	0.00	NUM
iajs-3030	80	3	g2	g2	PROPN
iajs-3030	80	4	115.41±	115.41±	PROPN
iajs-3030	80	5	5.09a	5.09a	NUM
iajs-3030	80	6	,	,	PUNCT
iajs-3030	80	7	c	c	PROPN
iajs-3030	80	8	g3	g3	PROPN
iajs-3030	80	9	137.67±	137.67±	NUM
iajs-3030	80	10	1.52b	1.52b	NUM
iajs-3030	80	11	,	,	PUNCT
iajs-3030	80	12	c	c	PROPN
iajs-3030	80	13	vldl	vldl	PROPN
iajs-3030	80	14	g1	g1	PROPN
iajs-3030	80	15	29.52±	29.52±	NUM
iajs-3030	80	16	0.75	0.75	NUM
iajs-3030	80	17	0.02	0.02	NUM
iajs-3030	80	18	g2	g2	PROPN
iajs-3030	80	19	30.23±	30.23±	NUM
iajs-3030	80	20	1.16	1.16	NUM
iajs-3030	80	21	g3	g3	NOUN
iajs-3030	80	22	32.61±	32.61±	NUM
iajs-3030	80	23	0.74b	0.74b	NUM
iajs-3030	80	24	got	get	AUX
iajs-3030	80	25	g1	g1	VERB
iajs-3030	80	26	29.86±	29.86±	NUM
iajs-3030	80	27	0.91	0.91	NUM
iajs-3030	80	28	0.00	0.00	NUM
iajs-3030	80	29	g2	g2	PROPN
iajs-3030	80	30	30.76±	30.76±	NUM
iajs-3030	80	31	1.49	1.49	NUM
iajs-3030	80	32	g3	g3	NOUN
iajs-3030	80	33	45.52±	45.52±	NUM
iajs-3030	80	34	0.83b	0.83b	NOUN
iajs-3030	80	35	,	,	PUNCT
iajs-3030	80	36	c	c	PROPN
iajs-3030	80	37	gpt	gpt	PROPN
iajs-3030	80	38	g1	g1	PROPN
iajs-3030	80	39	26.03±	26.03±	NUM
iajs-3030	80	40	0.88	0.88	NUM
iajs-3030	80	41	0.00	0.00	NUM
iajs-3030	80	42	g2	g2	PROPN
iajs-3030	80	43	26.37±	26.37±	NUM
iajs-3030	80	44	1.34	1.34	NUM
iajs-3030	80	45	g3	g3	PROPN
iajs-3030	80	46	39.50±	39.50±	NUM
iajs-3030	80	47	0.67b	0.67b	NOUN
iajs-3030	80	48	,	,	PUNCT
iajs-3030	80	49	c	c	PROPN
iajs-3030	80	50	the	the	DET
iajs-3030	80	51	mean	mean	ADJ
iajs-3030	80	52	difference	difference	NOUN
iajs-3030	80	53	is	be	AUX
iajs-3030	80	54	significant	significant	ADJ
iajs-3030	80	55	at	at	ADP
iajs-3030	80	56	the	the	DET
iajs-3030	80	57	0.05	0.05	NUM
iajs-3030	80	58	level	level	NOUN
iajs-3030	80	59	have	have	AUX
iajs-3030	80	60	been	be	AUX
iajs-3030	80	61	identified	identify	VERB
iajs-3030	80	62	using	use	VERB
iajs-3030	80	63	anova	anova	PROPN
iajs-3030	80	64	test	test	NOUN
iajs-3030	80	65	.	.	PUNCT
iajs-3030	81	1	a	a	DET
iajs-3030	81	2	:	:	PUNCT
iajs-3030	81	3	significant	significant	ADJ
iajs-3030	81	4	difference	difference	NOUN
iajs-3030	81	5	between	between	ADP
iajs-3030	81	6	g1	g1	PROPN
iajs-3030	81	7	(	(	PUNCT
iajs-3030	81	8	control	control	NOUN
iajs-3030	81	9	)	)	PUNCT
iajs-3030	81	10	and	and	CCONJ
iajs-3030	81	11	g2	g2	PROPN
iajs-3030	81	12	(	(	PUNCT
iajs-3030	81	13	dm	dm	PROPN
iajs-3030	81	14	without	without	ADP
iajs-3030	81	15	treatment	treatment	NOUN
iajs-3030	81	16	)	)	PUNCT
iajs-3030	81	17	b	b	NOUN
iajs-3030	81	18	:	:	PUNCT
iajs-3030	81	19	significant	significant	ADJ
iajs-3030	81	20	difference	difference	NOUN
iajs-3030	81	21	between	between	ADP
iajs-3030	81	22	control	control	NOUN
iajs-3030	81	23	g1	g1	PROPN
iajs-3030	81	24	(	(	PUNCT
iajs-3030	81	25	control	control	NOUN
iajs-3030	81	26	)	)	PUNCT
iajs-3030	81	27	and	and	CCONJ
iajs-3030	81	28	g3	g3	PROPN
iajs-3030	81	29	(	(	PUNCT
iajs-3030	81	30	dm	dm	NOUN
iajs-3030	81	31	with	with	ADP
iajs-3030	81	32	treatment	treatment	NOUN
iajs-3030	81	33	)	)	PUNCT
iajs-3030	81	34	c	c	NOUN
iajs-3030	81	35	:	:	PUNCT
iajs-3030	81	36	significant	significant	ADJ
iajs-3030	81	37	difference	difference	NOUN
iajs-3030	81	38	between	between	ADP
iajs-3030	81	39	g2	g2	PROPN
iajs-3030	81	40	(	(	PUNCT
iajs-3030	81	41	dm	dm	PROPN
iajs-3030	81	42	without	without	ADP
iajs-3030	81	43	treatment	treatment	NOUN
iajs-3030	81	44	)	)	PUNCT
iajs-3030	81	45	and	and	CCONJ
iajs-3030	81	46	g3	g3	PROPN
iajs-3030	81	47	9	9	NUM
iajs-3030	81	48	dm	dm	NOUN
iajs-3030	81	49	with	with	ADP
iajs-3030	81	50	treatment	treatment	NOUN
iajs-3030	81	51	)	)	PUNCT
iajs-3030	81	52	results	result	NOUN
iajs-3030	81	53	of	of	ADP
iajs-3030	81	54	fbg	fbg	NOUN
iajs-3030	81	55	,	,	PUNCT
iajs-3030	81	56	hba1c	hba1c	PROPN
iajs-3030	81	57	,	,	PUNCT
iajs-3030	81	58	cholesterol	cholesterol	NOUN
iajs-3030	81	59	,	,	PUNCT
iajs-3030	81	60	and	and	CCONJ
iajs-3030	81	61	ldl	ldl	NOUN
iajs-3030	81	62	levels	level	NOUN
iajs-3030	81	63	show	show	VERB
iajs-3030	81	64	significant	significant	ADJ
iajs-3030	81	65	difference	difference	NOUN
iajs-3030	81	66	between	between	ADP
iajs-3030	81	67	control	control	NOUN
iajs-3030	81	68	and	and	CCONJ
iajs-3030	81	69	newly	newly	ADJ
iajs-3030	81	70	groups	group	NOUN
iajs-3030	81	71	,	,	PUNCT
iajs-3030	81	72	control	control	NOUN
iajs-3030	81	73	and	and	CCONJ
iajs-3030	81	74	treatment	treatment	NOUN
iajs-3030	81	75	groups	group	NOUN
iajs-3030	81	76	and	and	CCONJ
iajs-3030	81	77	between	between	ADP
iajs-3030	81	78	control	control	NOUN
iajs-3030	81	79	and	and	CCONJ
iajs-3030	81	80	newly	newly	ADJ
iajs-3030	81	81	groups	group	NOUN
iajs-3030	81	82	.	.	PUNCT
iajs-3030	82	1	triglyceride	triglyceride	ADJ
iajs-3030	82	2	and	and	CCONJ
iajs-3030	82	3	vldl	vldl	NOUN
iajs-3030	82	4	levels	level	NOUN
iajs-3030	82	5	are	be	AUX
iajs-3030	82	6	significantly	significantly	ADV
iajs-3030	82	7	different	different	ADJ
iajs-3030	82	8	between	between	ADP
iajs-3030	82	9	the	the	DET
iajs-3030	82	10	control	control	NOUN
iajs-3030	82	11	and	and	CCONJ
iajs-3030	82	12	treatment	treatment	NOUN
iajs-3030	82	13	groups	group	NOUN
iajs-3030	82	14	,	,	PUNCT
iajs-3030	82	15	but	but	CCONJ
iajs-3030	82	16	not	not	PART
iajs-3030	82	17	different	different	ADJ
iajs-3030	82	18	between	between	ADP
iajs-3030	82	19	the	the	DET
iajs-3030	82	20	control	control	NOUN
iajs-3030	82	21	and	and	CCONJ
iajs-3030	82	22	newly	newly	ADJ
iajs-3030	82	23	groups	group	NOUN
iajs-3030	82	24	or	or	CCONJ
iajs-3030	82	25	between	between	ADP
iajs-3030	82	26	the	the	DET
iajs-3030	82	27	treatment	treatment	NOUN
iajs-3030	82	28	and	and	CCONJ
iajs-3030	82	29	newly	newly	ADJ
iajs-3030	82	30	groups	group	NOUN
iajs-3030	82	31	.	.	PUNCT
iajs-3030	83	1	results	result	NOUN
iajs-3030	83	2	of	of	ADP
iajs-3030	83	3	hdl	hdl	PROPN
iajs-3030	83	4	,	,	PUNCT
iajs-3030	83	5	got	get	VERB
iajs-3030	83	6	,	,	PUNCT
iajs-3030	83	7	and	and	CCONJ
iajs-3030	83	8	gpt	gpt	NOUN
iajs-3030	83	9	levels	level	NOUN
iajs-3030	83	10	showed	show	VERB
iajs-3030	83	11	significant	significant	ADJ
iajs-3030	83	12	different	different	ADV
iajs-3030	83	13	between	between	ADP
iajs-3030	83	14	the	the	DET
iajs-3030	83	15	control	control	NOUN
iajs-3030	83	16	and	and	CCONJ
iajs-3030	83	17	treatment	treatment	NOUN
iajs-3030	83	18	groups	group	NOUN
iajs-3030	83	19	,	,	PUNCT
iajs-3030	83	20	as	as	ADV
iajs-3030	83	21	well	well	ADV
iajs-3030	83	22	as	as	ADP
iajs-3030	83	23	between	between	ADP
iajs-3030	83	24	the	the	DET
iajs-3030	83	25	treatment	treatment	NOUN
iajs-3030	83	26	and	and	CCONJ
iajs-3030	83	27	newly	newly	ADJ
iajs-3030	83	28	groups	group	NOUN
iajs-3030	83	29	,	,	PUNCT
iajs-3030	83	30	but	but	CCONJ
iajs-3030	83	31	not	not	PART
iajs-3030	83	32	different	different	ADJ
iajs-3030	83	33	significant	significant	ADJ
iajs-3030	83	34	between	between	ADP
iajs-3030	83	35	the	the	DET
iajs-3030	83	36	control	control	NOUN
iajs-3030	83	37	and	and	CCONJ
iajs-3030	83	38	newly	newly	ADV
iajs-3030	83	39	developed	develop	VERB
iajs-3030	83	40	groups	group	NOUN
iajs-3030	83	41	.	.	PUNCT
iajs-3030	84	1	the	the	DET
iajs-3030	84	2	who	who	PRON
iajs-3030	84	3	consultation	consultation	NOUN
iajs-3030	84	4	concluded	conclude	VERB
iajs-3030	84	5	that	that	SCONJ
iajs-3030	84	6	hba1c	hba1c	PROPN
iajs-3030	84	7	and	and	CCONJ
iajs-3030	84	8	fsg	fsg	PROPN
iajs-3030	84	9	used	use	VERB
iajs-3030	84	10	as	as	ADP
iajs-3030	84	11	a	a	DET
iajs-3030	84	12	diabetes	diabetes	NOUN
iajs-3030	84	13	diagnostic	diagnostic	ADJ
iajs-3030	84	14	test	test	NOUN
iajs-3030	85	1	[	[	X
iajs-3030	85	2	11	11	NUM
iajs-3030	85	3	]	]	PUNCT
iajs-3030	85	4	.	.	PUNCT
iajs-3030	86	1	(	(	PUNCT
iajs-3030	86	2	vergès	vergès	ADJ
iajs-3030	86	3	,	,	PUNCT
iajs-3030	86	4	2009	2009	NUM
iajs-3030	86	5	)	)	PUNCT
iajs-3030	86	6	pointed	point	VERB
iajs-3030	86	7	in	in	ADP
iajs-3030	86	8	there	there	ADV
iajs-3030	86	9	studied	study	VERB
iajs-3030	86	10	that	that	SCONJ
iajs-3030	86	11	t1	t1	NOUN
iajs-3030	86	12	dm	dm	NOUN
iajs-3030	86	13	patients	patient	NOUN
iajs-3030	86	14	also	also	ADV
iajs-3030	86	15	have	have	VERB
iajs-3030	86	16	lipid	lipid	ADJ
iajs-3030	86	17	turbulence	turbulence	NOUN
iajs-3030	86	18	.	.	PUNCT
iajs-3030	87	1	lipoprotein	lipoprotein	ADJ
iajs-3030	87	2	quantitative	quantitative	ADJ
iajs-3030	87	3	abnormalities	abnormality	NOUN
iajs-3030	87	4	are	be	AUX
iajs-3030	87	5	seen	see	VERB
iajs-3030	87	6	in	in	ADP
iajs-3030	87	7	t1d	t1d	PROPN
iajs-3030	87	8	patients	patient	NOUN
iajs-3030	87	9	with	with	ADP
iajs-3030	87	10	poor	poor	ADJ
iajs-3030	87	11	glycemic	glycemic	ADJ
iajs-3030	87	12	control	control	NOUN
iajs-3030	87	13	(	(	PUNCT
iajs-3030	87	14	raise	raise	VERB
iajs-3030	87	15	plasma	plasma	NOUN
iajs-3030	87	16	triglycerides	triglyceride	NOUN
iajs-3030	87	17	and	and	CCONJ
iajs-3030	87	18	ldl	ldl	NOUN
iajs-3030	87	19	cholesterol	cholesterol	NOUN
iajs-3030	87	20	)	)	PUNCT
iajs-3030	87	21	or	or	CCONJ
iajs-3030	87	22	nephropathy	nephropathy	NOUN
iajs-3030	87	23	(	(	PUNCT
iajs-3030	87	24	raise	raise	VERB
iajs-3030	87	25	triglycerides	triglyceride	NOUN
iajs-3030	87	26	and	and	CCONJ
iajs-3030	87	27	ldl	ldl	NOUN
iajs-3030	87	28	cholesterol	cholesterol	NOUN
iajs-3030	87	29	,	,	PUNCT
iajs-3030	87	30	low	low	ADJ
iajs-3030	87	31	level	level	NOUN
iajs-3030	87	32	of	of	ADP
iajs-3030	87	33	high	high	ADJ
iajs-3030	87	34	density	density	NOUN
iajs-3030	87	35	lipoprotein	lipoprotein	ADJ
iajs-3030	87	36	[	[	X
iajs-3030	87	37	hdl	hdl	X
iajs-3030	87	38	]	]	X
iajs-3030	87	39	cholesterol	cholesterol	NOUN
iajs-3030	87	40	)	)	PUNCT
iajs-3030	88	1	[	[	X
iajs-3030	88	2	12	12	NUM
iajs-3030	88	3	]	]	PUNCT
iajs-3030	88	4	.	.	PUNCT
iajs-3030	89	1	(	(	PUNCT
iajs-3030	89	2	valentina	valentina	PROPN
iajs-3030	89	3	guarnotta	guarnotta	PROPN
iajs-3030	89	4	,	,	PUNCT
iajs-3030	89	5	2018	2018	NUM
iajs-3030	89	6	)	)	PUNCT
iajs-3030	89	7	pointed	point	VERB
iajs-3030	89	8	out	out	ADP
iajs-3030	89	9	https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-018-0341-6#auth-valentina-guarnotta	https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-018-0341-6#auth-valentina-guarnotta	ADP
iajs-3030	89	10	ihjpas	ihjpas	PROPN
iajs-3030	89	11	.	.	PUNCT
iajs-3030	90	1	36	36	NUM
iajs-3030	90	2	(	(	PUNCT
iajs-3030	90	3	3	3	NUM
iajs-3030	90	4	)	)	PUNCT
iajs-3030	90	5	2023	2023	NUM
iajs-3030	90	6	172	172	NUM
iajs-3030	90	7	that	that	PRON
iajs-3030	90	8	idm	idm	NOUN
iajs-3030	90	9	patients	patient	NOUN
iajs-3030	90	10	had	have	VERB
iajs-3030	90	11	a	a	DET
iajs-3030	90	12	significantly	significantly	ADV
iajs-3030	90	13	higher	high	ADJ
iajs-3030	90	14	bmi	bmi	NOUN
iajs-3030	90	15	(	(	PUNCT
iajs-3030	90	16	p	p	PROPN
iajs-3030	90	17	0.012	0.012	NUM
iajs-3030	90	18	)	)	PUNCT
iajs-3030	90	19	,	,	PUNCT
iajs-3030	91	1	ldl	ldl	NOUN
iajs-3030	91	2	-	-	PUNCT
iajs-3030	91	3	cholesterol	cholesterol	NOUN
iajs-3030	91	4	(	(	PUNCT
iajs-3030	91	5	p	p	NOUN
iajs-3030	91	6	0.027	0.027	NUM
iajs-3030	91	7	)	)	PUNCT
iajs-3030	91	8	,	,	PUNCT
iajs-3030	91	9	got	get	VERB
iajs-3030	91	10	(	(	PUNCT
iajs-3030	91	11	p	p	NOUN
iajs-3030	91	12	0.005	0.005	NUM
iajs-3030	91	13	)	)	PUNCT
iajs-3030	91	14	,	,	PUNCT
iajs-3030	91	15	and	and	CCONJ
iajs-3030	91	16	gpt	gpt	NOUN
iajs-3030	91	17	(	(	PUNCT
iajs-3030	91	18	p	p	NOUN
iajs-3030	91	19	0.001	0.001	NUM
iajs-3030	91	20	)	)	PUNCT
iajs-3030	91	21	,	,	PUNCT
iajs-3030	91	22	with	with	ADP
iajs-3030	91	23	concomitantly	concomitantly	ADV
iajs-3030	91	24	lower	low	ADJ
iajs-3030	91	25	hdl	hdl	NOUN
iajs-3030	91	26	-	-	PUNCT
iajs-3030	91	27	cholesterol	cholesterol	NOUN
iajs-3030	91	28	(	(	PUNCT
iajs-3030	91	29	p	p	NOUN
iajs-3030	91	30	0.001	0.001	NUM
iajs-3030	91	31	)	)	PUNCT
iajs-3030	92	1	[	[	X
iajs-3030	92	2	13	13	NUM
iajs-3030	92	3	]	]	PUNCT
iajs-3030	92	4	.	.	PUNCT
iajs-3030	93	1	regarding	regard	VERB
iajs-3030	93	2	to	to	PART
iajs-3030	93	3	oxidative	oxidative	ADJ
iajs-3030	93	4	stress	stress	NOUN
iajs-3030	93	5	markers	marker	NOUN
iajs-3030	93	6	,	,	PUNCT
iajs-3030	93	7	there	there	PRON
iajs-3030	93	8	is	be	VERB
iajs-3030	93	9	a	a	DET
iajs-3030	93	10	non	non	ADJ
iajs-3030	93	11	-	-	ADJ
iajs-3030	93	12	significant	significant	ADJ
iajs-3030	93	13	in	in	ADP
iajs-3030	93	14	tos	tos	NOUN
iajs-3030	93	15	and	and	CCONJ
iajs-3030	93	16	tas	ta	NOUN
iajs-3030	93	17	but	but	CCONJ
iajs-3030	93	18	osi	osi	PROPN
iajs-3030	93	19	has	have	VERB
iajs-3030	93	20	a	a	DET
iajs-3030	93	21	significant	significant	ADJ
iajs-3030	93	22	difference	difference	NOUN
iajs-3030	93	23	between	between	ADP
iajs-3030	93	24	the	the	DET
iajs-3030	93	25	newly	newly	ADJ
iajs-3030	93	26	and	and	CCONJ
iajs-3030	93	27	treatment	treatment	NOUN
iajs-3030	93	28	groups	group	NOUN
iajs-3030	93	29	as	as	SCONJ
iajs-3030	93	30	shown	show	VERB
iajs-3030	93	31	in	in	ADP
iajs-3030	93	32	table	table	NOUN
iajs-3030	93	33	3	3	NUM
iajs-3030	93	34	.	.	PUNCT
iajs-3030	93	35	table	table	NOUN
iajs-3030	93	36	3	3	NUM
iajs-3030	93	37	.	.	PUNCT
iajs-3030	94	1	mean	mean	NOUN
iajs-3030	94	2	±	±	NUM
iajs-3030	94	3	sd	sd	ADP
iajs-3030	94	4	value	value	NOUN
iajs-3030	94	5	of	of	ADP
iajs-3030	94	6	tos	tos	NOUN
iajs-3030	94	7	,	,	PUNCT
iajs-3030	94	8	tas	ta	NOUN
iajs-3030	94	9	and	and	CCONJ
iajs-3030	94	10	osi	osi	PROPN
iajs-3030	94	11	for	for	ADP
iajs-3030	94	12	the	the	DET
iajs-3030	94	13	studied	study	VERB
iajs-3030	94	14	groups	group	NOUN
iajs-3030	94	15	.	.	PUNCT
iajs-3030	95	1	parameters	parameter	NOUN
iajs-3030	95	2	mean	mean	VERB
iajs-3030	95	3	±	±	NUM
iajs-3030	95	4	se	se	X
iajs-3030	96	1	p	p	NOUN
iajs-3030	96	2	-	-	PUNCT
iajs-3030	96	3	value	value	NOUN
iajs-3030	96	4	tos	tos	NOUN
iajs-3030	96	5	g1	g1	NOUN
iajs-3030	96	6	0.04±	0.04±	PROPN
iajs-3030	96	7	0.008	0.008	NUM
iajs-3030	96	8	0.4	0.4	NUM
iajs-3030	96	9	g2	g2	PROPN
iajs-3030	96	10	0.07±	0.07±	NOUN
iajs-3030	97	1	0.01	0.01	NUM
iajs-3030	97	2	g3	g3	NOUN
iajs-3030	97	3	0.06±	0.06±	NOUN
iajs-3030	97	4	0.01	0.01	NUM
iajs-3030	97	5	tas	ta	NOUN
iajs-3030	97	6	g1	g1	PROPN
iajs-3030	97	7	1.61±	1.61±	NUM
iajs-3030	97	8	0.05	0.05	NUM
iajs-3030	97	9	0.6	0.6	NUM
iajs-3030	97	10	g2	g2	PROPN
iajs-3030	97	11	1.48±	1.48±	NUM
iajs-3030	97	12	0.10	0.10	NUM
iajs-3030	97	13	g3	g3	NOUN
iajs-3030	97	14	1.76±	1.76±	NUM
iajs-3030	97	15	0.21	0.21	NUM
iajs-3030	97	16	osi	osi	PROPN
iajs-3030	97	17	g1	g1	NOUN
iajs-3030	97	18	0.059±	0.059±	NUM
iajs-3030	97	19	0.004	0.004	NUM
iajs-3030	97	20	0.03	0.03	NUM
iajs-3030	97	21	g2	g2	PROPN
iajs-3030	97	22	0.09±	0.09±	NOUN
iajs-3030	97	23	0.01	0.01	NUM
iajs-3030	97	24	g3	g3	NOUN
iajs-3030	97	25	0.04±	0.04±	NOUN
iajs-3030	97	26	0.01c	0.01c	NOUN
iajs-3030	97	27	the	the	DET
iajs-3030	97	28	mean	mean	ADJ
iajs-3030	97	29	difference	difference	NOUN
iajs-3030	97	30	is	be	AUX
iajs-3030	97	31	significant	significant	ADJ
iajs-3030	97	32	at	at	ADP
iajs-3030	97	33	the	the	DET
iajs-3030	97	34	0.05	0.05	NUM
iajs-3030	97	35	level	level	NOUN
iajs-3030	97	36	have	have	AUX
iajs-3030	97	37	been	be	AUX
iajs-3030	97	38	identified	identify	VERB
iajs-3030	97	39	using	use	VERB
iajs-3030	97	40	anova	anova	PROPN
iajs-3030	97	41	test	test	NOUN
iajs-3030	97	42	.	.	PUNCT
iajs-3030	98	1	a	a	DET
iajs-3030	98	2	:	:	PUNCT
iajs-3030	98	3	significant	significant	ADJ
iajs-3030	98	4	difference	difference	NOUN
iajs-3030	98	5	between	between	ADP
iajs-3030	98	6	g1	g1	PROPN
iajs-3030	98	7	(	(	PUNCT
iajs-3030	98	8	control	control	NOUN
iajs-3030	98	9	)	)	PUNCT
iajs-3030	98	10	and	and	CCONJ
iajs-3030	98	11	g2	g2	PROPN
iajs-3030	98	12	(	(	PUNCT
iajs-3030	98	13	dm	dm	PROPN
iajs-3030	98	14	without	without	ADP
iajs-3030	98	15	treatment	treatment	NOUN
iajs-3030	98	16	)	)	PUNCT
iajs-3030	98	17	b	b	NOUN
iajs-3030	98	18	:	:	PUNCT
iajs-3030	98	19	significant	significant	ADJ
iajs-3030	98	20	difference	difference	NOUN
iajs-3030	98	21	between	between	ADP
iajs-3030	98	22	control	control	NOUN
iajs-3030	98	23	g1	g1	PROPN
iajs-3030	98	24	(	(	PUNCT
iajs-3030	98	25	control	control	NOUN
iajs-3030	98	26	)	)	PUNCT
iajs-3030	98	27	and	and	CCONJ
iajs-3030	98	28	g3	g3	PROPN
iajs-3030	98	29	(	(	PUNCT
iajs-3030	98	30	dm	dm	NOUN
iajs-3030	98	31	with	with	ADP
iajs-3030	98	32	treatment	treatment	NOUN
iajs-3030	98	33	)	)	PUNCT
iajs-3030	98	34	c	c	NOUN
iajs-3030	98	35	:	:	PUNCT
iajs-3030	98	36	significant	significant	ADJ
iajs-3030	98	37	difference	difference	NOUN
iajs-3030	98	38	between	between	ADP
iajs-3030	98	39	g2	g2	PROPN
iajs-3030	98	40	(	(	PUNCT
iajs-3030	98	41	dm	dm	PROPN
iajs-3030	98	42	without	without	ADP
iajs-3030	98	43	treatment	treatment	NOUN
iajs-3030	98	44	)	)	PUNCT
iajs-3030	98	45	and	and	CCONJ
iajs-3030	98	46	g3	g3	PROPN
iajs-3030	98	47	9	9	NUM
iajs-3030	98	48	dm	dm	NOUN
iajs-3030	98	49	with	with	ADP
iajs-3030	98	50	treatment	treatment	NOUN
iajs-3030	98	51	)	)	PUNCT
iajs-3030	98	52	our	our	PRON
iajs-3030	98	53	study	study	NOUN
iajs-3030	98	54	agreed	agree	VERB
iajs-3030	98	55	with	with	ADP
iajs-3030	98	56	the	the	DET
iajs-3030	98	57	results	result	NOUN
iajs-3030	98	58	of	of	ADP
iajs-3030	98	59	(	(	PUNCT
iajs-3030	98	60	zainab	zainab	PROPN
iajs-3030	98	61	m.etal,2022	m.etal,2022	PROPN
iajs-3030	98	62	)	)	PUNCT
iajs-3030	98	63	for	for	ADP
iajs-3030	98	64	both	both	CCONJ
iajs-3030	98	65	tos	tos	NOUN
iajs-3030	98	66	and	and	CCONJ
iajs-3030	98	67	tas	ta	NOUN
iajs-3030	98	68	,	,	PUNCT
iajs-3030	98	69	which	which	PRON
iajs-3030	98	70	showed	show	VERB
iajs-3030	98	71	non	non	ADJ
iajs-3030	98	72	-	-	ADJ
iajs-3030	98	73	significant	significant	ADJ
iajs-3030	98	74	difference	difference	NOUN
iajs-3030	98	75	for	for	ADP
iajs-3030	98	76	type	type	NOUN
iajs-3030	98	77	1	1	NUM
iajs-3030	98	78	diabetes	diabetes	NOUN
iajs-3030	98	79	patients	patient	NOUN
iajs-3030	98	80	[	[	X
iajs-3030	98	81	14	14	NUM
iajs-3030	98	82	]	]	PUNCT
iajs-3030	98	83	.	.	PUNCT
iajs-3030	99	1	statistically	statistically	ADV
iajs-3030	99	2	there	there	PRON
iajs-3030	99	3	is	be	VERB
iajs-3030	99	4	significant	significant	ADJ
iajs-3030	99	5	in	in	ADP
iajs-3030	99	6	fbxw7	fbxw7	PROPN
iajs-3030	99	7	protein	protein	NOUN
iajs-3030	99	8	,	,	PUNCT
iajs-3030	99	9	the	the	DET
iajs-3030	99	10	significant	significant	ADJ
iajs-3030	99	11	difference	difference	NOUN
iajs-3030	99	12	between	between	ADP
iajs-3030	99	13	control	control	NOUN
iajs-3030	99	14	group	group	NOUN
iajs-3030	99	15	and	and	CCONJ
iajs-3030	99	16	treatment	treatment	NOUN
iajs-3030	99	17	group	group	NOUN
iajs-3030	99	18	,	,	PUNCT
iajs-3030	99	19	also	also	ADV
iajs-3030	99	20	have	have	VERB
iajs-3030	99	21	different	different	ADJ
iajs-3030	99	22	significant	significant	ADJ
iajs-3030	99	23	between	between	ADP
iajs-3030	99	24	newly	newly	ADJ
iajs-3030	99	25	and	and	CCONJ
iajs-3030	99	26	treatment	treatment	NOUN
iajs-3030	99	27	groups	group	NOUN
iajs-3030	99	28	as	as	ADP
iajs-3030	99	29	show	show	NOUN
iajs-3030	99	30	in	in	ADP
iajs-3030	99	31	table	table	NOUN
iajs-3030	99	32	4	4	NUM
iajs-3030	99	33	.	.	PUNCT
iajs-3030	99	34	table	table	NOUN
iajs-3030	99	35	4	4	NUM
iajs-3030	99	36	.	.	PUNCT
iajs-3030	100	1	mean	mean	NOUN
iajs-3030	100	2	±	±	NUM
iajs-3030	100	3	sd	sd	ADP
iajs-3030	100	4	value	value	NOUN
iajs-3030	100	5	of	of	ADP
iajs-3030	100	6	fbxw7	fbxw7	PROPN
iajs-3030	100	7	for	for	ADP
iajs-3030	100	8	the	the	DET
iajs-3030	100	9	studied	study	VERB
iajs-3030	100	10	groups	group	NOUN
iajs-3030	100	11	.	.	PUNCT
iajs-3030	101	1	parameter	parameter	NOUN
iajs-3030	101	2	mean	mean	VERB
iajs-3030	101	3	±	±	NUM
iajs-3030	101	4	se	se	X
iajs-3030	101	5	p	p	NOUN
iajs-3030	101	6	-	-	PUNCT
iajs-3030	101	7	value	value	NOUN
iajs-3030	101	8	fbxw7_protein	fbxw7_protein	PROPN
iajs-3030	101	9	g1	g1	VERB
iajs-3030	101	10	1.99±0.041	1.99±0.041	PROPN
iajs-3030	101	11	0.00	0.00	NUM
iajs-3030	101	12	g2	g2	PROPN
iajs-3030	101	13	2.24±	2.24±	NUM
iajs-3030	101	14	0.053	0.053	NUM
iajs-3030	101	15	g3	g3	PROPN
iajs-3030	101	16	4.66±0.17436b	4.66±0.17436b	PROPN
iajs-3030	101	17	,	,	PUNCT
iajs-3030	101	18	c	c	PROPN
iajs-3030	101	19	the	the	DET
iajs-3030	101	20	mean	mean	ADJ
iajs-3030	101	21	difference	difference	NOUN
iajs-3030	101	22	is	be	AUX
iajs-3030	101	23	significant	significant	ADJ
iajs-3030	101	24	at	at	ADP
iajs-3030	101	25	the	the	DET
iajs-3030	101	26	0.05	0.05	NUM
iajs-3030	101	27	level	level	NOUN
iajs-3030	101	28	have	have	AUX
iajs-3030	101	29	been	be	AUX
iajs-3030	101	30	identified	identify	VERB
iajs-3030	101	31	using	use	VERB
iajs-3030	101	32	anova	anova	PROPN
iajs-3030	101	33	test	test	NOUN
iajs-3030	101	34	.	.	PUNCT
iajs-3030	102	1	a	a	DET
iajs-3030	102	2	:	:	PUNCT
iajs-3030	102	3	significant	significant	ADJ
iajs-3030	102	4	difference	difference	NOUN
iajs-3030	102	5	between	between	ADP
iajs-3030	102	6	g1	g1	PROPN
iajs-3030	102	7	(	(	PUNCT
iajs-3030	102	8	control	control	NOUN
iajs-3030	102	9	)	)	PUNCT
iajs-3030	102	10	and	and	CCONJ
iajs-3030	102	11	g2	g2	PROPN
iajs-3030	102	12	(	(	PUNCT
iajs-3030	102	13	dm	dm	PROPN
iajs-3030	102	14	without	without	ADP
iajs-3030	102	15	treatment	treatment	NOUN
iajs-3030	102	16	)	)	PUNCT
iajs-3030	102	17	b	b	NOUN
iajs-3030	102	18	:	:	PUNCT
iajs-3030	102	19	significant	significant	ADJ
iajs-3030	102	20	difference	difference	NOUN
iajs-3030	102	21	between	between	ADP
iajs-3030	102	22	control	control	NOUN
iajs-3030	102	23	g1	g1	PROPN
iajs-3030	102	24	(	(	PUNCT
iajs-3030	102	25	control	control	NOUN
iajs-3030	102	26	)	)	PUNCT
iajs-3030	102	27	and	and	CCONJ
iajs-3030	102	28	g3	g3	PROPN
iajs-3030	102	29	(	(	PUNCT
iajs-3030	102	30	dm	dm	NOUN
iajs-3030	102	31	with	with	ADP
iajs-3030	102	32	treatment	treatment	NOUN
iajs-3030	102	33	)	)	PUNCT
iajs-3030	102	34	c	c	NOUN
iajs-3030	102	35	:	:	PUNCT
iajs-3030	102	36	significant	significant	ADJ
iajs-3030	102	37	difference	difference	NOUN
iajs-3030	102	38	between	between	ADP
iajs-3030	102	39	g2	g2	PROPN
iajs-3030	102	40	(	(	PUNCT
iajs-3030	102	41	dm	dm	PROPN
iajs-3030	102	42	without	without	ADP
iajs-3030	102	43	treatment	treatment	NOUN
iajs-3030	102	44	)	)	PUNCT
iajs-3030	102	45	and	and	CCONJ
iajs-3030	102	46	g3	g3	PROPN
iajs-3030	102	47	9	9	NUM
iajs-3030	102	48	dm	dm	NOUN
iajs-3030	102	49	with	with	ADP
iajs-3030	102	50	treatment	treatment	NOUN
iajs-3030	102	51	)	)	PUNCT
iajs-3030	102	52	the	the	DET
iajs-3030	102	53	fbxw7	fbxw7	NOUN
iajs-3030	102	54	protein	protein	NOUN
iajs-3030	102	55	was	be	AUX
iajs-3030	102	56	chosen	choose	VERB
iajs-3030	102	57	as	as	ADP
iajs-3030	102	58	the	the	DET
iajs-3030	102	59	marker	marker	NOUN
iajs-3030	102	60	for	for	ADP
iajs-3030	102	61	the	the	DET
iajs-3030	102	62	current	current	ADJ
iajs-3030	102	63	study	study	NOUN
iajs-3030	102	64	,	,	PUNCT
iajs-3030	102	65	and	and	CCONJ
iajs-3030	102	66	when	when	SCONJ
iajs-3030	102	67	compared	compare	VERB
iajs-3030	102	68	to	to	ADP
iajs-3030	102	69	the	the	DET
iajs-3030	102	70	previous	previous	ADJ
iajs-3030	102	71	study	study	NOUN
iajs-3030	102	72	on	on	ADP
iajs-3030	102	73	dm	dm	PROPN
iajs-3030	102	74	with	with	ADP
iajs-3030	102	75	type	type	NOUN
iajs-3030	102	76	2	2	NUM
iajs-3030	102	77	,	,	PUNCT
iajs-3030	102	78	suhayla	suhayla	NOUN
iajs-3030	102	79	k.	k.	PROPN
iajs-3030	102	80	mohammed	mohammed	PROPN
iajs-3030	102	81	pointed	point	VERB
iajs-3030	102	82	out	out	ADP
iajs-3030	102	83	in	in	ADP
iajs-3030	102	84	their	their	PRON
iajs-3030	102	85	study	study	NOUN
iajs-3030	102	86	that	that	SCONJ
iajs-3030	102	87	fbxw7	fbxw7	NOUN
iajs-3030	102	88	protein	protein	NOUN
iajs-3030	102	89	was	be	AUX
iajs-3030	102	90	highly	highly	ADV
iajs-3030	102	91	associated	associate	VERB
iajs-3030	102	92	with	with	ADP
iajs-3030	102	93	g1	g1	PROPN
iajs-3030	102	94	(	(	PUNCT
iajs-3030	102	95	newly	newly	ADV
iajs-3030	102	96	diagnosed	diagnose	VERB
iajs-3030	102	97	patients	patient	NOUN
iajs-3030	102	98	)	)	PUNCT
iajs-3030	102	99	,	,	PUNCT
iajs-3030	102	100	they	they	PRON
iajs-3030	102	101	suggested	suggest	VERB
iajs-3030	102	102	that	that	SCONJ
iajs-3030	102	103	serum	serum	NOUN
iajs-3030	102	104	fbxw7	fbxw7	PROPN
iajs-3030	102	105	may	may	AUX
iajs-3030	102	106	be	be	AUX
iajs-3030	102	107	used	use	VERB
iajs-3030	102	108	as	as	ADP
iajs-3030	102	109	an	an	DET
iajs-3030	102	110	early	early	ADJ
iajs-3030	102	111	diagnostic	diagnostic	ADJ
iajs-3030	102	112	test	test	NOUN
iajs-3030	102	113	in	in	ADP
iajs-3030	102	114	patients	patient	NOUN
iajs-3030	102	115	with	with	ADP
iajs-3030	102	116	dm	dm	PROPN
iajs-3030	102	117	,	,	PUNCT
iajs-3030	102	118	and	and	CCONJ
iajs-3030	102	119	metformin	metformin	NOUN
iajs-3030	102	120	significantly	significantly	ADV
iajs-3030	102	121	reduces	reduce	VERB
iajs-3030	102	122	fbxw7	fbxw7	NOUN
iajs-3030	102	123	level	level	NOUN
iajs-3030	102	124	[	[	X
iajs-3030	102	125	15	15	NUM
iajs-3030	102	126	]	]	PUNCT
iajs-3030	102	127	.	.	PUNCT
iajs-3030	103	1	in	in	ADP
iajs-3030	103	2	the	the	DET
iajs-3030	103	3	first	first	ADJ
iajs-3030	103	4	study	study	NOUN
iajs-3030	103	5	of	of	ADP
iajs-3030	103	6	fbxw-7	fbxw-7	NUM
iajs-3030	103	7	protein	protein	NOUN
iajs-3030	103	8	in	in	ADP
iajs-3030	103	9	t1	t1	PROPN
iajs-3030	103	10	dm	dm	NUM
iajs-3030	103	11	in	in	ADP
iajs-3030	103	12	2021	2021	NUM
iajs-3030	103	13	,	,	PUNCT
iajs-3030	103	14	clearly	clearly	ADV
iajs-3030	103	15	,	,	PUNCT
iajs-3030	103	16	the	the	DET
iajs-3030	103	17	mechanism	mechanism	NOUN
iajs-3030	103	18	of	of	ADP
iajs-3030	103	19	ezh2	ezh2	NOUN
iajs-3030	103	20	/	/	SYM
iajs-3030	103	21	zbtb16	zbtb16	NOUN
iajs-3030	103	22	in	in	ADP
iajs-3030	103	23	t1	t1	NOUN
iajs-3030	103	24	dm	dm	NUM
iajs-3030	103	25	inhibition	inhibition	NOUN
iajs-3030	103	26	by	by	ADP
iajs-3030	103	27	fbw-7	fbw-7	NOUN
iajs-3030	103	28	is	be	AUX
iajs-3030	103	29	clarified	clarify	VERB
iajs-3030	103	30	,	,	PUNCT
iajs-3030	103	31	suggesting	suggest	VERB
iajs-3030	103	32	that	that	SCONJ
iajs-3030	103	33	fbw-7	fbw-7	NOUN
iajs-3030	103	34	is	be	AUX
iajs-3030	103	35	a	a	DET
iajs-3030	103	36	promising	promising	ADJ
iajs-3030	103	37	target	target	NOUN
iajs-3030	103	38	of	of	ADP
iajs-3030	103	39	t1	t1	PROPN
iajs-3030	103	40	dm	dm	NOUN
iajs-3030	103	41	therapy	therapy	NOUN
iajs-3030	103	42	.	.	PUNCT
iajs-3030	104	1	overexpression	overexpression	NOUN
iajs-3030	104	2	of	of	ADP
iajs-3030	104	3	fbw-7	fbw-7	NOUN
iajs-3030	104	4	in	in	ADP
iajs-3030	104	5	the	the	DET
iajs-3030	104	6	nod	nod	NOUN
iajs-3030	104	7	mice	mouse	NOUN
iajs-3030	104	8	inhibits	inhibit	VERB
iajs-3030	104	9	proinflammatory	proinflammatory	ADJ
iajs-3030	104	10	cytosine	cytosine	NOUN
iajs-3030	104	11	release	release	NOUN
iajs-3030	104	12	in	in	ADP
iajs-3030	104	13	the	the	DET
iajs-3030	104	14	splenocyles	splenocyle	NOUN
iajs-3030	104	15	and	and	CCONJ
iajs-3030	104	16	the	the	DET
iajs-3030	104	17	apoptosis	apoptosis	NOUN
iajs-3030	104	18	of	of	ADP
iajs-3030	104	19	islet	islet	NOUN
iajs-3030	104	20	beta	beta	NOUN
iajs-3030	104	21	cells	cell	NOUN
iajs-3030	104	22	[	[	X
iajs-3030	104	23	16	16	NUM
iajs-3030	104	24	]	]	PUNCT
iajs-3030	104	25	.	.	PUNCT
iajs-3030	105	1	ihjpas	ihjpas	PROPN
iajs-3030	105	2	.	.	PUNCT
iajs-3030	106	1	36	36	NUM
iajs-3030	106	2	(	(	PUNCT
iajs-3030	106	3	3	3	NUM
iajs-3030	106	4	)	)	PUNCT
iajs-3030	106	5	2023	2023	NUM
iajs-3030	106	6	173	173	NUM
iajs-3030	106	7	the	the	DET
iajs-3030	106	8	amount	amount	NOUN
iajs-3030	106	9	of	of	ADP
iajs-3030	106	10	serum	serum	NOUN
iajs-3030	106	11	fbxw7	fbxw7	NOUN
iajs-3030	106	12	protein	protein	NOUN
iajs-3030	106	13	and	and	CCONJ
iajs-3030	106	14	its	its	PRON
iajs-3030	106	15	relationship	relationship	NOUN
iajs-3030	106	16	to	to	ADP
iajs-3030	106	17	other	other	ADJ
iajs-3030	106	18	parameter	parameter	NOUN
iajs-3030	106	19	in	in	ADP
iajs-3030	106	20	the	the	DET
iajs-3030	106	21	examined	examine	VERB
iajs-3030	106	22	population	population	NOUN
iajs-3030	106	23	in	in	ADP
iajs-3030	106	24	the	the	DET
iajs-3030	106	25	patient	patient	NOUN
iajs-3030	106	26	group	group	NOUN
iajs-3030	106	27	,	,	PUNCT
iajs-3030	106	28	we	we	PRON
iajs-3030	106	29	studied	study	VERB
iajs-3030	106	30	the	the	DET
iajs-3030	106	31	connection	connection	NOUN
iajs-3030	106	32	between	between	ADP
iajs-3030	106	33	the	the	DET
iajs-3030	106	34	fbxw7	fbxw7	NOUN
iajs-3030	106	35	protein	protein	NOUN
iajs-3030	106	36	level	level	NOUN
iajs-3030	106	37	and	and	CCONJ
iajs-3030	106	38	numerous	numerous	ADJ
iajs-3030	106	39	other	other	ADJ
iajs-3030	106	40	parameters	parameter	NOUN
iajs-3030	106	41	table	table	VERB
iajs-3030	106	42	1	1	NUM
iajs-3030	106	43	.	.	PUNCT
iajs-3030	107	1	in	in	ADP
iajs-3030	107	2	patients	patient	NOUN
iajs-3030	107	3	groups	group	NOUN
iajs-3030	107	4	,	,	PUNCT
iajs-3030	107	5	fbxw7	fbxw7	PROPN
iajs-3030	107	6	serum	serum	NOUN
iajs-3030	107	7	have	have	VERB
iajs-3030	107	8	positive	positive	ADJ
iajs-3030	107	9	correlation	correlation	NOUN
iajs-3030	107	10	with	with	ADP
iajs-3030	107	11	these	these	DET
iajs-3030	107	12	parameter	parameter	NOUN
iajs-3030	107	13	fbg	fbg	NOUN
iajs-3030	107	14	,	,	PUNCT
iajs-3030	107	15	tg	tg	PROPN
iajs-3030	107	16	,	,	PUNCT
iajs-3030	107	17	cholesterol	cholesterol	NOUN
iajs-3030	107	18	,	,	PUNCT
iajs-3030	107	19	gpt	gpt	NOUN
iajs-3030	107	20	,	,	PUNCT
iajs-3030	107	21	got	get	VERB
iajs-3030	107	22	,	,	PUNCT
iajs-3030	107	23	ldl	ldl	NOUN
iajs-3030	107	24	,	,	PUNCT
iajs-3030	107	25	vldl	vldl	NOUN
iajs-3030	107	26	and	and	CCONJ
iajs-3030	107	27	have	have	VERB
iajs-3030	107	28	negative	negative	ADJ
iajs-3030	107	29	correlation	correlation	NOUN
iajs-3030	107	30	with	with	ADP
iajs-3030	107	31	hdl	hdl	PROPN
iajs-3030	107	32	.	.	PUNCT
iajs-3030	108	1	moreover	moreover	ADV
iajs-3030	108	2	,	,	PUNCT
iajs-3030	108	3	fbxw7	fbxw7	PROPN
iajs-3030	108	4	have	have	VERB
iajs-3030	108	5	significant	significant	ADJ
iajs-3030	108	6	with	with	ADP
iajs-3030	108	7	all	all	DET
iajs-3030	108	8	these	these	DET
iajs-3030	108	9	parameter	parameter	NOUN
iajs-3030	108	10	in	in	ADP
iajs-3030	108	11	patients	patient	NOUN
iajs-3030	108	12	.	.	PUNCT
iajs-3030	109	1	in	in	ADP
iajs-3030	109	2	control	control	NOUN
iajs-3030	109	3	all	all	PRON
iajs-3030	109	4	have	have	VERB
iajs-3030	109	5	positive	positive	ADJ
iajs-3030	109	6	correlation	correlation	NOUN
iajs-3030	109	7	.	.	PUNCT
iajs-3030	110	1	moreover	moreover	ADV
iajs-3030	110	2	,	,	PUNCT
iajs-3030	110	3	we	we	PRON
iajs-3030	110	4	found	find	VERB
iajs-3030	110	5	significant	significant	ADJ
iajs-3030	110	6	correlation	correlation	NOUN
iajs-3030	110	7	with	with	ADP
iajs-3030	110	8	all	all	DET
iajs-3030	110	9	parameter	parameter	NOUN
iajs-3030	110	10	in	in	ADP
iajs-3030	110	11	table	table	NOUN
iajs-3030	110	12	5	5	NUM
iajs-3030	110	13	.	.	PUNCT
iajs-3030	110	14	table	table	NOUN
iajs-3030	110	15	5	5	NUM
iajs-3030	110	16	.	.	PUNCT
iajs-3030	110	17	correlation	correlation	NOUN
iajs-3030	110	18	analysis	analysis	NOUN
iajs-3030	110	19	of	of	ADP
iajs-3030	110	20	variable	variable	NOUN
iajs-3030	110	21	associated	associate	VERB
iajs-3030	110	22	with	with	ADP
iajs-3030	110	23	serum	serum	NOUN
iajs-3030	110	24	fbxw7	fbxw7	NOUN
iajs-3030	110	25	protein	protein	NOUN
iajs-3030	110	26	levels	level	NOUN
iajs-3030	110	27	in	in	ADP
iajs-3030	110	28	the	the	DET
iajs-3030	110	29	study	study	NOUN
iajs-3030	110	30	populations	population	NOUN
iajs-3030	110	31	.	.	PUNCT
iajs-3030	111	1	variable	variable	ADJ
iajs-3030	111	2	sample	sample	NOUN
iajs-3030	111	3	patients	patient	NOUN
iajs-3030	111	4	control	control	VERB
iajs-3030	111	5	r	r	NOUN
iajs-3030	111	6	p	p	NOUN
iajs-3030	111	7	r	r	NOUN
iajs-3030	111	8	p	p	NOUN
iajs-3030	111	9	fbg	fbg	PROPN
iajs-3030	111	10	0.5	0.5	NUM
iajs-3030	111	11	0.00	0.00	NUM
iajs-3030	111	12	0.39	0.39	NUM
iajs-3030	111	13	0.02	0.02	NUM
iajs-3030	111	14	tg	tg	PROPN
iajs-3030	111	15	0.3	0.3	NUM
iajs-3030	111	16	0.00	0.00	NUM
iajs-3030	111	17	0.61	0.61	NUM
iajs-3030	111	18	0.0	0.0	NUM
iajs-3030	111	19	cholesterol	cholesterol	NOUN
iajs-3030	111	20	0.34	0.34	NUM
iajs-3030	111	21	0.00	0.00	NUM
iajs-3030	111	22	0.47	0.47	NUM
iajs-3030	111	23	0.006	0.006	NUM
iajs-3030	111	24	hdl	hdl	PROPN
iajs-3030	111	25	-0.3	-0.3	PROPN
iajs-3030	112	1	0.00	0.00	NUM
iajs-3030	112	2	0.4	0.4	NUM
iajs-3030	112	3	0.006	0.006	NUM
iajs-3030	112	4	gpt	gpt	NOUN
iajs-3030	112	5	0.5	0.5	NUM
iajs-3030	112	6	0.00	0.00	NUM
iajs-3030	112	7	got	get	VERB
iajs-3030	112	8	0.5	0.5	NUM
iajs-3030	112	9	0.00	0.00	NUM
iajs-3030	112	10	ldl	ldl	NOUN
iajs-3030	112	11	0.4	0.4	NUM
iajs-3030	112	12	0.00	0.00	NUM
iajs-3030	112	13	vldl	vldl	NOUN
iajs-3030	112	14	0.3	0.3	NUM
iajs-3030	112	15	0.00	0.00	NUM
iajs-3030	112	16	0.6	0.6	NUM
iajs-3030	112	17	0.0	0.0	NUM
iajs-3030	112	18	roc	roc	PROPN
iajs-3030	112	19	curve	curve	NOUN
iajs-3030	112	20	of	of	ADP
iajs-3030	112	21	protein	protein	NOUN
iajs-3030	112	22	fbxw7	fbxw7	NOUN
iajs-3030	112	23	according	accord	VERB
iajs-3030	112	24	to	to	ADP
iajs-3030	112	25	the	the	DET
iajs-3030	112	26	receiver	receiver	NOUN
iajs-3030	112	27	operating	operate	VERB
iajs-3030	112	28	characteristic	characteristic	NOUN
iajs-3030	112	29	(	(	PUNCT
iajs-3030	112	30	roc	roc	PROPN
iajs-3030	112	31	)	)	PUNCT
iajs-3030	112	32	,	,	PUNCT
iajs-3030	112	33	the	the	DET
iajs-3030	112	34	best	good	ADJ
iajs-3030	112	35	cutoff	cutoff	NOUN
iajs-3030	112	36	point	point	NOUN
iajs-3030	112	37	in	in	ADP
iajs-3030	112	38	the	the	DET
iajs-3030	112	39	fbxw-7	fbxw-7	PROPN
iajs-3030	112	40	has	have	VERB
iajs-3030	112	41	a	a	DET
iajs-3030	112	42	sensitivity	sensitivity	NOUN
iajs-3030	112	43	of	of	ADP
iajs-3030	112	44	80	80	NUM
iajs-3030	112	45	%	%	NOUN
iajs-3030	112	46	and	and	CCONJ
iajs-3030	112	47	a	a	DET
iajs-3030	112	48	1	1	NUM
iajs-3030	112	49	-	-	PUNCT
iajs-3030	112	50	specificity	specificity	NOUN
iajs-3030	112	51	of	of	ADP
iajs-3030	112	52	48.8	48.8	NUM
iajs-3030	112	53	%	%	NOUN
iajs-3030	112	54	in	in	ADP
iajs-3030	112	55	area	area	NOUN
iajs-3030	112	56	0.8	0.8	NUM
iajs-3030	112	57	with	with	ADP
iajs-3030	112	58	cut	cut	VERB
iajs-3030	112	59	off	off	ADP
iajs-3030	112	60	1.9	1.9	NUM
iajs-3030	112	61	,	,	PUNCT
iajs-3030	112	62	the	the	DET
iajs-3030	112	63	fbg	fbg	NOUN
iajs-3030	112	64	has	have	VERB
iajs-3030	112	65	a	a	DET
iajs-3030	112	66	sensitivity	sensitivity	NOUN
iajs-3030	112	67	of	of	ADP
iajs-3030	112	68	75	75	NUM
iajs-3030	112	69	%	%	NOUN
iajs-3030	112	70	and	and	CCONJ
iajs-3030	112	71	a	a	DET
iajs-3030	112	72	1	1	NUM
iajs-3030	112	73	-	-	PUNCT
iajs-3030	112	74	specificity	specificity	NOUN
iajs-3030	112	75	of	of	ADP
iajs-3030	112	76	60	60	NUM
iajs-3030	112	77	%	%	NOUN
iajs-3030	112	78	in	in	ADP
iajs-3030	112	79	area	area	NOUN
iajs-3030	112	80	0.68	0.68	NUM
iajs-3030	112	81	with	with	ADP
iajs-3030	112	82	cut	cut	VERB
iajs-3030	112	83	off	off	ADP
iajs-3030	112	84	105	105	NUM
iajs-3030	112	85	,	,	PUNCT
iajs-3030	112	86	and	and	CCONJ
iajs-3030	112	87	the	the	DET
iajs-3030	112	88	hba1c	hba1c	PROPN
iajs-3030	112	89	has	have	VERB
iajs-3030	112	90	a	a	DET
iajs-3030	112	91	sensitivity	sensitivity	NOUN
iajs-3030	112	92	of	of	ADP
iajs-3030	112	93	100	100	NUM
iajs-3030	112	94	%	%	NOUN
iajs-3030	112	95	and	and	CCONJ
iajs-3030	112	96	a	a	DET
iajs-3030	112	97	1	1	NUM
iajs-3030	112	98	-	-	PUNCT
iajs-3030	112	99	specificity	specificity	NOUN
iajs-3030	112	100	of	of	ADP
iajs-3030	112	101	100	100	NUM
iajs-3030	112	102	%	%	NOUN
iajs-3030	112	103	in	in	ADP
iajs-3030	112	104	area	area	NOUN
iajs-3030	112	105	1	1	NUM
iajs-3030	112	106	with	with	SCONJ
iajs-3030	112	107	cut	cut	VERB
iajs-3030	112	108	off	off	ADP
iajs-3030	112	109	6.2	6.2	NUM
iajs-3030	112	110	in	in	ADP
iajs-3030	112	111	the	the	DET
iajs-3030	112	112	newly	newly	ADV
iajs-3030	112	113	as	as	ADP
iajs-3030	112	114	show	show	NOUN
iajs-3030	112	115	in	in	ADP
iajs-3030	112	116	table	table	NOUN
iajs-3030	112	117	6	6	NUM
iajs-3030	112	118	figure	figure	NOUN
iajs-3030	112	119	1	1	NUM
iajs-3030	112	120	.	.	PUNCT
iajs-3030	113	1	therefore	therefore	ADV
iajs-3030	113	2	,	,	PUNCT
iajs-3030	113	3	fbxw7	fbxw7	PROPN
iajs-3030	113	4	can	can	AUX
iajs-3030	113	5	be	be	AUX
iajs-3030	113	6	considered	consider	VERB
iajs-3030	113	7	as	as	ADP
iajs-3030	113	8	an	an	DET
iajs-3030	113	9	indicator	indicator	NOUN
iajs-3030	113	10	because	because	SCONJ
iajs-3030	113	11	it	it	PRON
iajs-3030	113	12	gave	give	VERB
iajs-3030	113	13	a	a	DET
iajs-3030	113	14	high	high	ADJ
iajs-3030	113	15	sensitivity	sensitivity	NOUN
iajs-3030	113	16	80	80	NUM
iajs-3030	113	17	%	%	NOUN
iajs-3030	113	18	.	.	PUNCT
iajs-3030	114	1	table	table	NOUN
iajs-3030	114	2	6	6	NUM
iajs-3030	114	3	.	.	PUNCT
iajs-3030	115	1	the	the	DET
iajs-3030	115	2	roc	roc	PROPN
iajs-3030	115	3	curve	curve	NOUN
iajs-3030	115	4	analysis	analysis	NOUN
iajs-3030	115	5	of	of	ADP
iajs-3030	115	6	hba1c	hba1c	PROPN
iajs-3030	115	7	,	,	PUNCT
iajs-3030	115	8	fbg	fbg	PROPN
iajs-3030	115	9	and	and	CCONJ
iajs-3030	115	10	fbxw7	fbxw7	NOUN
iajs-3030	115	11	protein	protein	NOUN
iajs-3030	115	12	using	use	VERB
iajs-3030	115	13	patients	patient	NOUN
iajs-3030	115	14	dm	dm	VERB
iajs-3030	115	15	without	without	ADP
iajs-3030	115	16	treatment	treatment	NOUN
iajs-3030	115	17	.	.	PUNCT
iajs-3030	116	1	parameters	parameter	NOUN
iajs-3030	116	2	area	area	NOUN
iajs-3030	116	3	sensitivity	sensitivity	NOUN
iajs-3030	116	4	specificity	specificity	NOUN
iajs-3030	116	5	cutoff	cutoff	ADP
iajs-3030	116	6	asymptotic	asymptotic	ADJ
iajs-3030	116	7	95	95	NUM
iajs-3030	116	8	%	%	NOUN
iajs-3030	116	9	confidence	confidence	NOUN
iajs-3030	116	10	interval	interval	NOUN
iajs-3030	116	11	lower	lower	ADV
iajs-3030	116	12	bound	bind	VERB
iajs-3030	116	13	upper	upper	ADJ
iajs-3030	116	14	bound	bind	VERB
iajs-3030	116	15	fbxw7	fbxw7	NOUN
iajs-3030	116	16	protein	protein	NOUN
iajs-3030	116	17	0.80	0.80	NUM
iajs-3030	116	18	80	80	NUM
iajs-3030	116	19	%	%	NOUN
iajs-3030	116	20	48.8	48.8	NUM
iajs-3030	116	21	%	%	NOUN
iajs-3030	116	22	1.9	1.9	NUM
iajs-3030	116	23	0.69	0.69	NUM
iajs-3030	116	24	0.92	0.92	NUM
iajs-3030	116	25	fbg	fbg	NOUN
iajs-3030	116	26	0.68	0.68	NUM
iajs-3030	116	27	75	75	NUM
iajs-3030	116	28	%	%	NOUN
iajs-3030	116	29	60	60	NUM
iajs-3030	116	30	%	%	NOUN
iajs-3030	116	31	105	105	NUM
iajs-3030	116	32	0.51	0.51	NUM
iajs-3030	116	33	0.84	0.84	NUM
iajs-3030	116	34	hba1c	hba1c	NOUN
iajs-3030	116	35	1	1	NUM
iajs-3030	116	36	100	100	NUM
iajs-3030	116	37	%	%	NOUN
iajs-3030	116	38	100	100	NUM
iajs-3030	116	39	%	%	NOUN
iajs-3030	116	40	6.2	6.2	NUM
iajs-3030	116	41	1	1	NUM
iajs-3030	116	42	1	1	NUM
iajs-3030	116	43	null	null	ADJ
iajs-3030	116	44	hypothesis	hypothesis	NOUN
iajs-3030	116	45	:	:	PUNCT
iajs-3030	116	46	true	true	ADJ
iajs-3030	116	47	area	area	NOUN
iajs-3030	116	48	=	=	SYM
iajs-3030	116	49	0.5	0.5	NUM
iajs-3030	116	50	ihjpas	ihjpa	NOUN
iajs-3030	116	51	.	.	PUNCT
iajs-3030	117	1	36	36	NUM
iajs-3030	117	2	(	(	PUNCT
iajs-3030	117	3	3	3	NUM
iajs-3030	117	4	)	)	PUNCT
iajs-3030	117	5	2023	2023	NUM
iajs-3030	117	6	174	174	NUM
iajs-3030	117	7	figure	figure	NOUN
iajs-3030	117	8	2	2	NUM
iajs-3030	117	9	.	.	PUNCT
iajs-3030	118	1	the	the	DET
iajs-3030	118	2	roc	roc	PROPN
iajs-3030	118	3	curve	curve	NOUN
iajs-3030	118	4	analysis	analysis	NOUN
iajs-3030	118	5	of	of	ADP
iajs-3030	118	6	the	the	DET
iajs-3030	118	7	prognostic	prognostic	ADJ
iajs-3030	118	8	value	value	NOUN
iajs-3030	118	9	of	of	ADP
iajs-3030	118	10	blood	blood	NOUN
iajs-3030	118	11	fbxw-7	fbxw-7	NUM
iajs-3030	118	12	protein	protein	NOUN
iajs-3030	118	13	content	content	NOUN
iajs-3030	118	14	in	in	ADP
iajs-3030	118	15	newly	newly	ADV
iajs-3030	118	16	diagnosed	diagnose	VERB
iajs-3030	118	17	diabetic	diabetic	ADJ
iajs-3030	118	18	patients	patient	NOUN
iajs-3030	118	19	.	.	PUNCT
iajs-3030	119	1	while	while	SCONJ
iajs-3030	119	2	on	on	ADP
iajs-3030	119	3	insulin	insulin	NOUN
iajs-3030	119	4	treatment	treatment	NOUN
iajs-3030	119	5	,	,	PUNCT
iajs-3030	119	6	the	the	DET
iajs-3030	119	7	fbxw-7	fbxw-7	PROPN
iajs-3030	119	8	has	have	VERB
iajs-3030	119	9	a	a	DET
iajs-3030	119	10	sensitivity	sensitivity	NOUN
iajs-3030	119	11	of	of	ADP
iajs-3030	119	12	100	100	NUM
iajs-3030	119	13	%	%	NOUN
iajs-3030	119	14	and	and	CCONJ
iajs-3030	119	15	a	a	DET
iajs-3030	119	16	1	1	NUM
iajs-3030	119	17	-	-	PUNCT
iajs-3030	119	18	specificity	specificity	NOUN
iajs-3030	119	19	of	of	ADP
iajs-3030	119	20	98.5	98.5	NUM
iajs-3030	119	21	%	%	NOUN
iajs-3030	119	22	in	in	ADP
iajs-3030	119	23	area	area	NOUN
iajs-3030	119	24	0.99	0.99	NUM
iajs-3030	119	25	with	with	AUX
iajs-3030	119	26	cut	cut	VERB
iajs-3030	119	27	off	off	ADP
iajs-3030	119	28	2.1	2.1	NUM
iajs-3030	119	29	,	,	PUNCT
iajs-3030	119	30	the	the	DET
iajs-3030	119	31	fbg	fbg	NOUN
iajs-3030	119	32	has	have	VERB
iajs-3030	119	33	a	a	DET
iajs-3030	119	34	sensitivity	sensitivity	NOUN
iajs-3030	119	35	of	of	ADP
iajs-3030	119	36	97	97	NUM
iajs-3030	119	37	%	%	NOUN
iajs-3030	119	38	and	and	CCONJ
iajs-3030	119	39	a	a	DET
iajs-3030	119	40	1	1	NUM
iajs-3030	119	41	-	-	PUNCT
iajs-3030	119	42	specificity	specificity	NOUN
iajs-3030	119	43	of	of	ADP
iajs-3030	119	44	98	98	NUM
iajs-3030	119	45	%	%	NOUN
iajs-3030	119	46	in	in	ADP
iajs-3030	119	47	area	area	NOUN
iajs-3030	119	48	0.95	0.95	NUM
iajs-3030	119	49	with	with	ADP
iajs-3030	119	50	cut	cut	VERB
iajs-3030	119	51	off	off	ADP
iajs-3030	119	52	118	118	NUM
iajs-3030	119	53	,	,	PUNCT
iajs-3030	119	54	and	and	CCONJ
iajs-3030	119	55	the	the	DET
iajs-3030	119	56	hba1c	hba1c	PROPN
iajs-3030	119	57	has	have	VERB
iajs-3030	119	58	a	a	DET
iajs-3030	119	59	sensitivity	sensitivity	NOUN
iajs-3030	119	60	of	of	ADP
iajs-3030	119	61	95	95	NUM
iajs-3030	119	62	%	%	NOUN
iajs-3030	119	63	and	and	CCONJ
iajs-3030	119	64	a	a	DET
iajs-3030	119	65	1	1	NUM
iajs-3030	119	66	-	-	PUNCT
iajs-3030	119	67	specificity	specificity	NOUN
iajs-3030	119	68	of	of	ADP
iajs-3030	119	69	100	100	NUM
iajs-3030	119	70	%	%	NOUN
iajs-3030	119	71	in	in	ADP
iajs-3030	119	72	area	area	NOUN
iajs-3030	119	73	0.99	0.99	NUM
iajs-3030	119	74	with	with	ADP
iajs-3030	119	75	cut	cut	VERB
iajs-3030	119	76	off	off	ADP
iajs-3030	119	77	6	6	NUM
iajs-3030	119	78	as	as	ADP
iajs-3030	119	79	show	show	NOUN
iajs-3030	119	80	in	in	ADP
iajs-3030	119	81	table	table	NOUN
iajs-3030	119	82	7	7	NUM
iajs-3030	119	83	figure	figure	NOUN
iajs-3030	119	84	2	2	NUM
iajs-3030	119	85	.	.	PUNCT
iajs-3030	119	86	therefore	therefore	ADV
iajs-3030	119	87	,	,	PUNCT
iajs-3030	119	88	fbxw7	fbxw7	PROPN
iajs-3030	119	89	can	can	AUX
iajs-3030	119	90	be	be	AUX
iajs-3030	119	91	considered	consider	VERB
iajs-3030	119	92	as	as	ADP
iajs-3030	119	93	an	an	DET
iajs-3030	119	94	indicator	indicator	NOUN
iajs-3030	119	95	because	because	SCONJ
iajs-3030	119	96	it	it	PRON
iajs-3030	119	97	revealed	reveal	VERB
iajs-3030	119	98	a	a	DET
iajs-3030	119	99	high	high	ADJ
iajs-3030	119	100	sensitivity	sensitivity	NOUN
iajs-3030	119	101	100	100	NUM
iajs-3030	119	102	%	%	NOUN
iajs-3030	119	103	and	and	CCONJ
iajs-3030	119	104	high	high	ADJ
iajs-3030	119	105	specificity	specificity	NOUN
iajs-3030	119	106	98.5	98.5	NUM
iajs-3030	119	107	%	%	NOUN
iajs-3030	119	108	.	.	PUNCT
iajs-3030	120	1	table	table	NOUN
iajs-3030	120	2	7	7	NUM
iajs-3030	120	3	.	.	PUNCT
iajs-3030	121	1	roc	roc	PROPN
iajs-3030	121	2	curve	curve	NOUN
iajs-3030	121	3	analysis	analysis	NOUN
iajs-3030	121	4	of	of	ADP
iajs-3030	121	5	hba1c	hba1c	PROPN
iajs-3030	121	6	,	,	PUNCT
iajs-3030	121	7	fbg	fbg	PROPN
iajs-3030	121	8	and	and	CCONJ
iajs-3030	121	9	fbxw7	fbxw7	NOUN
iajs-3030	121	10	protein	protein	NOUN
iajs-3030	121	11	using	use	VERB
iajs-3030	121	12	patients	patient	NOUN
iajs-3030	121	13	dm	dm	VERB
iajs-3030	121	14	with	with	ADP
iajs-3030	121	15	treatment	treatment	NOUN
iajs-3030	121	16	.	.	PUNCT
iajs-3030	122	1	parameters	parameter	NOUN
iajs-3030	122	2	area	area	NOUN
iajs-3030	122	3	sensitivity	sensitivity	NOUN
iajs-3030	122	4	specificity	specificity	NOUN
iajs-3030	122	5	cutoff	cutoff	ADP
iajs-3030	122	6	asymptotic	asymptotic	ADJ
iajs-3030	122	7	95	95	NUM
iajs-3030	122	8	%	%	NOUN
iajs-3030	122	9	confidence	confidence	NOUN
iajs-3030	122	10	interval	interval	NOUN
iajs-3030	122	11	lower	lower	ADV
iajs-3030	122	12	bound	bind	VERB
iajs-3030	122	13	upper	upper	ADJ
iajs-3030	122	14	bound	bind	VERB
iajs-3030	122	15	fbxw7	fbxw7	NOUN
iajs-3030	122	16	protein	protein	NOUN
iajs-3030	122	17	0.99	0.99	NUM
iajs-3030	122	18	100	100	NUM
iajs-3030	122	19	%	%	NOUN
iajs-3030	122	20	98.5	98.5	NUM
iajs-3030	122	21	%	%	NOUN
iajs-3030	122	22	2.1	2.1	NUM
iajs-3030	122	23	0.98	0.98	NUM
iajs-3030	122	24	1	1	NUM
iajs-3030	122	25	fbg	fbg	NOUN
iajs-3030	122	26	0.95	0.95	NUM
iajs-3030	122	27	97	97	NUM
iajs-3030	122	28	%	%	NOUN
iajs-3030	122	29	98	98	NUM
iajs-3030	122	30	%	%	NOUN
iajs-3030	122	31	118	118	NUM
iajs-3030	122	32	0.90	0.90	NUM
iajs-3030	122	33	0.99	0.99	NUM
iajs-3030	123	1	hba1c	hba1c	NOUN
iajs-3030	123	2	0.99	0.99	NUM
iajs-3030	123	3	95	95	NUM
iajs-3030	123	4	%	%	NOUN
iajs-3030	123	5	100	100	NUM
iajs-3030	123	6	%	%	NOUN
iajs-3030	123	7	6	6	NUM
iajs-3030	123	8	0.99	0.99	NUM
iajs-3030	123	9	1	1	NUM
iajs-3030	123	10	null	null	ADJ
iajs-3030	123	11	hypothesis	hypothesis	NOUN
iajs-3030	123	12	:	:	PUNCT
iajs-3030	123	13	true	true	ADJ
iajs-3030	123	14	area	area	NOUN
iajs-3030	123	15	=	=	SYM
iajs-3030	123	16	0.5	0.5	NUM
iajs-3030	123	17	figure	figure	NOUN
iajs-3030	123	18	2	2	NUM
iajs-3030	123	19	.	.	PUNCT
iajs-3030	124	1	roc	roc	PROPN
iajs-3030	124	2	curve	curve	NOUN
iajs-3030	124	3	analysis	analysis	NOUN
iajs-3030	124	4	of	of	ADP
iajs-3030	124	5	the	the	DET
iajs-3030	124	6	predictive	predictive	ADJ
iajs-3030	124	7	value	value	NOUN
iajs-3030	124	8	of	of	ADP
iajs-3030	124	9	serum	serum	NOUN
iajs-3030	124	10	concentration	concentration	NOUN
iajs-3030	124	11	of	of	ADP
iajs-3030	124	12	fbxw-7	fbxw-7	NUM
iajs-3030	124	13	protein	protein	NOUN
iajs-3030	124	14	in	in	ADP
iajs-3030	124	15	insulin	insulin	NOUN
iajs-3030	124	16	therapy	therapy	NOUN
iajs-3030	124	17	patients	patient	NOUN
iajs-3030	124	18	with	with	ADP
iajs-3030	124	19	diabetes	diabetes	NOUN
iajs-3030	124	20	.	.	PUNCT
iajs-3030	125	1	ihjpas	ihjpas	PROPN
iajs-3030	125	2	.	.	PUNCT
iajs-3030	126	1	36	36	NUM
iajs-3030	126	2	(	(	PUNCT
iajs-3030	126	3	3	3	NUM
iajs-3030	126	4	)	)	PUNCT
iajs-3030	126	5	2023	2023	NUM
iajs-3030	126	6	175	175	NUM
iajs-3030	126	7	4	4	NUM
iajs-3030	126	8	.	.	PUNCT
iajs-3030	126	9	conclusion	conclusion	VERB
iajs-3030	126	10	the	the	DET
iajs-3030	126	11	fbxw-7	fbxw-7	NUM
iajs-3030	126	12	protein	protein	NOUN
iajs-3030	126	13	was	be	AUX
iajs-3030	126	14	high	high	ADJ
iajs-3030	126	15	associated	associate	VERB
iajs-3030	126	16	with	with	ADP
iajs-3030	126	17	g3	g3	PROPN
iajs-3030	126	18	(	(	PUNCT
iajs-3030	126	19	treatment	treatment	NOUN
iajs-3030	126	20	)	)	PUNCT
iajs-3030	126	21	in	in	ADP
iajs-3030	126	22	the	the	DET
iajs-3030	126	23	area	area	NOUN
iajs-3030	126	24	(	(	PUNCT
iajs-3030	126	25	0.99	0.99	NUM
iajs-3030	126	26	)	)	PUNCT
iajs-3030	126	27	as	as	SCONJ
iajs-3030	126	28	shown	show	VERB
iajs-3030	126	29	in	in	ADP
iajs-3030	126	30	the	the	DET
iajs-3030	126	31	roc	roc	PROPN
iajs-3030	126	32	curve	curve	NOUN
iajs-3030	126	33	,	,	PUNCT
iajs-3030	126	34	and	and	CCONJ
iajs-3030	126	35	also	also	ADV
iajs-3030	126	36	it	it	PRON
iajs-3030	126	37	was	be	AUX
iajs-3030	126	38	good	good	ADJ
iajs-3030	126	39	associated	associate	VERB
iajs-3030	126	40	with	with	ADP
iajs-3030	126	41	g2	g2	PROPN
iajs-3030	126	42	(	(	PUNCT
iajs-3030	126	43	newly	newly	ADV
iajs-3030	126	44	)	)	PUNCT
iajs-3030	126	45	in	in	ADP
iajs-3030	126	46	the	the	DET
iajs-3030	126	47	area	area	NOUN
iajs-3030	126	48	(	(	PUNCT
iajs-3030	126	49	0.80	0.80	NUM
iajs-3030	126	50	)	)	PUNCT
iajs-3030	126	51	,	,	PUNCT
iajs-3030	126	52	also	also	ADV
iajs-3030	126	53	as	as	SCONJ
iajs-3030	126	54	shown	show	VERB
iajs-3030	126	55	in	in	ADP
iajs-3030	126	56	the	the	DET
iajs-3030	126	57	roc	roc	PROPN
iajs-3030	126	58	curve	curve	NOUN
iajs-3030	126	59	.	.	PUNCT
iajs-3030	127	1	so	so	ADV
iajs-3030	127	2	we	we	PRON
iajs-3030	127	3	suggested	suggest	VERB
iajs-3030	127	4	that	that	SCONJ
iajs-3030	127	5	fbxw7	fbxw7	PROPN
iajs-3030	127	6	used	use	VERB
iajs-3030	127	7	as	as	ADP
iajs-3030	127	8	indicator	indicator	NOUN
iajs-3030	127	9	to	to	PART
iajs-3030	127	10	diagnose	diagnose	VERB
iajs-3030	127	11	in	in	ADP
iajs-3030	127	12	patient	patient	NOUN
iajs-3030	127	13	with	with	ADP
iajs-3030	127	14	dm	dm	PROPN
iajs-3030	127	15	.	.	PUNCT
iajs-3030	127	16	insulin	insulin	NOUN
iajs-3030	127	17	not	not	PART
iajs-3030	127	18	reduce	reduce	VERB
iajs-3030	127	19	fbxw7	fbxw7	NOUN
iajs-3030	127	20	level	level	NOUN
iajs-3030	127	21	significantly	significantly	ADV
iajs-3030	127	22	.	.	PUNCT
iajs-3030	128	1	5	5	X
iajs-3030	128	2	.	.	X
iajs-3030	128	3	ethical	ethical	ADJ
iajs-3030	128	4	approval	approval	NOUN
iajs-3030	128	5	the	the	DET
iajs-3030	128	6	studies	study	NOUN
iajs-3030	128	7	have	have	AUX
iajs-3030	128	8	been	be	AUX
iajs-3030	128	9	approved	approve	VERB
iajs-3030	128	10	by	by	ADP
iajs-3030	128	11	committee	committee	NOUN
iajs-3030	128	12	of	of	ADP
iajs-3030	128	13	the	the	DET
iajs-3030	128	14	university	university	PROPN
iajs-3030	128	15	of	of	ADP
iajs-3030	128	16	baghdad	baghdad	PROPN
iajs-3030	128	17	college	college	PROPN
iajs-3030	128	18	of	of	ADP
iajs-3030	128	19	science	science	NOUN
iajs-3030	128	20	for	for	ADP
iajs-3030	128	21	women	woman	NOUN
iajs-3030	128	22	,	,	PUNCT
iajs-3030	128	23	and	and	CCONJ
iajs-3030	128	24	have	have	AUX
iajs-3030	128	25	been	be	AUX
iajs-3030	128	26	performed	perform	VERB
iajs-3030	128	27	in	in	ADP
iajs-3030	128	28	accordance	accordance	NOUN
iajs-3030	128	29	with	with	ADP
iajs-3030	128	30	the	the	DET
iajs-3030	128	31	ethical	ethical	ADJ
iajs-3030	128	32	standard	standard	NOUN
iajs-3030	128	33	as	as	SCONJ
iajs-3030	128	34	laid	lay	VERB
iajs-3030	128	35	down	down	ADP
iajs-3030	128	36	in	in	ADP
iajs-3030	128	37	the	the	DET
iajs-3030	128	38	1964	1964	NUM
iajs-3030	128	39	,	,	PUNCT
iajs-3030	128	40	i	i	PRON
iajs-3030	128	41	confirm	confirm	VERB
iajs-3030	128	42	that	that	SCONJ
iajs-3030	128	43	the	the	DET
iajs-3030	128	44	participant	participant	NOUN
iajs-3030	128	45	was	be	AUX
iajs-3030	128	46	given	give	VERB
iajs-3030	128	47	an	an	DET
iajs-3030	128	48	opportunity	opportunity	NOUN
iajs-3030	128	49	to	to	PART
iajs-3030	128	50	ask	ask	VERB
iajs-3030	128	51	questions	question	NOUN
iajs-3030	128	52	about	about	ADP
iajs-3030	128	53	the	the	DET
iajs-3030	128	54	study	study	NOUN
iajs-3030	128	55	,	,	PUNCT
iajs-3030	128	56	and	and	CCONJ
iajs-3030	128	57	all	all	DET
iajs-3030	128	58	the	the	DET
iajs-3030	128	59	questions	question	NOUN
iajs-3030	128	60	asked	ask	VERB
iajs-3030	128	61	by	by	ADP
iajs-3030	128	62	the	the	DET
iajs-3030	128	63	participant	participant	NOUN
iajs-3030	128	64	have	have	AUX
iajs-3030	128	65	been	be	AUX
iajs-3030	128	66	answered	answer	VERB
iajs-3030	128	67	correctly	correctly	ADV
iajs-3030	128	68	and	and	CCONJ
iajs-3030	128	69	to	to	ADP
iajs-3030	128	70	the	the	DET
iajs-3030	128	71	best	good	ADJ
iajs-3030	128	72	of	of	ADP
iajs-3030	128	73	my	my	PRON
iajs-3030	128	74	ability	ability	NOUN
iajs-3030	128	75	.	.	PUNCT
iajs-3030	129	1	i	i	PRON
iajs-3030	129	2	confirm	confirm	VERB
iajs-3030	129	3	that	that	SCONJ
iajs-3030	129	4	the	the	DET
iajs-3030	129	5	individual	individual	NOUN
iajs-3030	129	6	has	have	AUX
iajs-3030	129	7	not	not	PART
iajs-3030	129	8	been	be	AUX
iajs-3030	129	9	coerced	coerce	VERB
iajs-3030	129	10	into	into	ADP
iajs-3030	129	11	giving	give	VERB
iajs-3030	129	12	consent	consent	NOUN
iajs-3030	129	13	,	,	PUNCT
iajs-3030	129	14	and	and	CCONJ
iajs-3030	129	15	the	the	DET
iajs-3030	129	16	consent	consent	NOUN
iajs-3030	129	17	has	have	AUX
iajs-3030	129	18	been	be	AUX
iajs-3030	129	19	given	give	VERB
iajs-3030	129	20	freely	freely	ADV
iajs-3030	129	21	and	and	CCONJ
iajs-3030	129	22	voluntarily	voluntarily	ADV
iajs-3030	129	23	.	.	PUNCT
iajs-3030	130	1	6	6	X
iajs-3030	130	2	.	.	X
iajs-3030	130	3	conflict	conflict	NOUN
iajs-3030	130	4	of	of	ADP
iajs-3030	130	5	interest	interest	NOUN
iajs-3030	130	6	the	the	DET
iajs-3030	130	7	authors	author	NOUN
iajs-3030	130	8	announce	announce	VERB
iajs-3030	130	9	that	that	SCONJ
iajs-3030	130	10	they	they	PRON
iajs-3030	130	11	have	have	VERB
iajs-3030	130	12	no	no	DET
iajs-3030	130	13	contending	contend	VERB
iajs-3030	130	14	interests	interest	NOUN
iajs-3030	130	15	.	.	PUNCT
iajs-3030	131	1	7	7	X
iajs-3030	131	2	.	.	X
iajs-3030	131	3	source	source	NOUN
iajs-3030	131	4	of	of	ADP
iajs-3030	131	5	funding	funding	NOUN
iajs-3030	131	6	no	no	DET
iajs-3030	131	7	funding	funding	NOUN
iajs-3030	131	8	source	source	NOUN
iajs-3030	131	9	8	8	NUM
iajs-3030	131	10	.	.	PUNCT
iajs-3030	131	11	guarantor	guarantor	NOUN
iajs-3030	131	12	asst	asst	PROPN
iajs-3030	131	13	.	.	PUNCT
iajs-3030	132	1	prof	prof	PROPN
iajs-3030	132	2	.	.	PUNCT
iajs-3030	133	1	dr	dr	PROPN
iajs-3030	133	2	.	.	PROPN
iajs-3030	133	3	ekhlass	ekhlass	PROPN
iajs-3030	133	4	m.	m.	PROPN
iajs-3030	133	5	taha	taha	PROPN
iajs-3030	133	6	9	9	NUM
iajs-3030	133	7	.	.	PUNCT
iajs-3030	133	8	abbreviations	abbreviation	NOUN
iajs-3030	133	9	t1	t1	PROPN
iajs-3030	133	10	dm	dm	NOUN
iajs-3030	133	11	,	,	PUNCT
iajs-3030	133	12	type	type	NOUN
iajs-3030	133	13	1	1	NUM
iajs-3030	133	14	diabetes	diabetes	NOUN
iajs-3030	133	15	;	;	PUNCT
iajs-3030	133	16	fbg	fbg	PROPN
iajs-3030	133	17	,	,	PUNCT
iajs-3030	133	18	fasting	fast	VERB
iajs-3030	133	19	blood	blood	NOUN
iajs-3030	133	20	glucose	glucose	NOUN
iajs-3030	133	21	;	;	PUNCT
iajs-3030	133	22	hba1c	hba1c	PROPN
iajs-3030	133	23	,	,	PUNCT
iajs-3030	133	24	glycated	glycate	VERB
iajs-3030	133	25	hemoglobin	hemoglobin	NOUN
iajs-3030	133	26	;	;	PUNCT
iajs-3030	133	27	ldl	ldl	NOUN
iajs-3030	133	28	,	,	PUNCT
iajs-3030	133	29	low	low	ADJ
iajs-3030	133	30	density	density	NOUN
iajs-3030	133	31	lipoprotein	lipoprotein	ADJ
iajs-3030	133	32	;	;	PUNCT
iajs-3030	133	33	hdl	hdl	X
iajs-3030	133	34	,	,	PUNCT
iajs-3030	133	35	high	high	ADJ
iajs-3030	133	36	density	density	NOUN
iajs-3030	133	37	lipoprotein	lipoprotein	ADJ
iajs-3030	133	38	;	;	PUNCT
iajs-3030	133	39	vldl	vldl	NOUN
iajs-3030	133	40	,	,	PUNCT
iajs-3030	133	41	very	very	ADV
iajs-3030	133	42	low	low	ADJ
iajs-3030	133	43	density	density	NOUN
iajs-3030	133	44	lipoprotein	lipoprotein	ADJ
iajs-3030	133	45	;	;	PUNCT
iajs-3030	133	46	tc	tc	X
iajs-3030	133	47	,	,	PUNCT
iajs-3030	133	48	total	total	ADJ
iajs-3030	133	49	cholesterol	cholesterol	NOUN
iajs-3030	133	50	;	;	PUNCT
iajs-3030	133	51	tg	tg	X
iajs-3030	133	52	,	,	PUNCT
iajs-3030	133	53	triglyceride	triglyceride	ADV
iajs-3030	133	54	;	;	PUNCT
iajs-3030	133	55	got	get	VERB
iajs-3030	133	56	,	,	PUNCT
iajs-3030	133	57	glutamic	glutamic	ADJ
iajs-3030	133	58	oxalocetic	oxalocetic	ADJ
iajs-3030	133	59	transaminase	transaminase	NOUN
iajs-3030	133	60	;	;	PUNCT
iajs-3030	133	61	gpt	gpt	NOUN
iajs-3030	133	62	,	,	PUNCT
iajs-3030	133	63	glutamic	glutamic	ADJ
iajs-3030	133	64	pyruvic	pyruvic	ADJ
iajs-3030	133	65	transaminase	transaminase	NOUN
iajs-3030	133	66	;	;	PUNCT
iajs-3030	134	1	tos	to	NOUN
iajs-3030	134	2	,	,	PUNCT
iajs-3030	134	3	total	total	ADJ
iajs-3030	134	4	oxidant	oxidant	ADJ
iajs-3030	134	5	status	status	NOUN
iajs-3030	134	6	;	;	PUNCT
iajs-3030	134	7	tas	ta	NOUN
iajs-3030	134	8	,	,	PUNCT
iajs-3030	134	9	total	total	ADJ
iajs-3030	134	10	antioxidant	antioxidant	ADJ
iajs-3030	134	11	status	status	NOUN
iajs-3030	134	12	;	;	PUNCT
iajs-3030	134	13	osi	osi	NOUN
iajs-3030	134	14	,	,	PUNCT
iajs-3030	134	15	oxidative	oxidative	ADJ
iajs-3030	134	16	stress	stress	NOUN
iajs-3030	134	17	index	index	NOUN
iajs-3030	134	18	;	;	PUNCT
iajs-3030	134	19	dm	dm	X
iajs-3030	134	20	,	,	PUNCT
iajs-3030	134	21	diabetes	diabetes	NOUN
iajs-3030	134	22	mellitus	mellitus	NOUN
iajs-3030	134	23	;	;	PUNCT
iajs-3030	134	24	fbxw7	fbxw7	PROPN
iajs-3030	134	25	,	,	PUNCT
iajs-3030	134	26	f	f	X
iajs-3030	134	27	-	-	PUNCT
iajs-3030	134	28	box	box	PROPN
iajs-3030	134	29	and	and	CCONJ
iajs-3030	134	30	wd	wd	PROPN
iajs-3030	134	31	repeat	repeat	NOUN
iajs-3030	134	32	domain	domain	NOUN
iajs-3030	134	33	containing	contain	VERB
iajs-3030	134	34	7	7	NUM
iajs-3030	134	35	.	.	PUNCT
iajs-3030	134	36	references	reference	NOUN
iajs-3030	134	37	1	1	NUM
iajs-3030	134	38	.	.	PUNCT
iajs-3030	135	1	katsarou	katsarou	PROPN
iajs-3030	135	2	,	,	PUNCT
iajs-3030	135	3	a.	a.	NOUN
iajs-3030	135	4	;	;	PUNCT
iajs-3030	135	5	gudbjörnsdottir	gudbjörnsdottir	PROPN
iajs-3030	135	6	,	,	PUNCT
iajs-3030	135	7	s.	s.	PROPN
iajs-3030	135	8	;	;	PUNCT
iajs-3030	135	9	rawshani	rawshani	PROPN
iajs-3030	135	10	,	,	PUNCT
iajs-3030	135	11	a.	a.	NOUN
iajs-3030	135	12	;	;	PUNCT
iajs-3030	135	13	dabelea	dabelea	ADV
iajs-3030	135	14	,	,	PUNCT
iajs-3030	135	15	d.	d.	PROPN
iajs-3030	135	16	;	;	PUNCT
iajs-3030	135	17	bonifacio	bonifacio	PROPN
iajs-3030	135	18	,	,	PUNCT
iajs-3030	135	19	e.	e.	PROPN
iajs-3030	135	20	;	;	PUNCT
iajs-3030	135	21	anderson	anderson	PROPN
iajs-3030	135	22	,	,	PUNCT
iajs-3030	135	23	b.j	b.j	PROPN
iajs-3030	135	24	.	.	PROPN
iajs-3030	135	25	;	;	PUNCT
iajs-3030	135	26	jacobsen	jacobsen	PROPN
iajs-3030	135	27	,	,	PUNCT
iajs-3030	135	28	l.m	l.m	PROPN
iajs-3030	135	29	.	.	PROPN
iajs-3030	135	30	;	;	PUNCT
iajs-3030	135	31	schatz	schatz	PROPN
iajs-3030	135	32	,	,	PUNCT
iajs-3030	135	33	d.a	d.a	PROPN
iajs-3030	135	34	.	.	PROPN
iajs-3030	135	35	;	;	PUNCT
iajs-3030	135	36	lernmark	lernmark	PROPN
iajs-3030	135	37	,	,	PUNCT
iajs-3030	135	38	a.	a.	NOUN
iajs-3030	135	39	type	type	NOUN
iajs-3030	135	40	1	1	NUM
iajs-3030	135	41	diabetes	diabetes	NOUN
iajs-3030	135	42	mellitus	mellitus	NOUN
iajs-3030	135	43	.	.	PUNCT
iajs-3030	136	1	nature	nature	NOUN
iajs-3030	136	2	reviews	review	NOUN
iajs-3030	136	3	disease	disease	NOUN
iajs-3030	136	4	primers	primer	NOUN
iajs-3030	136	5	.	.	PUNCT
iajs-3030	137	1	2017	2017	NUM
iajs-3030	137	2	,	,	PUNCT
iajs-3030	137	3	3.1	3.1	NUM
iajs-3030	137	4	:	:	SYM
iajs-3030	137	5	1	1	NUM
iajs-3030	137	6	-	-	SYM
iajs-3030	137	7	17	17	NUM
iajs-3030	137	8	.	.	NOUN
iajs-3030	138	1	2	2	NUM
iajs-3030	138	2	.	.	X
iajs-3030	138	3	levitsky	levitsky	PROPN
iajs-3030	138	4	,	,	PUNCT
iajs-3030	138	5	l.l	l.l	PROPN
iajs-3030	138	6	.	.	PROPN
iajs-3030	138	7	;	;	PUNCT
iajs-3030	138	8	misra	misra	NUM
iajs-3030	138	9	,	,	PUNCT
iajs-3030	138	10	m.	m.	NOUN
iajs-3030	138	11	complications	complication	NOUN
iajs-3030	138	12	and	and	CCONJ
iajs-3030	138	13	screening	screen	VERB
iajs-3030	138	14	in	in	ADP
iajs-3030	138	15	children	child	NOUN
iajs-3030	138	16	and	and	CCONJ
iajs-3030	138	17	adolescents	adolescent	NOUN
iajs-3030	138	18	with	with	ADP
iajs-3030	138	19	type	type	NOUN
iajs-3030	138	20	1	1	NUM
iajs-3030	138	21	diabetes	diabetes	NOUN
iajs-3030	138	22	mellitus	mellitus	NOUN
iajs-3030	138	23	.	.	PUNCT
iajs-3030	139	1	2007	2007	NUM
iajs-3030	139	2	up	up	ADP
iajs-3030	139	3	to	to	ADP
iajs-3030	139	4	date	date	NOUN
iajs-3030	139	5	,	,	PUNCT
iajs-3030	139	6	17.1	17.1	NUM
iajs-3030	139	7	.	.	PUNCT
iajs-3030	140	1	3	3	X
iajs-3030	140	2	.	.	X
iajs-3030	140	3	scott	scott	PROPN
iajs-3030	140	4	,	,	PUNCT
iajs-3030	140	5	s.n	s.n	PROPN
iajs-3030	140	6	.	.	PROPN
iajs-3030	140	7	;	;	PUNCT
iajs-3030	140	8	anderson	anderson	PROPN
iajs-3030	140	9	,	,	PUNCT
iajs-3030	140	10	l.	l.	PROPN
iajs-3030	140	11	;	;	PUNCT
iajs-3030	140	12	morton	morton	PROPN
iajs-3030	140	13	,	,	PUNCT
iajs-3030	140	14	j.p	j.p	PROPN
iajs-3030	140	15	.	.	PROPN
iajs-3030	140	16	;	;	PUNCT
iajs-3030	140	17	wagenmakers	wagenmaker	NOUN
iajs-3030	140	18	,	,	PUNCT
iajs-3030	140	19	a.j.m	a.j.m	NOUN
iajs-3030	140	20	.	.	PUNCT
iajs-3030	140	21	;	;	PUNCT
iajs-3030	141	1	riddell	riddell	PROPN
iajs-3030	141	2	,	,	PUNCT
iajs-3030	141	3	m.c	m.c	PROPN
iajs-3030	141	4	.	.	PROPN
iajs-3030	141	5	carbohydrate	carbohydrate	NOUN
iajs-3030	141	6	restriction	restriction	NOUN
iajs-3030	141	7	in	in	ADP
iajs-3030	141	8	type	type	NOUN
iajs-3030	141	9	1	1	NUM
iajs-3030	141	10	diabetes	diabete	NOUN
iajs-3030	141	11	:	:	PUNCT
iajs-3030	141	12	a	a	DET
iajs-3030	141	13	realistic	realistic	ADJ
iajs-3030	141	14	therapy	therapy	NOUN
iajs-3030	141	15	for	for	ADP
iajs-3030	141	16	improved	improve	VERB
iajs-3030	141	17	glycaemic	glycaemic	ADJ
iajs-3030	141	18	control	control	NOUN
iajs-3030	141	19	and	and	CCONJ
iajs-3030	141	20	athletic	athletic	ADJ
iajs-3030	141	21	performance	performance	NOUN
iajs-3030	141	22	?	?	PUNCT
iajs-3030	141	23	.	.	PUNCT
iajs-3030	142	1	nutrients	nutrient	NOUN
iajs-3030	142	2	.	.	PUNCT
iajs-3030	143	1	2019	2019	NUM
iajs-3030	143	2	,	,	PUNCT
iajs-3030	143	3	11.5	11.5	NUM
iajs-3030	143	4	:	:	SYM
iajs-3030	143	5	1022	1022	NUM
iajs-3030	143	6	.	.	PUNCT
iajs-3030	144	1	4	4	X
iajs-3030	144	2	.	.	X
iajs-3030	144	3	cao	cao	PROPN
iajs-3030	144	4	,	,	PUNCT
iajs-3030	144	5	j.	j.	PROPN
iajs-3030	144	6	;	;	PUNCT
iajs-3030	144	7	ge	ge	PROPN
iajs-3030	144	8	,	,	PUNCT
iajs-3030	144	9	m.h	m.h	PROPN
iajs-3030	144	10	.	.	PROPN
iajs-3030	144	11	;	;	PUNCT
iajs-3030	144	12	ling	ling	PROPN
iajs-3030	144	13	,	,	PUNCT
iajs-3030	144	14	z.q	z.q	PROPN
iajs-3030	144	15	.	.	PUNCT
iajs-3030	144	16	fbxw7	fbxw7	PROPN
iajs-3030	144	17	tumor	tumor	PROPN
iajs-3030	144	18	suppressor	suppressor	NOUN
iajs-3030	144	19	:	:	PUNCT
iajs-3030	144	20	a	a	DET
iajs-3030	144	21	vital	vital	ADJ
iajs-3030	144	22	regulator	regulator	NOUN
iajs-3030	144	23	contributes	contribute	VERB
iajs-3030	144	24	to	to	ADP
iajs-3030	144	25	human	human	ADJ
iajs-3030	144	26	tumorigenesis	tumorigenesis	NOUN
iajs-3030	144	27	.	.	PUNCT
iajs-3030	145	1	medicine	medicine	NOUN
iajs-3030	145	2	.	.	PUNCT
iajs-3030	146	1	2016	2016	NUM
iajs-3030	146	2	,	,	PUNCT
iajs-3030	146	3	95.7	95.7	NUM
iajs-3030	146	4	.	.	PUNCT
iajs-3030	147	1	5	5	NUM
iajs-3030	147	2	.	.	X
iajs-3030	147	3	tejomayee	tejomayee	PROPN
iajs-3030	147	4	,	,	PUNCT
iajs-3030	147	5	s.	s.	PROPN
iajs-3030	147	6	functionalization	functionalization	NOUN
iajs-3030	147	7	of	of	ADP
iajs-3030	147	8	cancer	cancer	NOUN
iajs-3030	147	9	-	-	PUNCT
iajs-3030	147	10	associated	associate	VERB
iajs-3030	147	11	mutant	mutant	ADJ
iajs-3030	147	12	alleles	allele	NOUN
iajs-3030	147	13	of	of	ADP
iajs-3030	147	14	human	human	ADJ
iajs-3030	147	15	cdc4	cdc4	NOUN
iajs-3030	147	16	(	(	PUNCT
iajs-3030	147	17	fbxw7	fbxw7	PROPN
iajs-3030	147	18	)	)	PUNCT
iajs-3030	147	19	phd	phd	NOUN
iajs-3030	147	20	[	[	PUNCT
iajs-3030	147	21	dissertation	dissertation	NOUN
iajs-3030	147	22	]	]	PUNCT
iajs-3030	147	23	,	,	PUNCT
iajs-3030	147	24	university	university	NOUN
iajs-3030	147	25	of	of	ADP
iajs-3030	147	26	british	british	PROPN
iajs-3030	147	27	columbia	columbia	PROPN
iajs-3030	147	28	.	.	PUNCT
iajs-3030	148	1	2013	2013	NUM
iajs-3030	148	2	.	.	PUNCT
iajs-3030	149	1	6	6	NUM
iajs-3030	149	2	.	.	X
iajs-3030	150	1	li	li	PROPN
iajs-3030	150	2	,	,	PUNCT
iajs-3030	150	3	m.r	m.r	PROPN
iajs-3030	150	4	.	.	PROPN
iajs-3030	150	5	;	;	PUNCT
iajs-3030	151	1	zhu	zhu	PROPN
iajs-3030	151	2	,	,	PUNCT
iajs-3030	151	3	c.c	c.c	PROPN
iajs-3030	151	4	.	.	PROPN
iajs-3030	151	5	;	;	PUNCT
iajs-3030	151	6	ling	ling	PROPN
iajs-3030	151	7	,	,	PUNCT
iajs-3030	151	8	t.l	t.l	PROPN
iajs-3030	151	9	.	.	PROPN
iajs-3030	151	10	;	;	PUNCT
iajs-3030	151	11	zhang	zhang	PROPN
iajs-3030	151	12	,	,	PUNCT
iajs-3030	151	13	y.q	y.q	PROPN
iajs-3030	151	14	.	.	PROPN
iajs-3030	151	15	;	;	PUNCT
iajs-3030	151	16	xu	xu	PROPN
iajs-3030	151	17	,	,	PUNCT
iajs-3030	151	18	j.	j.	PROPN
iajs-3030	151	19	;	;	PUNCT
iajs-3030	151	20	zhao	zhao	PROPN
iajs-3030	151	21	,	,	PUNCT
iajs-3030	151	22	e.h	e.h	PROPN
iajs-3030	151	23	.	.	PROPN
iajs-3030	151	24	;	;	PUNCT
iajs-3030	151	25	zhao	zhao	PROPN
iajs-3030	151	26	,	,	PUNCT
iajs-3030	151	27	g.	g.	PROPN
iajs-3030	151	28	fbxw7	fbxw7	PROPN
iajs-3030	151	29	expression	expression	NOUN
iajs-3030	151	30	is	be	AUX
iajs-3030	151	31	associated	associate	VERB
iajs-3030	151	32	with	with	ADP
iajs-3030	151	33	prognosis	prognosis	NOUN
iajs-3030	151	34	and	and	CCONJ
iajs-3030	151	35	chemotherapeutic	chemotherapeutic	ADJ
iajs-3030	151	36	outcome	outcome	NOUN
iajs-3030	151	37	in	in	ADP
iajs-3030	151	38	chinese	chinese	ADJ
iajs-3030	151	39	patients	patient	NOUN
iajs-3030	151	40	with	with	ADP
iajs-3030	151	41	gastric	gastric	ADJ
iajs-3030	151	42	adenocarcinoma	adenocarcinoma	NOUN
iajs-3030	151	43	.	.	PUNCT
iajs-3030	152	1	bmc	bmc	ADJ
iajs-3030	152	2	gastroenterology	gastroenterology	NOUN
iajs-3030	152	3	.	.	PUNCT
iajs-3030	153	1	2017	2017	NUM
iajs-3030	153	2	,	,	PUNCT
iajs-3030	153	3	17.1	17.1	NUM
iajs-3030	153	4	:	:	SYM
iajs-3030	153	5	1	1	NUM
iajs-3030	153	6	-	-	SYM
iajs-3030	153	7	8	8	NUM
iajs-3030	153	8	.	.	PUNCT
iajs-3030	154	1	https://sciprofiles.com/profile/197901	https://sciprofiles.com/profile/197901	ADJ
iajs-3030	154	2	ihjpas	ihjpa	NOUN
iajs-3030	154	3	.	.	PUNCT
iajs-3030	155	1	36	36	NUM
iajs-3030	155	2	(	(	PUNCT
iajs-3030	155	3	3	3	NUM
iajs-3030	155	4	)	)	PUNCT
iajs-3030	155	5	2023	2023	NUM
iajs-3030	155	6	176	176	NUM
iajs-3030	155	7	7	7	NUM
iajs-3030	155	8	.	.	PUNCT
iajs-3030	155	9	welcker	welcker	PROPN
iajs-3030	155	10	,	,	PUNCT
iajs-3030	155	11	m.	m.	NOUN
iajs-3030	155	12	;	;	PUNCT
iajs-3030	155	13	orian	orian	PROPN
iajs-3030	155	14	,	,	PUNCT
iajs-3030	155	15	a.	a.	NOUN
iajs-3030	155	16	;	;	PUNCT
iajs-3030	155	17	grim	grim	ADJ
iajs-3030	155	18	,	,	PUNCT
iajs-3030	155	19	j.a	j.a	PROPN
iajs-3030	155	20	.	.	PROPN
iajs-3030	155	21	;	;	PUNCT
iajs-3030	155	22	eisenman	eisenman	PROPN
iajs-3030	155	23	,	,	PUNCT
iajs-3030	155	24	r.n	r.n	PROPN
iajs-3030	155	25	.	.	PROPN
iajs-3030	155	26	;	;	PUNCT
iajs-3030	155	27	clurman	clurman	PROPN
iajs-3030	155	28	,	,	PUNCT
iajs-3030	155	29	b.a	b.a	PROPN
iajs-3030	155	30	.	.	PROPN
iajs-3030	155	31	a	a	DET
iajs-3030	155	32	nucleolar	nucleolar	ADJ
iajs-3030	155	33	isoform	isoform	NOUN
iajs-3030	155	34	of	of	ADP
iajs-3030	155	35	the	the	DET
iajs-3030	155	36	fbw7	fbw7	PROPN
iajs-3030	155	37	ubiquitin	ubiquitin	PROPN
iajs-3030	155	38	ligase	ligase	PROPN
iajs-3030	155	39	regulates	regulate	VERB
iajs-3030	155	40	c	c	NOUN
iajs-3030	155	41	-	-	PUNCT
iajs-3030	155	42	myc	myc	NOUN
iajs-3030	155	43	and	and	CCONJ
iajs-3030	155	44	cell	cell	NOUN
iajs-3030	155	45	size	size	NOUN
iajs-3030	155	46	.	.	PUNCT
iajs-3030	156	1	current	current	ADJ
iajs-3030	156	2	biology	biology	NOUN
iajs-3030	156	3	.	.	PUNCT
iajs-3030	157	1	2004	2004	NUM
iajs-3030	157	2	,	,	PUNCT
iajs-3030	157	3	14.20	14.20	NUM
iajs-3030	157	4	:	:	SYM
iajs-3030	157	5	1852	1852	NUM
iajs-3030	157	6	-	-	SYM
iajs-3030	157	7	1857	1857	NUM
iajs-3030	157	8	.	.	PUNCT
iajs-3030	158	1	8	8	NUM
iajs-3030	158	2	.	.	X
iajs-3030	158	3	bae	bae	PROPN
iajs-3030	158	4	,	,	PUNCT
iajs-3030	158	5	y.u	y.u	PROPN
iajs-3030	158	6	.	.	PROPN
iajs-3030	158	7	;	;	PUNCT
iajs-3030	158	8	you	you	PRON
iajs-3030	158	9	,	,	PUNCT
iajs-3030	158	10	j.h	j.h	PROPN
iajs-3030	158	11	.	.	PROPN
iajs-3030	158	12	;	;	PUNCT
iajs-3030	158	13	cho	cho	PROPN
iajs-3030	158	14	,	,	PUNCT
iajs-3030	158	15	n.h	n.h	PROPN
iajs-3030	158	16	.	.	PROPN
iajs-3030	158	17	;	;	PUNCT
iajs-3030	159	1	kim	kim	PROPN
iajs-3030	159	2	,	,	PUNCT
iajs-3030	159	3	l.e	l.e	PROPN
iajs-3030	159	4	.	.	PROPN
iajs-3030	159	5	;	;	PUNCT
iajs-3030	159	6	shim	shim	NOUN
iajs-3030	159	7	,	,	PUNCT
iajs-3030	159	8	h.m	h.m	PROPN
iajs-3030	159	9	.	.	PROPN
iajs-3030	159	10	;	;	PUNCT
iajs-3030	159	11	park	park	PROPN
iajs-3030	159	12	,	,	PUNCT
iajs-3030	159	13	j.h	j.h	PROPN
iajs-3030	159	14	.	.	PROPN
iajs-3030	159	15	;	;	PUNCT
iajs-3030	159	16	cho	cho	PROPN
iajs-3030	159	17	,	,	PUNCT
iajs-3030	159	18	h.c	h.c	PROPN
iajs-3030	159	19	.	.	PROPN
iajs-3030	159	20	association	association	NOUN
iajs-3030	159	21	of	of	ADP
iajs-3030	159	22	protein	protein	NOUN
iajs-3030	159	23	z	z	PROPN
iajs-3030	159	24	with	with	ADP
iajs-3030	159	25	prediabetes	prediabete	NOUN
iajs-3030	159	26	and	and	CCONJ
iajs-3030	159	27	type	type	NOUN
iajs-3030	159	28	2	2	NUM
iajs-3030	159	29	diabetes	diabetes	NOUN
iajs-3030	159	30	.	.	PUNCT
iajs-3030	160	1	endocrinology	endocrinology	NOUN
iajs-3030	160	2	and	and	CCONJ
iajs-3030	160	3	metabolism	metabolism	NOUN
iajs-3030	160	4	.	.	PUNCT
iajs-3030	161	1	2021	2021	NUM
iajs-3030	161	2	,	,	PUNCT
iajs-3030	161	3	36.3	36.3	NUM
iajs-3030	161	4	:	:	PUNCT
iajs-3030	161	5	637	637	NUM
iajs-3030	161	6	.	.	NOUN
iajs-3030	161	7	9	9	X
iajs-3030	161	8	.	.	X
iajs-3030	161	9	kyvik	kyvik	PROPN
iajs-3030	161	10	,	,	PUNCT
iajs-3030	161	11	k.o	k.o	PROPN
iajs-3030	161	12	.	.	PROPN
iajs-3030	161	13	;	;	PUNCT
iajs-3030	161	14	nystrom	nystrom	PROPN
iajs-3030	161	15	,	,	PUNCT
iajs-3030	161	16	l.	l.	PROPN
iajs-3030	161	17	;	;	PUNCT
iajs-3030	161	18	songini	songini	PROPN
iajs-3030	161	19	,	,	PUNCT
iajs-3030	161	20	m.	m.	NOUN
iajs-3030	161	21	;	;	PUNCT
iajs-3030	161	22	oestman	oestman	ADJ
iajs-3030	161	23	,	,	PUNCT
iajs-3030	161	24	j.	j.	PROPN
iajs-3030	161	25	;	;	PUNCT
iajs-3030	161	26	castell	castell	PROPN
iajs-3030	161	27	,	,	PUNCT
iajs-3030	161	28	c.	c.	PROPN
iajs-3030	161	29	;	;	PUNCT
iajs-3030	161	30	green	green	ADJ
iajs-3030	161	31	,	,	PUNCT
iajs-3030	161	32	a.	a.	NOUN
iajs-3030	161	33	;	;	PUNCT
iajs-3030	161	34	guyrus	guyrus	PROPN
iajs-3030	161	35	,	,	PUNCT
iajs-3030	161	36	e.	e.	PROPN
iajs-3030	161	37	;	;	PUNCT
iajs-3030	161	38	tirgoviste	tirgoviste	VERB
iajs-3030	161	39	,	,	PUNCT
iajs-3030	161	40	c.i	c.i	PROPN
iajs-3030	161	41	.	.	PROPN
iajs-3030	161	42	;	;	PUNCT
iajs-3030	161	43	mckinney	mckinney	PROPN
iajs-3030	161	44	,	,	PUNCT
iajs-3030	161	45	p.a	p.a	PROPN
iajs-3030	161	46	.	.	PROPN
iajs-3030	161	47	;	;	PUNCT
iajs-3030	161	48	michalkova	michalkova	PROPN
iajs-3030	161	49	,	,	PUNCT
iajs-3030	161	50	d.	d.	PROPN
iajs-3030	161	51	;	;	PUNCT
iajs-3030	161	52	ostrauskas	ostrauskas	PROPN
iajs-3030	161	53	,	,	PUNCT
iajs-3030	161	54	r.	r.	PROPN
iajs-3030	161	55	;	;	PUNCT
iajs-3030	161	56	raymond	raymond	PROPN
iajs-3030	161	57	,	,	PUNCT
iajs-3030	161	58	n.t	n.t	PROPN
iajs-3030	161	59	.	.	PROPN
iajs-3030	162	1	the	the	DET
iajs-3030	162	2	epidemiology	epidemiology	NOUN
iajs-3030	162	3	of	of	ADP
iajs-3030	162	4	type	type	NOUN
iajs-3030	162	5	1	1	NUM
iajs-3030	162	6	diabetes	diabetes	NOUN
iajs-3030	162	7	mellitus	mellitus	NOUN
iajs-3030	162	8	is	be	AUX
iajs-3030	162	9	not	not	PART
iajs-3030	162	10	the	the	DET
iajs-3030	162	11	same	same	ADJ
iajs-3030	162	12	in	in	ADP
iajs-3030	162	13	young	young	ADJ
iajs-3030	162	14	adults	adult	NOUN
iajs-3030	162	15	as	as	ADP
iajs-3030	162	16	in	in	ADP
iajs-3030	162	17	children	child	NOUN
iajs-3030	162	18	.	.	PUNCT
iajs-3030	163	1	diabetologia	diabetologia	NOUN
iajs-3030	163	2	.	.	PUNCT
iajs-3030	164	1	2004	2004	NUM
iajs-3030	164	2	,	,	PUNCT
iajs-3030	164	3	47.3	47.3	NUM
iajs-3030	164	4	:	:	PUNCT
iajs-3030	164	5	377	377	NUM
iajs-3030	164	6	-	-	SYM
iajs-3030	164	7	384	384	NUM
iajs-3030	164	8	.	.	PUNCT
iajs-3030	164	9	10	10	NUM
iajs-3030	164	10	.	.	PUNCT
iajs-3030	164	11	ferrara	ferrara	PROPN
iajs-3030	164	12	,	,	PUNCT
iajs-3030	164	13	c.	c.	PROPN
iajs-3030	164	14	t.	t.	PROPN
iajs-3030	164	15	;	;	PUNCT
iajs-3030	164	16	geyer	geyer	PROPN
iajs-3030	164	17	,	,	PUNCT
iajs-3030	164	18	s.	s.	PROPN
iajs-3030	164	19	m.	m.	PROPN
iajs-3030	164	20	;	;	PUNCT
iajs-3030	164	21	liu	liu	PROPN
iajs-3030	164	22	,	,	PUNCT
iajs-3030	164	23	y.	y.	PROPN
iajs-3030	164	24	f.	f.	PROPN
iajs-3030	164	25	;	;	PUNCT
iajs-3030	164	26	evans	evans	PROPN
iajs-3030	164	27	-	-	PUNCT
iajs-3030	164	28	molina	molina	PROPN
iajs-3030	164	29	,	,	PUNCT
iajs-3030	164	30	c.	c.	PROPN
iajs-3030	164	31	;	;	PUNCT
iajs-3030	164	32	libman	libman	NOUN
iajs-3030	164	33	,	,	PUNCT
iajs-3030	164	34	i.	i.	NOUN
iajs-3030	164	35	m.	m.	NOUN
iajs-3030	164	36	;	;	PUNCT
iajs-3030	164	37	besser	besser	NOUN
iajs-3030	164	38	,	,	PUNCT
iajs-3030	164	39	r.	r.	PROPN
iajs-3030	164	40	,	,	PUNCT
iajs-3030	164	41	...	...	PUNCT
iajs-3030	164	42	&	&	CCONJ
iajs-3030	164	43	type	type	NOUN
iajs-3030	164	44	1	1	NUM
iajs-3030	164	45	diabetes	diabetes	NOUN
iajs-3030	164	46	trialnet	trialnet	NOUN
iajs-3030	164	47	study	study	NOUN
iajs-3030	164	48	group	group	NOUN
iajs-3030	164	49	.	.	PUNCT
iajs-3030	164	50	.	.	PUNCT
iajs-3030	165	1	excess	excess	ADJ
iajs-3030	165	2	bmi	bmi	NOUN
iajs-3030	165	3	in	in	ADP
iajs-3030	165	4	childhood	childhood	NOUN
iajs-3030	165	5	:	:	PUNCT
iajs-3030	165	6	a	a	DET
iajs-3030	165	7	modifiable	modifiable	ADJ
iajs-3030	165	8	risk	risk	NOUN
iajs-3030	165	9	factor	factor	NOUN
iajs-3030	165	10	for	for	ADP
iajs-3030	165	11	type	type	NOUN
iajs-3030	165	12	1	1	NUM
iajs-3030	165	13	diabetes	diabetes	NOUN
iajs-3030	165	14	development	development	NOUN
iajs-3030	165	15	?	?	PUNCT
iajs-3030	165	16	.	.	PUNCT
iajs-3030	166	1	diabetes	diabetes	NOUN
iajs-3030	166	2	care	care	VERB
iajs-3030	166	3	.	.	PUNCT
iajs-3030	167	1	2017	2017	NUM
iajs-3030	167	2	,	,	PUNCT
iajs-3030	167	3	40(5	40(5	NOUN
iajs-3030	167	4	)	)	PUNCT
iajs-3030	167	5	,	,	PUNCT
iajs-3030	167	6	698	698	NUM
iajs-3030	167	7	-	-	SYM
iajs-3030	167	8	701	701	NUM
iajs-3030	167	9	.	.	PUNCT
iajs-3030	168	1	11	11	NUM
iajs-3030	168	2	.	.	PUNCT
iajs-3030	169	1	world	world	PROPN
iajs-3030	169	2	health	health	PROPN
iajs-3030	169	3	organization	organization	PROPN
iajs-3030	169	4	.	.	PUNCT
iajs-3030	170	1	use	use	NOUN
iajs-3030	170	2	of	of	ADP
iajs-3030	170	3	glycated	glycate	VERB
iajs-3030	170	4	haemoglobin	haemoglobin	NOUN
iajs-3030	170	5	(	(	PUNCT
iajs-3030	170	6	hba1c	hba1c	PROPN
iajs-3030	170	7	)	)	PUNCT
iajs-3030	170	8	in	in	ADP
iajs-3030	170	9	diagnosis	diagnosis	NOUN
iajs-3030	170	10	of	of	ADP
iajs-3030	170	11	diabetes	diabetes	NOUN
iajs-3030	170	12	mellitus	mellitus	NOUN
iajs-3030	170	13	:	:	PUNCT
iajs-3030	170	14	abbreviated	abbreviate	VERB
iajs-3030	170	15	report	report	NOUN
iajs-3030	170	16	of	of	ADP
iajs-3030	170	17	a	a	DET
iajs-3030	170	18	who	who	PRON
iajs-3030	170	19	consultation	consultation	NOUN
iajs-3030	170	20	.	.	PUNCT
iajs-3030	171	1	world	world	PROPN
iajs-3030	171	2	health	health	PROPN
iajs-3030	171	3	organization	organization	NOUN
iajs-3030	171	4	,	,	PUNCT
iajs-3030	171	5	2011	2011	NUM
iajs-3030	171	6	,	,	PUNCT
iajs-3030	171	7	no	no	INTJ
iajs-3030	171	8	.	.	PUNCT
iajs-3030	172	1	who	who	PRON
iajs-3030	172	2	/	/	SYM
iajs-3030	172	3	nmh	nmh	NOUN
iajs-3030	172	4	/	/	SYM
iajs-3030	172	5	chp	chp	NOUN
iajs-3030	172	6	/	/	SYM
iajs-3030	172	7	cpm/	cpm/	NOUN
iajs-3030	172	8	11.1	11.1	NUM
iajs-3030	172	9	12	12	NUM
iajs-3030	172	10	.	.	PUNCT
iajs-3030	173	1	bruno	bruno	PROPN
iajs-3030	173	2	,	,	PUNCT
iajs-3030	173	3	v.	v.	ADP
iajs-3030	173	4	lipid	lipid	NOUN
iajs-3030	173	5	disorders	disorder	NOUN
iajs-3030	173	6	in	in	ADP
iajs-3030	173	7	type	type	NOUN
iajs-3030	173	8	1	1	NUM
iajs-3030	173	9	diabetes	diabetes	NOUN
iajs-3030	173	10	.	.	PUNCT
iajs-3030	174	1	diabetes	diabetes	NOUN
iajs-3030	174	2	&	&	CCONJ
iajs-3030	174	3	metabolism	metabolism	NOUN
iajs-3030	174	4	.	.	PUNCT
iajs-3030	175	1	2009	2009	NUM
iajs-3030	175	2	,	,	PUNCT
iajs-3030	175	3	35.5	35.5	NUM
iajs-3030	175	4	:	:	PUNCT
iajs-3030	175	5	353	353	NUM
iajs-3030	175	6	-	-	SYM
iajs-3030	175	7	360	360	NUM
iajs-3030	175	8	.	.	PUNCT
iajs-3030	176	1	13	13	NUM
iajs-3030	176	2	.	.	PUNCT
iajs-3030	177	1	guarnotta	guarnotta	PROPN
iajs-3030	177	2	,	,	PUNCT
iajs-3030	177	3	v.	v.	PROPN
iajs-3030	177	4	;	;	PUNCT
iajs-3030	177	5	vigneri	vigneri	PROPN
iajs-3030	177	6	,	,	PUNCT
iajs-3030	177	7	e.	e.	PROPN
iajs-3030	177	8	;	;	PUNCT
iajs-3030	177	9	pillitteri	pillitteri	ADJ
iajs-3030	177	10	,	,	PUNCT
iajs-3030	177	11	g.	g.	PROPN
iajs-3030	177	12	;	;	PUNCT
iajs-3030	177	13	ciresi	ciresi	PROPN
iajs-3030	177	14	,	,	PUNCT
iajs-3030	177	15	a.	a.	NOUN
iajs-3030	177	16	;	;	PUNCT
iajs-3030	177	17	pizzolanti	pizzolanti	ADJ
iajs-3030	177	18	,	,	PUNCT
iajs-3030	177	19	g.	g.	PROPN
iajs-3030	177	20	;	;	PUNCT
iajs-3030	177	21	giordano	giordano	PROPN
iajs-3030	177	22	,	,	PUNCT
iajs-3030	177	23	c.	c.	PROPN
iajs-3030	177	24	higher	high	ADJ
iajs-3030	177	25	cardiometabolic	cardiometabolic	PROPN
iajs-3030	177	26	risk	risk	NOUN
iajs-3030	177	27	in	in	ADP
iajs-3030	177	28	idiopathic	idiopathic	ADJ
iajs-3030	177	29	versus	versus	ADP
iajs-3030	177	30	autoimmune	autoimmune	ADJ
iajs-3030	177	31	type	type	NOUN
iajs-3030	177	32	1	1	NUM
iajs-3030	177	33	diabetes	diabetes	NOUN
iajs-3030	177	34	:	:	PUNCT
iajs-3030	177	35	a	a	DET
iajs-3030	177	36	retrospective	retrospective	ADJ
iajs-3030	177	37	analysis	analysis	NOUN
iajs-3030	177	38	.	.	PUNCT
iajs-3030	178	1	diabetology	diabetology	NOUN
iajs-3030	178	2	&	&	CCONJ
iajs-3030	178	3	metabolic	metabolic	PROPN
iajs-3030	178	4	syndrome	syndrome	PROPN
iajs-3030	178	5	.	.	PUNCT
iajs-3030	179	1	2018	2018	NUM
iajs-3030	179	2	,	,	PUNCT
iajs-3030	179	3	10.1	10.1	NUM
iajs-3030	179	4	:	:	SYM
iajs-3030	179	5	1	1	NUM
iajs-3030	179	6	-	-	SYM
iajs-3030	179	7	8	8	NUM
iajs-3030	179	8	.	.	PUNCT
iajs-3030	180	1	14	14	NUM
iajs-3030	180	2	.	.	PUNCT
iajs-3030	181	1	qassam	qassam	PROPN
iajs-3030	181	2	,	,	PUNCT
iajs-3030	181	3	z.m	z.m	PROPN
iajs-3030	181	4	.	.	PROPN
iajs-3030	181	5	;	;	PUNCT
iajs-3030	181	6	taha	taha	PROPN
iajs-3030	181	7	,	,	PUNCT
iajs-3030	181	8	e.m	e.m	PROPN
iajs-3030	181	9	.	.	PROPN
iajs-3030	181	10	study	study	VERB
iajs-3030	181	11	the	the	DET
iajs-3030	181	12	dynamic	dynamic	ADJ
iajs-3030	181	13	thiol	thiol	NOUN
iajs-3030	181	14	-disulfide	-disulfide	NOUN
iajs-3030	181	15	homeostasis	homeostasis	NOUN
iajs-3030	181	16	in	in	ADP
iajs-3030	181	17	patients	patient	NOUN
iajs-3030	181	18	with	with	ADP
iajs-3030	181	19	diabetes	diabetes	NOUN
iajs-3030	181	20	type	type	NOUN
iajs-3030	181	21	i	i	PRON
iajs-3030	181	22	and	and	CCONJ
iajs-3030	181	23	type	type	NOUN
iajs-3030	181	24	2	2	NUM
iajs-3030	181	25	.	.	NOUN
iajs-3030	181	26	2022	2022	NUM
iajs-3030	181	27	.	.	PUNCT
iajs-3030	182	1	15	15	NUM
iajs-3030	182	2	.	.	PUNCT
iajs-3030	183	1	mohammed	mohammed	PROPN
iajs-3030	183	2	,	,	PUNCT
iajs-3030	183	3	s.k	s.k	PROPN
iajs-3030	183	4	.	.	PROPN
iajs-3030	183	5	;	;	PUNCT
iajs-3030	183	6	taha	taha	PROPN
iajs-3030	183	7	,	,	PUNCT
iajs-3030	183	8	e.m	e.m	PROPN
iajs-3030	183	9	.	.	PROPN
iajs-3030	183	10	;	;	PUNCT
iajs-3030	183	11	muhi	muhi	PROPN
iajs-3030	183	12	,	,	PUNCT
iajs-3030	183	13	s.a	s.a	PROPN
iajs-3030	183	14	.	.	PROPN
iajs-3030	183	15	;	;	PUNCT
iajs-3030	183	16	a	a	DET
iajs-3030	183	17	case	case	NOUN
iajs-3030	183	18	-	-	PUNCT
iajs-3030	183	19	control	control	NOUN
iajs-3030	183	20	study	study	NOUN
iajs-3030	183	21	to	to	ADP
iajs-3030	183	22	determination	determination	NOUN
iajs-3030	183	23	fbxw7	fbxw7	NOUN
iajs-3030	183	24	and	and	CCONJ
iajs-3030	183	25	fetuin	fetuin	NOUN
iajs-3030	183	26	-	-	PUNCT
iajs-3030	183	27	a	a	DET
iajs-3030	183	28	levels	level	NOUN
iajs-3030	183	29	in	in	ADP
iajs-3030	183	30	patients	patient	NOUN
iajs-3030	183	31	with	with	ADP
iajs-3030	183	32	type	type	NOUN
iajs-3030	183	33	2	2	NUM
iajs-3030	183	34	diabetes	diabetes	NOUN
iajs-3030	183	35	in	in	ADP
iajs-3030	183	36	iraq	iraq	PROPN
iajs-3030	183	37	.	.	PUNCT
iajs-3030	184	1	journal	journal	PROPN
iajs-3030	184	2	of	of	ADP
iajs-3030	184	3	diabetes	diabetes	PROPN
iajs-3030	184	4	&	&	CCONJ
iajs-3030	184	5	metabolic	metabolic	NOUN
iajs-3030	184	6	disorders	disorder	NOUN
iajs-3030	184	7	.	.	PUNCT
iajs-3030	185	1	2021	2021	NUM
iajs-3030	185	2	,	,	PUNCT
iajs-3030	185	3	20.1	20.1	NUM
iajs-3030	185	4	:	:	SYM
iajs-3030	185	5	237	237	NUM
iajs-3030	185	6	-	-	SYM
iajs-3030	185	7	243	243	NUM
iajs-3030	185	8	.	.	PUNCT
iajs-3030	186	1	16	16	NUM
iajs-3030	186	2	.	.	PUNCT
iajs-3030	187	1	guo	guo	PROPN
iajs-3030	187	2	,	,	PUNCT
iajs-3030	187	3	y.	y.	PROPN
iajs-3030	187	4	;	;	PUNCT
iajs-3030	187	5	li	li	PROPN
iajs-3030	187	6	,	,	PUNCT
iajs-3030	187	7	j.	j.	PROPN
iajs-3030	187	8	;	;	PUNCT
iajs-3030	187	9	fan	fan	PROPN
iajs-3030	187	10	,	,	PUNCT
iajs-3030	187	11	s	s	PROPN
iajs-3030	187	12	;	;	PUNCT
iajs-3030	187	13	giordano	giordano	PROPN
iajs-3030	187	14	,	,	PUNCT
iajs-3030	187	15	q.h	q.h	PROPN
iajs-3030	187	16	.	.	PROPN
iajs-3030	187	17	suppressive	suppressive	ADJ
iajs-3030	187	18	role	role	NOUN
iajs-3030	187	19	of	of	ADP
iajs-3030	187	20	e3	e3	NOUN
iajs-3030	187	21	ubiquitin	ubiquitin	ADJ
iajs-3030	187	22	ligase	ligase	PROPN
iajs-3030	187	23	fbw7	fbw7	PROPN
iajs-3030	187	24	in	in	ADP
iajs-3030	187	25	type	type	NOUN
iajs-3030	187	26	i	i	PRON
iajs-3030	187	27	diabetes	diabete	VERB
iajs-3030	187	28	in	in	ADP
iajs-3030	187	29	non	non	ADJ
iajs-3030	187	30	-	-	ADJ
iajs-3030	187	31	obese	obese	ADJ
iajs-3030	187	32	diabetic	diabetic	ADJ
iajs-3030	187	33	mice	mouse	NOUN
iajs-3030	187	34	through	through	ADP
iajs-3030	187	35	mediation	mediation	NOUN
iajs-3030	187	36	of	of	ADP
iajs-3030	187	37	ubiquitination	ubiquitination	NOUN
iajs-3030	187	38	of	of	ADP
iajs-3030	187	39	ezh2	ezh2	PROPN
iajs-3030	187	40	.	.	PUNCT
iajs-3030	188	1	cell	cell	NOUN
iajs-3030	188	2	death	death	NOUN
iajs-3030	188	3	discovery	discovery	NOUN
iajs-3030	188	4	.	.	PUNCT
iajs-3030	189	1	2021	2021	NUM
iajs-3030	189	2	,	,	PUNCT
iajs-3030	189	3	7.1	7.1	NUM
iajs-3030	189	4	:	:	SYM
iajs-3030	189	5	1	1	NUM
iajs-3030	189	6	-	-	SYM
iajs-3030	189	7	9	9	NUM
iajs-3030	189	8	.	.	PUNCT